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Abstract 
Prostate cancer is one of the most prevalent cancers worldwide. The early stages of 
prostate cancer (PCa) are highly dependent on the androgen receptor (AR) pathway and hence 
therapies target this signalling axis. This approach is successful initially but invariably fails and 
the tumours progress to castration resistant prostate cancer (CRPC), for which few therapeutic 
options exist. Therefore, there is a great need to identify and characterize novel therapeutic 
targets for this stage of the disease.  
Cancer cells undergo alterations that allow them to survive and proliferate, and 
metabolic reprogramming is one of the most important manifestations in cancer progression. 
Therefore, targeting tumour metabolism is an attractive approach to treat cancer. Screening for 
novel metabolic targets was performed using an siRNA library. 26 metabolic factors were 
identified to affect proliferation and/or migration, and these were found to be involved in 
essential pathways including lipogenesis, heme-biosynthesis, redox homeostasis, and 
glycolysis. The lead targets were validated in a range of cell lines and additional assays 
performed to investigate the effect upon cell cycle and cell death.  
UROS, the fourth step of heme synthesis, was further investigated and depletion of this 
enzyme significantly inhibited prostate cancer proliferation and migration, promoted cell cycle 
arrest and induced cell death. Further, inhibition of heme synthesis using the inhibitor 
succinylacetone was found to significantly induce caspase-independent cell death and to 
sensitise cells to ROS. Importantly, the inhibitory activity of succinylacetone in combination 
with ROS showed specificity for cancer cell lines. Targeting heme synthesis therefore 
represents a novel targeted treatment option for prostate cancer and further work is needed to 
develop this into a therapeutic strategy. 
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1! Chapter 1 Introduction 
1.1! Prostate gland development and Structure  
The prostate gland is an essential part of the male reproductive system. This secretory 
gland forms a small acorn-shaped tissue with ductal features (Abate-Shen & Shen 2000), and it 
surrounds the urethra under the neck of the bladder anterior to the rectum (Figure 1.1). In 
humans and other mammals, the prostate develops as a single organ consisting of glandular 
regions that become histologically distinct after sexual maturity (Meeks & Schaeffer 2011). 
The  secretions of the prostate play an important part in male fertility; contributing important 
factors to the seminal fluid (Hoover & Naz 2012).  
Structurally, the prostate is formed of two main compartments, the stroma and 
epithelium. The epithelial tissue forms the inside layer of the prostate ducts which are enclosed 
by stroma (Aaron et al. 2016). The anatomy of the prostate as stated in Verze et al. (2016) is 
described as having three mains zones: the central zone which surrounds the ejaculatory ducts 
and projects under the bladder base, the transition zone which encloses the urethra, and the 
peripheral zone making the apical, posterior and lateral parts of the prostate (Figure 1.2) (Verze 
et al. 2016). The importance of this anatomical structure comes from its relationship to prostatic 
diseases, where for example the Benign Prostatic Hyperplasia (BPH), a non-malignant growth, 
occurs in the transition zone, while 70-80 % of Prostatic Carcinoma (PCa) usually arise in the 
peripheral zone (Abate-Shen & Shen 2000; Sinnott et al. 2015).   
Prostate gland development can be divided into five stages including determination, 
initiation or budding, branching morphogenesis, differentiation, and maturation (Prins & Putz 
2008). The human prostate initially develops during the foetal stages from the urogenital sinus 
(UGS) (Figure 1.3), a hindgut endodermal structure, that produces 5a-reductase, an enzyme that 
converts testosterone to dihydrotestosterone (DHT) (Marker et al. 2003). The production of 
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Figure 1.1 The prostate gland location in the male reproductive system. 
The prostate is located under the neck of the bladder and anterior to the rectum. 
 
 
 
 
 
 
 
Urethra
Prostate*gland
Bladder
Penis
Rectum
Anus
Testicle
Scortum
Seminal*vesicles
 
 
22 
 
 
 
Figure 1.2 The anatomy of prostate gland. 
Anatomical illustration of the prostate gland highlighting the main zones of the prostate gland. The 
central zone forms a cone shape surrounding the ejaculatory ducts and stretches to the bladder’s base 
and contributes 20-25% of the glandular tissue of the prostate. The transition zone is separated from the 
other glandular compartments by a fibromuscular band of tissue and it forms 5-10% of the glandular 
tissue of the prostate. The fibromuscular zone is a thick band of muscle fibres and fibrous connective 
tissues forming the apex of the prostate. The peripheral zone accounts for most of the glandular tissue 
of the prostate (70%) and forms the posterior and lateral aspects of the gland. The Periuretheral gland 
region forms a narrow area that consists of short ducts close to the urethra. [Illustration taken form 
Vertez et al, 2016].  
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Figure 1.3 Schematic showing the development of the prostate gland. 
A: The urogenital sinus (UGS) is the main endodermal structure from where the prostate develops in 
foetal stages. The UGS is composed of epithelium (red) and mesenchyme (blue). B:  The binding of 
androgens to AR in the mesenchyme stimulates the epithelial budding. C: Elongation of epithelial buds 
into solid cords of tissues that then forms ducts. D: Later development phase of prostate stimulates 
branching of epithelial tissues.  
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androgens (from leydig cells) then stimulates the UGS to develop into epithelial buds, ducts 
and branching ( Meeks & Schaeffer 2011; Nieto et al. 2014). Paracrine signalling is suggested 
to be responsible for the early development of the prostate where the mesenchymal AR signals 
induces the growth, invasion and differentiation of the epithelial tissue into prostatic ducts 
(Cunha 1975). This process occurs as early as 10 weeks’ gestation in humans (Meeks & 
Schaeffer 2011). The development and proliferation induced by this mesenchymal AR 
signalling occurs only in early development, but it can be reactivated later in life, leading to 
disease occurrence. In contrast, AR signalling in the epithelium is required later in development 
and initiates the production of prostatic secretions that initiate cell type differentiation, ductal 
morphogenesis and prostate maturation during puberty (Schaeffer et al. 2008). 
The prostate develops as a result of signalling between the mesenchyme and epithelium 
(Peng & Joyner 2015).  Experiments have shown that the absence of the former causes prostatic 
formation to fail, demonstrating the importance of signalling coming from the stroma to the 
epithelium during embryonic prostatic development (Cunha 1994). However, this vital 
signalling does not only maintain the normal prostatic development and homeostasis, but can 
also lead to tumour formation (Peng & Joyner 2015). 
 The epithelium consists of three distinct cell types (Figure 1.4). These, as described by 
Abate-Shen & Shen (2000), include secretory luminal cells, which exhibit androgen-sensitivity 
and produce prostatic secretory proteins and are characterized by the expression of the androgen 
receptor, cytokeratins 8 and 18 and the CD57 cell surface marker. The second type of prostatic 
epithelial cells are the basal cells that are embedded between the luminal cells and the basement 
membrane; these cells show low levels of AR and express cytokeratins 5 and 14 and CD44 
(Abate-Shen & Shen 2000). The third type of prostatic epithelial cells are the neuroendocrine 
cells that forms the minority of epithelial cells and they are androgen-independent and thought  
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Figure 1.4 Cell types of the adult human prostate. 
The endothelium of the prostate composed of secretory luminal cells, basal cells, neuroendocrine cells, 
and rarely some intermediate cells. The endothelium is separated from stromal part by a basement 
membrane, and the stroma consists of smooth muscle cells, endothelial cells, fibroblast cells, and 
neurons.   
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to produce paracrine signals that help development of the luminal cells (Abate-Shen & Shen 
2000). 
1.2! Functions and diseases of the prostate 
The prostate plays an essential role in male reproduction and is responsible for secreting 
enzymes, lipids, amines and metal ions that are required for maintaining the normal function of 
the prostate and spermatozoa (Kumar & Majumder 1995). Prostatic secretions are normally 
produced by the epithelial compartment and they account for one-fifth to one-third of the whole 
ejaculation fluid (Nieto et al. 2014). The factors produced by the prostatic epithelium include 
kallikreins (KLKs), for example the serine protease prostate specific antigen (PSA, KLK3), 
citrate, which is an intermediate metabolite implicated in the Krebs Cycle, and Zn+2, a trace 
element found in the cytoplasm of the prostatic epithelium ( Franklin et al. 2005; Medrano et 
al. 2006; Franz et al. 2013; Verze et al. 2016). Zn+2 accumulation in prostatic cells is vital for 
its role in citrate production and secretion, and the prostatic fluid enriched in Zn+2 , citrate and 
kallikreins is important for the molecular synchronization of the functional pathways stimulated 
by the ejaculatory stimuli (Verze et al. 2016). The accumulation of Zn+2 and subsequent 
production of citrate is found to be lost in prostate malignancy and this loss is regarded as an 
important characteristic of PCa (Franklin et al. 2005). The epithelial cells of the prostate gland 
are the only human cells that rely on energy production using aerobic glycolysis by the 
conversion of glucose into lactic acid rather than its complete oxidation through the Krebs 
Cycle, and this phenotype is also a hallmark of cancerous cells (Verze et al. 2016).  
 After maturity the prostate gland stops growing, however, androgens continue to play 
a vital role in maintaining its normal function (Brooke & Bevan 2009). In some cases, an 
abnormal growth of the prostate occurs resulting in conditions including benign prostatic 
hyperplasia (BPH), and premalignant prostatic intraepithelial neoplasia (PIN) or prostate cancer 
(PCa) (Brooke & Bevan 2009). Another disease called prostatitis (inflammation of prostate) 
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occurs in 11-13 % of adult men. This condition is predominantly caused by bacterial infection 
and the resulting inflammation can have a significant impact upon quality of life (Roberts et al. 
1997; Wagenlehner et al. 2013). The inflammation of the prostate is believed to result in high 
damage in prostatic epithelial tissues. BPH is a benign condition affecting males over 50 years, 
and it is characterized by prostatic cell proliferation, enlargement of the prostate and urethral 
obstruction leading to lower urinary tract symptoms (Skinder et al. 2016). The risk of BPH 
development correlates with age where the prevalence increases by 8%, 50%, and 80% in the 
4th, 6th, and 9th decades of life, respectively (Lim 2017). BPH occurs in the transition zone where 
epithelial and stromal cells of the prostate meet (Figure1.2). This growth is driven by altered 
androgen levels, specifically dihydrotestosterone (DHT) levels. This has been supported by the 
fact that BPH patients show a decrease in symptoms when treated with orchiectomy or 5a-
reductase inhibitors, which aim to block the conversion of testosterone to DHT (Homma et al. 
2011; Skinder et al. 2016). Further, DHT levels have been found to be higher in BPH patients 
compared with men with a normal prostate (Ho & Habib 2011).  
1.3! Prostate Cancer 
PCa is regarded as the most common cancer in Western male populations and forms the 
second leading cause of cancer-related deaths in men worldwide (Williams & Naz 2010; Kumar 
& Lupold 2016). It is believed to develop from damaged epithelial foci which is characterized 
as proliferative inflammatory atrophy (PIA) and/or prostatic intraepithelial neoplasia (Kumar 
& Lupold 2016). It is indicated that 80% of PCa cases originate as adenocarcinomas that arise 
from the secretory epithelial cells in the peripheral zone of the prostate (Franz et al. 2013). The 
risk of the disease increases with age (Brooke & Bevan 2009). Prostate tumours growth is 
almost always driven by the androgen-signalling axis (Brooke & Bevan 2009; Brooke et al. 
2014). Androgens, including testosterone and 5-alpha dihydrotestosterone, act through binding 
to the androgen receptor (AR) which then regulates the expression of downstream genes 
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involved in prostate cancer progression (Hirawat et al. 2003) (Figure 1.5). Androgen-dependent 
transcriptional activation is initiated by androgen binding to the AR which leads to dissociation 
of the HSP (heat shock protein) complex that holds the receptor in a ligand-binding competent  
state. Activated AR travels to the nucleus where it dimerizes and binds to AREs in the genome, 
subsequently regulating the expression of target genes (Heinlein & Chang 2004). The 
development of the prostate in human and rodent foetuses is largely based on androgen 
signalling because androgen ablation in early embryogenesis leads to inhibition of prostate 
development. Further, reduced prostate development is also seen in human and mice with 
complete AR dysfunction (Prins & Putz 2008). 
1.3.1! Aetiology and molecular biology of the disease  
PCa aetiology is not completely understood. However, genetic events are directly linked 
to this disease. Aberrant methylation of genes has been implicated in prostate cancer 
development (Donkena et al. 2010). For example, the hyper-methylation of tumour suppressor 
genes that are usually unmethylated could lead to tumour development (Woodson et al. 2003). 
For example, Woodson et al. (2003) demonstrated that GSTP1; a gene encoding the enzyme 
glutathione-S-transferase P1 (GSTP1), that catalyses the transfer of protons from the reduced 
glutathione to oxidants, is found to be hypermethylated in PIN and PCa: 70% of PIN lesions 
and 90% of prostate cancer tumours were found to have hypermethylation of GSTP1 whereas 
no methylation was detected in BPH or normal prostatic samples.  
 Approximately 5-10% of prostate cancers are hereditary and several loci have been 
implicated in this increased risk (Shand & Gelmann 2006). The number of genetic variations 
associated with PCa has been increased as a result of the development of genome-wide 
association study (GWAS) and sharing of large-scale genotype data (Lim 2017). PCa is highly 
heterogeneous disease in terms of genetic changes, although it has been found that the prostate 
epithelial cells demonstrate some common genetic changes when the transformation occurs. 
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Figure 1.5 The Androgen Receptor signalling axis. 
The androgen signalling cascade is activated by androgen binding to the Androgen Receptor (AR), 
resulting in dissociation of the Heat Shock Proteins (HSP) complex that keeps the receptor in a ligand-
binding competent state. Activated AR travels to the nucleus where it dimerizes and binds to Androgen 
Response Elements (AREs) in the genome and activates target gene expression. 
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Large genome-based studies led to subgrouping of prostate cancers according to the 
common genetic modifications which included alterations in the ERG, ETV1, ETV4, FLI1, 
SPOP, FOXA1, IDH1, and SPINK1 genes (Johnson et al. 2016; Wedge et al. 2018). ERG, ETVs 
and FLI1 are ETS (E26 transformation-specific) transcription factors that are commonly over-
expressed in some cases and involved in gene fusions (Tomlins et al. 2005; Paulo et al. 2012). 
In addition, the promoter of the androgen-regulated prostate-specific serine protease, TMPRSS2 
(transmembrane protease serine 2), has been found to be fused upstream of ETS family 
members, most commonly ERG. The resulting TMPRSS2:ERG gene fusion has been found in 
50 % of PCa patients, and more than 90 % of ERG-positive prostate cancers possess TMPRSS2-
ERG fusions (Tomlins et al. 2008). There are over 20 TMPRSS2-ERG fusion variants and the 
protein products of the fusion genes and their phenotypic implications in PCa still unclear, 
however, the presence of such rearrangements is correlated with poor cancer-related survival 
(Narod et al. 2008).  
SPOP point mutations are one of the most common mutations in PCa and are detected 
in 10% of primary and metastatic tumours (Blattner et al. 2017). SPINK1 overexpression was 
also detected in more than 10% of PCa patients as shown by a recent study conducted by 
Johnson et al. (2016). DH1 mutations were also reported in prostate cancers, although their 
occurrence is rare compared to other alterations. Therapeutics targeting such alterations would 
therefore only benefit a small group of patients (Flaherty et al. 2014; Hinsch et al. 2018). Other 
common mutations in tumour suppressor and oncogenes have also been reported in PCa such 
as TP53, PTEN, RB1, PIK3CA, KRAS and BRAF (Wedge et al. 2018).  
AR, TP53, and Bcl2 are implicated in progression and metastasis of PCa (Benedettini et 
al. 2008). The anti-apoptotic factor Bcl2 has been found to be upregulated in androgen-
independent prostate cancer cells and its silencing resulted in enhanced cell death and 
suppression of growth (Catz & Johnson 2003). Further, Lin et al. (2007) demonstrated that Bcl2 
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is required for the transition from androgen-dependence to androgen-independence. This 
transition was halted when the Bcl2 antagonist, Bax, was expressed or when Bcl2-shRNA was 
used (Lin et al. 2007). Other tumour suppressors like the transcription factor TP53 has also been 
found to be mutated in prostate cancer.  Mutations in the TP53 DNA-binding domain inhibit its 
ability to bind to target gene promoters and hence it loses its activity in cell cycle regulation 
(Chappell et al. 2012). A study on 90 tumour tissue samples obtained by radical prostatectomy 
showed that TP53 mutations were detected in 32 out of 90 patients (35.6%), and 40.6% of the 
patients with mutated TP53 exhibited tumour progression after 25 months while only 9% of 
wild-type TP53 patients showed tumour progression, but over a longer period of time (40 
months) (Ecke et al. 2010).   
AR drives PCa development and progression in several ways which results in alteration 
of PCa cells responsiveness to androgens. For example, somatic mutations can alter AR ligand 
specificity resulting in a receptor that is not only responsive to androgens but also to estrogens, 
progesterone, dehydroepiandrosterone, or even antiandrogens (Veldscholte et al. 1990). 
Additionally, AR splicing can result in constitutively active receptors that lack the ligand 
binding domain (Watson et al. 2010). Another mechanism that can alter androgen signalling is 
AR overexpression which makes tumour cells more sensitive to residual levels of androgens or 
other signals (Eisermann et al. 2013). However, some prostate carcinomas (particularly 
metastatic tumours) do not express AR as it is silenced by promoter hypermethylation and 
signalling for survival and growth is assumed to occur through peptide growth factors (Jarrard 
et al. 1998).  
New regions of genetic aberrations have also been found in PCa such as the 
identification of 8q24 as a significant prostate cancer risk region and the identification of the 
missense G84E variant in HOXB13 (Lim 2017). The former was regarded as non-coding with 
little or no transcriptional activity (Wallis & Nam 2015). However, recent studies have shown 
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that this region is involved in PCa progression through, for example, enhancers involved in the 
regulation of MYC which is located downstream of 8q24 region (Wasserman et al. 2010). 
Further, two metastatic PCa associated polymorphisms (rs4242382 and rs6983267) were found 
in this region (Ahn et al. 2011).  
1.3.2! Epidemiology 
PCa is one of the most prevalent cancers in males, with an expectation of 160,000 cases 
to be diagnosed in 2017 in the United States plus 3.3 million existing survivors (Miller et al. 
2016; Litwin & Tan 2017). Men have a 1:7 risk of developing PCa in their life (Siegel et al. 
2016). It is estimated that the global number of new cases will increase to 1.7 million cases and 
477,000 deaths by 2030 due to population growth and aging (Ferlay et al. 2010). In Europe, 
PCa incidence have been increasing, but mortality rates have decreased significantly and this 
has been attributed to improved prognosis through PSA screening and the availability of 
imaging techniques in these countries (Crocetti 2015). In the UK (Figure 1.6), there was an 
apparent increase in the incidence rates since 1993, but the mortality data demonstrated about 
20% declined in the time between 1990-2014. (Cancer Research UK 2014). In the USA, both 
the incidence and death rates of all races and ages (during 1975 to 2014) demonstrated more 
significant decline over the period of the past 20 years (Figure 1.7). 
 
 
 
33 
 
 
Figure 1.6 The UK incidence and deaths rates. 
(a)! The incidence rates of PCa from 1993-2015, (b) PCa death rates from 1971-2014. Date is age-
standardised and per 100,000 males and adapted from CRUK (Cancer Research UK 2014).  
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Figure 1.7 USA incidence and deaths rates from 1975 to 2014. 
Rates are per 100,000 people (All races males) and are age-adjusted. Data from the SEER Cancer 
Statistics Review 1975-2014. 
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1.3.3! Risk Factors 
To date, research could not link the occurrence of PCa to any lifestyle choices, however 
there still some risk factors that can be associated with the increased likelihood of developing 
the disease; these mainly include increasing age, ethnicity, and genetics (Strief 2007).  
Males over 60 years are regarded to be at greater risk of developing PCa than other ages; 
80% of cases are of ages over 60 years (Bostwick et al. 2004). Between 2007-2011(in the USA), 
only 0.6% of prostate cancer cases were diagnosed between 35 and 44; 9.7% between 45 and 
54; 32.7% between 55 and 64; 36.3% between 65 and 74; 16.8% between 75 and 84; and 3.8% 
for 85 years or older (Bashir 2015). The strong correlation between aging and PCa progression 
might be explained by the low proliferation rate of the prostatic epithelium, and the subsequent 
longer periods required for cells’ transformation to occur (Abate-Shen & Shen 2000).  
In addition, the incident of this disease is the highest in African-American males and 
Caucasians, with lower rates in Americans of Asian ancestry or white Americans; these racial 
differences might be due to exogenous factors such as dietary differences or endogenous factors 
which include the genetic differences  (Johns & Houlston 2003; Zeigler-Johnson et al. 2008). 
The incidence of PCa was more than 60 % higher in African-black men than white men in the 
USA between 1975-2014; the average incidence of black men was 223.7 per 100,000 men while 
white men had an incidence of 135.5 per 100,000 men (Figure 1.8) (SEER Cancer Statistics 
Review 2014). The mortality was also higher in black males according to SEER Cancer 
Statistics Review 1975-2014 (Figure 1.8).  
The genetic or familial risk is higher four times in first-degree relatives than that for the 
other general population, and it has been found that 50 % higher risk involved with monozygotic 
twins than dizygotic twins (Grönberg et al. 1994; Hemminki & Vaittinen 1998). In addition, as 
mentioned earlier, some rare mutations (e.g. rare BRCA2 mutations associated with breast and 
ovarian cancers) might mark a higher risk of PCa. 
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Rates are per 100,000 people (All races males) and are age-adjusted. Data from the SEER Cancer 
Statistics Review 1975-2014 (SEER Cancer Statistics Review 2014). 
 
 
Figure 1.8 Black versus white males’ incidence and mortality rates in the USA from 
1975-2014. 
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High body mass index (BMI) or gaining weight is believed to increase the risk of dying 
from PCa (Wright et al. 2007). Western lifestyle was thought to be promoting PCa 
development.  Western diet that is low in protective factors such as antioxidants, micronutrients, 
and vitamins and high in red meat, fatty food, and dairy products is thought to increase risk but 
there is still not enough data and evidence to support this (Masko et al. 2013) 
In addition to diet, the exogenous factors include the exposure to environmental agents 
that cause hormonal disruption; one example of these agents is endocrine disrupting chemicals 
(EDCs) that can enter human body through food ingestion, water or inhalation. EDCs result in 
hormone activity alteration and hence affect reproduction, development and carcinogenesis 
(Bostwick et al. 2004). An example of these chemicals is vinclozolin which is an antagonist of 
androgen and binds to AR and leads to decreased expression of androgen-regulated genes 
(Euling & Kimmel 2001).  
1.3.4! Symptoms and diagnosis/detection of prostate cancer 
The early stages of PCa are often symptomless.  Patients might show lower urinary track 
symptoms (LUTS) if the tumour reaches the urethra and/or the neck of the bladder leading to 
obstructive voiding symptoms (Pentyala et al. 2016). LUTS might include urgency, frequency, 
poor urinary stream, hesitancy, leakage, and erectile dysfunction (hematospermia and/or 
reduced ejaculatory volume due to ejaculatory duct obstruction) ( Hamilton & Sharp 2004; 
Pentyala et al. 2016).  
Comparative studies of symptoms between control and PCa patients have demonstrated 
that LUTS symptoms are not a sufficient indicator for PCa diagnosis and detection because 
such symptoms exist more commonly due to other benign conditions (Hamilton & Sharp 2004; 
Young et al. 2015). The LUTS are more specific to BPH than PCa (Strief 2007). Therefore, 
other diagnostic approaches are required to detect the disease. 
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The discovery of the biomarker prostate-specific antigen (PSA) has aided in PCa 
detection (Stephan et al. 2014). Serum levels of PSA are usually increased in response to 
abnormal prostate growth, however the diagnostic properties of PSA can be misleading as it 
can increase in non-tumour conditions and the levels cannot be detected in early stages of PCa 
(Wang et al. 1981; Williams & Naz 2010). It is estimated that the use of 4 ng/ml PSA as a cut-
off demonstrates only 21% sensitivity to detect PCa and this increases into 51% when higher-
grade PCa is present (Adhyam & Gupta 2012). In addition, PSA levels may not be a valid 
indicator of some rare prostatic carcinomas such as in the case of neuroendocrine PCa 
(anaplastic or small-cell carcinoma), which accounts for approximately 25 % of late stage 
tumours, that manifests low or undetectable PSA levels (Caubet et al. 2015).  
Digital rectal examination (DRE) is another routine examination performed by 
physicians to aid PCa detection. However, recent studies demonstrated that the use of DRE 
exhibits low specificity and sensitivity with or without the use of PSA screening so there have 
been no evidence to support the DRE efficacy in detecting PCa (Djulbegovic et al. 2010; Naji 
et al. 2018). Therefore, it has been recommended against the use of this routine in the primary 
care settings (Naji et al. 2018).  
Biopsy examination via microscopic techniques is argued to be the first choice that can 
give adequate details about the tissue state and hence precise staging of the cancer (Kumar et 
al. 2015). Biopsies of the prostate usually involves the collection of 10-12 tissue samples by 
transrectal ultrasound and a pathologist examines the samples and gives two Gleason scores 
(see Section 1.3.5) (Litwin & Tan 2017).  
The use of PSA, DRE, and biopsy examination might help in local PCa 
detection/staging; however, they cannot detect metastasis (Mapelli & Picchio 2015). Imaging 
modalities are therefore commonly used in PCa diagnosis and staging (Harvey & deSouza 
2016). Several imaging techniques are utilized, such as the morphological imaging modalities 
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which include MRI (magnetic resonance imaging), CT (computerised topography), and 
transrectal ultrasonography (TRUS) (Mapelli & Picchio 2015). All of these methods though 
have some limitations, for example CT imaging (Figure 1.9 (a)) relies on the size of the tumour 
and does not differentiate cancer form benign tumours, and both CT and MRI usually under-
stage metastasis.  Further, lesions smaller than 8-10 mm are usually missed (Mapelli & Picchio 
2015; Li et al. 2018). However, some recent studies investigating MRI for PCa bone metastasis 
detection demonstrated high sensitivity and specificity (>90%) and excellent diagnostic 
performance (Woo et al. 2016).  
Other promising alternatives of the mentioned PCa imaging modalities are the nuclear 
medicine techniques such as PET/CT (positron emission tomography/computed tomography) 
and PET/MRI that merges anatomic CT or MRI sequential images with a superimposed 
functional image demonstrating the distribution of a radiotracer or positron emitter (Rakheja et 
al. 2013; Ehman et al. 2017). An example of the latter is 18F-NaF (18F -sodium fluoride) which 
has high affinity for proliferating bones, and was demonstrated to be better in visualising both 
lytic and blastic lesions and small lesions compared to whole body bone scans due to the higher 
resolution of the sectional images and the enhanced target/background ratio (Araz et al. 2015; 
Harmon et al. 2018). In addition, measurements of standardised uptake values (SUV) of the 
radiotracer can give information to differentiate malignant from benign lesions, however 
standard values of the normal and/or benign tissues uptake need to be evaluated first and there 
have been no enough studies demonstrating the utility of the recent radiotracers (such as18F-
NaF) especially in PCa (Oldan et al. 2016).  
Radiolabelled precursors targeted to tumour biological processes such as metabolism, 
cellular proliferation and receptor binding have also been used in PET/CT and MRI to further 
stage PCa and investigate into the biochemical features of tumours after therapy failure or 
metastases (Sarkar & Das 2016). An example of that is the use of radiolabelled choline which  
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Figure 1.9 Detection/staging of PCa using different imaging modalities. 
 (a): Transaxial CT. (b): Transaxial 11C-choline-PET. (c): Transaxial PET/CT where a prostate tumour 
shows a higher uptake. Adapted from (Mapelli & Picchio 2015). 
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forms the most investigated functional imaging modality for PCa evaluation (Mapelli & Picchio 
2015). Choline is a constituent of cell membranes and as PCa induces membranes formation so 
the uptake of this tracer is higher in PCa tissues relative to normal prostatic tissues (Sarkar & 
Das 2016).  Figure 1.9 (b)-(c) shows higher 11C-choline uptake by PCa tumour in a 70 year old 
man with stage 7 PCa (Mapelli & Picchio 2015). Other tracers related to other biological 
processes are reviewed in: (Araz et al. 2015; Mapelli & Picchio 2015; Oldan et al. 2016; Woo 
et al. 2016; Sarkar & Das 2016; Harmon et al. 2018; Li et al. 2018), and the use of such 
techniques has been shown to improve the specificity and sensitivity of PCa detection and 
staging but some limitations and conflicting results regarding their performance have been 
noted. 
1.3.5! Histology and grading 
Analysis of PCa foci from small lesions, with similar phenotypes, revealed that they 
harbour different genotype which indicates that they evolve independently from each other 
(Macintosh et al. 1998). Previous studies outlined that PIN foci also arise independently in the 
same prostate, suggesting that PIN might be the origin of multi-focality or heterogeneity of 
prostate tumours (Bostwick et al. 1998). The heterogeneous and multi-focal nature of prostate 
tumours makes it difficult for prognostic studies and optimal treatments decisions. To assist, 
the Gleason grading system was developed and is used as prognostic indicator.   
Gleason grading uses needle biopsy that have been stained with Haematoxylin-Eosin 
(H&M), and lower magnification light microscopy (typically 4x or 10x) is employed to examine  
the tissues (Gordetsky & Epstein 2016). The decision on grading is based on the differentiation 
degree and architecture of the neoplastic cells (Humphrey 2004). The PCa staging according to 
Gleason system adds the most common pattern score, primary pattern (for example 2) to the 
score of the second most prevalent morphology of prostate neoplastic cells, secondary pattern 
(for example 3) to give one score (2+3=5). The scale of Gleason scores ranges from 2 to 10; 2 
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forms the most differentiated adenocarcinoma and as the Gleason score increases tumour cells 
so does the degree of de-differentiation (Table 1.1, Figure 1.10).  
The original system used for grading suffers from deficiencies that make it poor in 
differentiating between different grades of cancer. For example, it gives a Gleason score of 7 
for both 3+4 (mostly well differentiated cancer with smaller portion of poorly differentiated 
cancer) and 4+3 (mostly poorly differentiated proportion and less of well differentiated cancer) 
grades, however these are prognostically very different (Epstein et al. 2016). In addition, the 
lowest score used in practice is 6 although it is on a scale of 2-10 which leads to the incorrect 
thought that the patient is on the middle stage of the disease, which might result in unnecessary 
overtreatments (Epstein et al. 2016). Further, risk stratification or staging of patients after 
radical treatments using models like the D’Amico model (which stages non-metastatic PCa 
patients into either low, intermediate or high risk of biochemical reoccurrence after surgery 
according to their pre-treatment PSA level, clinical TNM-stage and Gleason score) suffered 
from weaknesses due to inaccuracy of Gleason scoring (Hernandez et al. 2007; Rodrigues et al. 
2012).  
Therefore, the grading system was revised to minimize confusion and is now graded on 
a scale of 1-5; where grade 1 represents Gleason scores of ≤ 6, grade 2 assigned to 3+4 Gleason 
score, grade 3 for 4+3 Gleason score, grade 4 for 8 Gleason scores, and grade 5 for 9-10 Gleason 
scores (Epstein et al. 2016; Litwin & Tan 2017). This new grading scheme was introduced since 
the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on 
Gleason Grading of Prostatic Carcinoma and the update shows more accurate grading 
stratification with the aim of reducing overtreatment (Pierorazio et al. 2013). This new system 
was also included in the 2016 Word Health Organization (WHO) classification of tumours and 
validated as an international standard for pathologists (Epstein et al. 2016). 
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Table 1.1 The Gleason staging system of prostate cancer tumours according to the most 
two predominant histological patterns. 
Gleason's Pattern Gleason's Score Histologic Grade 
1, 2 2, 3, 4 I. Well-differentiated 
3 5, 6 II. Moderately differentiated 
4, 5 7, 8,9,10 III. Poorly Differentiated 
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Figure 1.10 The Gleason Grading system. 
(a): Gleason scoring according to glandular architecture and patterns. Grade number 1 shows Packed, 
uniform, round, and well differentiated glands, number 2 glands exhibit less well defined masses, more 
stromal spaces and different sizes and shapes of glands, number 3 shows different sub-patterns of glands 
with lesser components of poorly formed glands that show more stromal spaces and elongated and 
stretched cells, number 4 glands seem to have ragged edges and poorly fused microacinar, cribriform, 
or papillary, and in number 5 necrotic phenotype is predominant, less glandular pattern with raggedly 
infiltrative sheet-like growth. (b): Gleason histological patterns and features of grades 3, 4, and 5. The 
drawing and images are adapted from (Humphrey 2004) and (Epstein et al. 2016). 
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1.4! Prostate cancer treatments  
1.4.1! Current therapies 
Treatments for localized PCa include therapies that target AR signalling, hormone 
therapy, brachytherapy, radical prostatectomy, or external beam radiation therapy (Duchesne 
2011). These management options have led to an increase in overall survival of patients with 
organ confined disease and locally advanced disease, however they can have a significant 
impact on quality of life for the patient and are not effective after relapse (Verze et al. 2016).  
The side effects of radical treatments, radical prostatectomy and radiotherapy, can 
include urinary symptoms and/or bowel toxicity, erectile dysfunction and haematuria (Keyes et 
al. 2013; Skowronek 2013). Hot flushes, loss of sex drive, weight increase and fatigue are 
commonly reported in the case of hormonal therapy ( Mohile et al. 2009; Boccon-Gibod et al. 
2011; Helsen et al. 2014; Gilson et al. 2015). There is limited evidence as to which of the 
treatment options have the best harm-benefit balance for patients and the decision on therapy 
will usually be according to preferences of a particular doctor and patient, symptoms, potential 
side effects, and economic considerations (Denis & Griffiths 2000). However, the 
overdiagnosis of insignificant disease, because of PSA screening, and the unnecessary 
treatments led to the development of some conservative management options (watchful waiting 
and active surveillance) which are advised to follow prior to treatments. 
1.4.1.1! Watchful waiting and active surveillance 
Screening for PCa has increased survival rates, but at the price of over-diagnosis and 
unnecessary treatment of patients with nonthreatening disease. As a result, 2 conservative 
management options were developed, active surveillance (AS) and watchful waiting (WW), to 
reduce unnecessary actions ( Kakehi 2003; Adolfsson 2008). WW is based on cancer 
monitoring and deferral of treatments until symptoms appear, it is the most suitable option for 
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patients with other health issues and/or elderly patients with localized disease to improve their 
quality of life with no curative intent (Keyes et al. 2013). AS also aims to delay active treatment 
and the associated side-effects of treatments when the disease is unthreatening. It is often used 
when patients are predicted to live for a long time (Lund et al. 2014). AS includes more frequent 
monitoring of disease progression indicators including PSA levels, Gleason score, the 
development of metastases and increased tumour volume ( Cooperberg et al. 2011; Tosoian et 
al. 2016). AS will be followed by active/curative treatment when cancer progression is reported 
(Xu et al. 2012). AS was shown to extend survival more than WW (Loeb et al. 2017).  
The American Society of Clinical Oncology (ASCO) has recommended that patients 
with local disease that manifests low- (Gleason score # 6) and intermediate-risk (Gleason score 
3+4= 7) should be managed by AS, but other factors such as age, tumour volume, and ethnicity 
should also be taken into account (Chen et al. 2016). However, there is no clinical or biological 
strategy that can stratify patients into those that are at low or high risk of disease progression 
and hence the AS strategy should be personalised according to the risk level based upon routine 
examinations (Tosoian et al. 2016).  
Recent studies comparing RP (radical prostatectomy) to AS demonstrated that radical 
therapies benefit only a sub-group of patients (Hadjipavlou et al. 2015). Other studies showed 
that there is a significant positive correlation between RP and survival and metastasis-free 
disease compared to AS (Bill-Axelson et al. 2014). WW and AS both include the close 
monitoring of disease progression to proceed to a palliative or active treatment when the disease 
becomes symptomatic or shows progression (Xu et al. 2012). Such strategies aim firstly to 
reduce overtreatment associated mortality and reduce the costs of therapies that might not 
benefit survival and quality of life, however some patients might opt for curative treatment 
options such as RP or RT to ease the anxiety associated with being diagnosed with cancer 
(Corcoran et al. 2010). 
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1.4.1.2! Radiation therapy 
Radiotherapy (RT) aims to kill cancer cells with little effect upon adjacent tissues. The 
approach is based on concentrating a beam of radiation on the tumour tissues which can be 
performed using an external source of radiation (external beam radiotherapy) or internally 
through what is called brachytherapy (Sadeghi et al. 2010). The latter involves the implantation 
of radioactive seeds that can emit radiation simultaneously for short-term; high dose-rate 
brachytherapy (HDRB), or long-term; low dose-rate brachytherapy (LDRB), according to the 
doses required (Skowronek 2013). This method generally is dependent on the detailed anatomy 
of the prostate, and the number of seeds injected is dependent on the area and size of the prostate 
where physicians are more conservative in areas close to other organs, such as the rectum and 
bladder to prevent unwanted tissue damage (Cesaretti et al. 2007).  
Treatment using radiation is generally offered to patients with clinically localised 
disease and used in combination with hormonal therapies in locally advanced PCa (Stein et al. 
2007). Like RP, this option shows side-effects, mainly minimum urinary symptoms and rectal 
toxicity (Keyes et al. 2013). Previous research work presented by Potosky et al. (2004), 
investigated follow-up data for PCa patient with localised disease treated with either RP or RT 
for five years. Their analysis showed that both RT or RP resulted in overall reduced sexual 
function, although erectile dysfunction was more frequent in RP-treated patients and only 5 % 
of RT patients developed incontinence compared to 14-16 % of RP patients. Further, the RT 
group demonstrated more frequency of bowel urgency and haemorrhoids than the RP group of 
patients (Potosky et al. 2004). To date, few comparable studies exist and hence it is difficult to 
conclude which of these therapies is the best option to treat localised PCa patients; each of these 
options affect the overall life quality of patients and the survival benefits of these therapies are 
not clear, but a recent analysis concluded that radiotherapy is correlated with higher mortality 
rates compared to RP (Wallis et al. 2016).  
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In addition to the typical side effects; including urinary incontinence and erectile 
dysfunction, radiotherapy has also been linked to the risk of inducing secondary malignancies 
as adjacent non-malignant tissues might receive genetic alterations without direct exposure to 
radiation because of the raised levels of reactive oxygen species (ROS) (Wallis et al. 2016). 
However, this is still uncertain because of the limited amount of data available, which mainly 
show a low rate of the risk of secondary tumours in close organs such as the bladder, rectum, 
and colon ( Jao et al. 1987; Neugut et al. 1997; Sountoulides et al. 2010). 
1.4.1.3! Radical prostatectomy 
 RP is the surgical removal of the prostate and it is used as a first line treatment option 
for PCa patients with organ-confined disease.  RP has been used to control local PCa for 100 
years (Walsh 2000). It was discussed by Hugosson et al. (2011) that in most patients RP cures 
the disease, and with the improved surgical techniques the pre-operative mortality rate has 
dropped to 0.1 %.  They also added that improvements in surgery have led to reduced 
incontinence, but 30 % of patients do claim light incontinence post RP.  Further the risk of 
stricture of vesico-urethral anastomosis has decreased from 10-20 % to only 2-9 % (Hugosson 
et al. 2011).  
RP is often offered to patients with localised tumours who are expected to live at least 
10 years (Lepor 2000). RP is mainly performed by either open (retropubic or perineal) or 
laparoscopic approaches (Salomon et al. 2004). The severity of the complications associated 
with retrotropic or perineal surgical approaches are mainly related to the individual’s anatomy, 
age, the surgical techniques used, and the experience and skills of the surgeon (McCullough 
2005). Comparisons between the open and laparoscopic techniques showed that they result in 
similar functional outcomes (erectile dysfunction and incontinence) (Damber & Khatami 2005). 
Recently a type of laparoscopic prostatectomy called Da Vinci, robotic-assisted prostatectomy, 
has been claimed to be a better option for its benefits over the traditional surgical approaches 
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in terms of intraoperative and postoperative outcomes (Seo et al. 2016). A recent comparison 
study by Niklas et al. (2016) demonstrated that robotic-assisted RP compared to open RP is 
exhibiting reduced surgical margins, reduced need for intraoperative blood transfusions, less 
catheter duration, less post-operative complications, and overall shorter hospitalisation time and 
hence reduced care costs. However, the intraoperative complications were similar in both 
groups but the operation time of robotic-assisted RP is longer than open RP (Niklas et al. 2016). 
1.4.1.4! Androgen deprivation hormonal therapies and antiandrogens 
 
Therapeutics for localized/metastatic PCa usually target the AR pathway to prevent AR-
dependent gene transcription (Karantanos et al. 2013). This is achieved by using drugs like 
luteinizing hormone releasing hormone (LHRH) (also known as gonadotropin-releasing 
hormone (GnRH)) analogues (Helsen et al. 2014), and recently GnRH antagonists (Cook & 
Sheridan 2000), and anti-androgens (Chen et al. 2009).  
Hormonal therapies form an important side of treatment of symptomatic metastatic PCa 
(Crawford 2004). However, hormone-based therapies are used in other different settings. They 
are used as a primary treatment option for localised PCa instead of surgery or radiotherapy, and 
in combination with surgery or radiotherapy or after biochemical reoccurrence (PSA increase) 
(Isbarn et al. 2009). AR-targeting therapies are highly successful at early stages of the disease, 
although most patients ultimately relapse after an average of 2-3 years and tumours progress to 
the more aggressive stage, CRPC (Karantanos et al. 2013). 
 Hormonal therapies work by the inhibition of androgens produced by adrenal glands, 
testes and tumour cells, or inhibiting the AR itself (Potter et al. 1995). Androgen castration can 
be achieved by surgical orchiectomy or androgen reducing drugs like estrogens (previously) or 
GnRH analogues; with or without anti-androgens (Crawford 2004; Duchesne 2011). GnRH 
agonists work by downregulating the GnRH receptors in the pituitary gland which regulates the 
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luteinizing hormone (LH) secretion and hence blocking testicular production of testosterone 
and DHT (Figure 1.11) (Debruyne 2004; Karantanos et al. 2013). The GnRH initially leads to 
a transient rise in serum LH levels and thus increasing testosterone serum levels, known as the 
testosterone surge (T surge). This in turn delays the desired suppression of testosterone 
production and can lead to clinical exacerbation of symptoms in advanced PCa patients, termed 
the “clinical flare” (Boccon-Gibod et al. 2011). The flare can be minimized by the use of 
antiandrogens (Table 1.2) to lessen the effect of the T surge.   
A trial study using one of the GnRH agonist goserelin (Table 1.2) demonstrated that T 
surge occurred in 22.6 % of patients after repeated injections of 3.6 or 10.8 mg of the drug, 
although none of the patients with T surge showed any tumour flare (Zinner et al. 2004). 
Another study, by Lundström et al. (2009), was conducted on 120 patients in South Africa using 
two injections of Triptoline 6 months’ formulation (22.5 mg). The study showed that 97.5 % of 
the patients achieved a castrate testosterone level (≤ 50 ng/dL) by 29 days and 93 % maintained 
castrate level in 2-12 months.  Further, 98.3 % of patients demonstrated no LH after the second 
dose of the drug. Triptoline treatment was also found to decrease testosterone levels to less than 
20 ng/dL after 6 months in 94 % of the patients, 92.2 % at 9 months, and 91.3 % at 12 months 
(Lundström et al. 2009).  
More recently, GnRH antagonists were demonstrated to be much more potent than the 
GnRH agonists as they do not cause the initial T surge (Crawford 2004). Degarelix is the most 
studied GnRH antagonist, it has been shown to have better clinical outcomes than leuprolide 
and has been shown to delay progression to CRPC (Shore 2013). In addition, the use of GnRH 
antagonists does not require the use of adjuvant anti-androgenic agents, therefore avoiding the 
adverse effects associated with these drugs (Boccon-Gibod et al. 2011).  
As mentioned, an additive treatment to the hormonal or surgical castration ( androgen 
deprivation therapies; ADT) is the use of anti-androgens to achieve maximal androgens  
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Figure 1.11 Endocrine control of prostatic growth. 
Normal prostate development and function requires AR signalling which is controlled by the binding of 
androgens which in turn are regulated by hypothalamic–pituitary–adrenal/gonadal axis. Synthesis of 
Androgens [testosterone (T), androstenedione (AD), dehydroepiandrosterone (DHEA)] and other 
steroids occurs in the testes or adrenal glands. Steroids (T, AD, and DHEA) release into the circulation 
is stimulated by specific hormonal signals including follicle stimulating hormone (FSH), gonadotropin 
releasing hormone (GnRH), luteinizing hormone (LH), luteinizing hormone releasing hormone 
(LHRH). Steroid hormone binding globulin (SHBG) transports testosterone to the prostate where it is 
converted by 5a-reductase to its active form (5a-dyhyrotestosterone, DHT). The pituitary releases the 
adrenocorticotropic hormone (ACTH) which stimulates adrenals to produce AD and DHEA.  
GnRH%
Pituitary gland
Hypothalamus
ACTH%FSH%LH%
Adrenal gland
Testes
ADDHEA%T
Prostate
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Table 1.2 List of first line/second line current drug options used for hormone therapy. 
 
Drug name Mechanism of action Reference 
Leuprolide 
A GnRH agonist works by 
desensitizing GnRH 
receptors. T flare occurs. 
(Tunn et al. 2013) 
Bruserelin 
a synthetic nonapeptide 
analogue of native LHRH. 
T flare initiated. 
(Soloway 1988) 
Abarelix 
A peptide antagonist of 
GnRH receptor. No T 
flare initiation. 
(Kirby et al. 2009) 
Degarelix 
A peptide antagonist of 
GnRH receptor. No T 
flare initiation. 
(Kirby et al. 2009) 
Goserelin 
(Zoladex) 
A GnRH agonist, T flare 
initiated. (Zinner et al. 2004) 
Triptorelin 
A GnRH agonist, T flare 
initiated. 
(Ploussard & 
Mongiat-Artus 
2013) 
Abiraterone acetate 
Steroidal anti-androgen, 
and irreversible inhibitor 
of CYP17. 
(Rehman & 
Rosenberg 2012) 
Cyproterone 
acetate (CPA) 
Steroidal anti-androgen. (Goldenberg & Bruchovsky 1991) 
Mifepristone 
(RU486) 
Steroidal anti-androgens, 
progesterone analogue. 
(Terakawa et al. 
1988), (Hazra & 
Pore 2001) 
Spironolactone  
Steroidal anti-androgens, 
Inhibition of cytochrome 
P450. 
(Walsh & Siiteri 
1975),(Sundar & 
Dickinson 2012)  
Galeterone 
(VN/124-1) 
Steroidal anti-androgen (Njar & Brodie 2015) 
Flutamide 
Non-steroidal anti-
androgen 
(Goldspiel & Kohler 
1990) 
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Nilutamide 
Non-steroidal anti-
androgen 
(Kassouf et al. 
2003)  
Bicalutamide 
Non-steroidal anti-
androgen 
(Goa & Spencer 
1998) 
Enzalutamide 
(MDV3100) 
Non-steroidal anti-
androgen; androgen 
receptor antagonist. 
(Scher et al. 2010) 
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blockade (MAB) (Klotz 2008). According to their chemical structures antiandrogens are of two 
classes; steroidal or non-steroidal (Table 1.2) (Akakura et al. 1998). The former works by 
blocking the production of androgens from adrenals, tumour cells, and tumour 
microenvironment by inhibiting an enzyme called cytochrome P-450-c17 (CYP17) (Karantanos 
et al. 2013). An example of steroidal antiandrogens is abiraterone acetate, which was shown to 
enhance the overall survival of metastatic CRPC patients who previously received 
chemotherapy (de Bono et al. 2011). The administration of steroidal antiandrogens, however, 
usually result in sexual dysfunction, and their steroidal nature explains the associated 
cardiovascular symptoms and fluid retentions (Mohile et al. 2009). This highlights the reason 
of the preference and tolerability of non-steroidal anti-androgens (NSAAs) over steroidal agents 
(Chen et al. 2009). NSAAs anti-androgens work by competing with endogenous androgens to 
bind to the AR ligand binding pocket, resulting in a conformational change in the receptor that 
promotes transcriptional silencing (Chen et al. 2009). NSAAs are pure anti-androgens; they do 
not interact with other steroid receptors, and as opposed to the steroidal anti-androgens they 
inhibit the negative feedback of androgens activity, and in consequence they increase LH and 
hence raise testosterone levels, however, this rise in androgens has no effect because of their 
AR inhibitory effect (Akakura et al. 1998; Kolvenbag & Furr 2009). NSAAs in clinical use 
include flutamide, nilutamide, and bicalutamide (Table 1.2); they all work as competitive 
inhibitors of androgens to AR and the antagonist-bound AR stays associated with heat shock 
factors in the cytoplasm or form transcriptionally inactive complex with DNA (Scher et al. 
2010).  
The symptoms associated with the non-steroidal AR antagonists include hot flushes, 
gastrointestinal symptoms, diarrhoea, and hepatotoxicity, reduction in haemoglobin, and 
increased levels of aminotransferases (McLeod 1997). The application of NSAAs as a single 
therapy has been preferred by young patients over the LHRH-targeted agents because they 
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preserve the sexual potency, however it can be less effective (Pope & Abel 2010). In respect to 
survival rates, available data shows that antiandrogens effect on survival rates is significant. 
For example, a new antiandrogen called enzalutamide has been shown to decrease PSA levels 
and improve the overall survival of patients with CRPC after chemotherapy (Dhingra et al. 
2013). In addition, a phase 3 study compared 800 patients treated with enzalutamide (daily 
doses of 160 mg) to 399 males treated with placebo found that the median overall survival was 
18.4 months in first group versus 13.6 months in the placebo group, and the decrease of PSA 
level by 50% or more was 54 % in the enzalutamide group compared to only 2 % in the placebo 
group, however an increased frequency of side effects was reported in the enzalutamide group 
(Scher et al. 2012). 
Hormone therapies are usually used for organ-confined or locally advanced PCa as 
adjuvant therapies, after a prior therapy (radiation therapy or prostatectomy), when 
reoccurrence is expected (Payne & Mason 2011). It was demonstrated that the use of hormonal 
drugs as adjuvant therapy improves the disease-free survival after prostatectomy and can even 
increase the overall survival if applied after radiotherapy (Kumar et al. 2006). Hormonal 
therapies can also be used as neo-adjuvant therapy, before or during radiotherapy, and this 
regimen was shown to improve the overall survival and reduce mortality of PCa patients (Jones 
et al. 2011). Hormonal therapies can be utilized as a single palliative therapy in cases when 
other primary therapies with curative intent cannot be performed (Studer et al. 2006). 
1.5! Hormone therapy failure and progression to CRPC 
Hormonal therapies are highly successful at early stages of the disease, although most 
patients ultimately relapse after an average of 2-3 years and the tumours progress to the more 
aggressive stage, termed CRPC which is associated with poor prognosis and lower survival 
rates (Karantanos et al. 2013). The survival for CRPC patients has a median of only 1-2 years 
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(Brooke et al. 2008; Mostaghel et al. 2010). CRPC was previously known as “hormone-
refractory” or “androgen-independent” PCa, but these terms are not precise as recent evidence 
has demonstrated that advanced/metastatic PCa is not “hormone-refractory” nor “androgen-
independent” (Foley & Mitsiades 2016). Androgen receptor signalling is believed to drive all 
stages of the disease (Coutinho et al. 2016). As discussed, the principle treatment for locally 
advanced PCa is hormone therapy which causes remission of the disease, but patients with 
castrate resistant disease no longer respond to such therapy regardless of testosterone levels 
(Karantanos et al. 2013). Until recently, the only therapeutic option for CRPC was 
chemotherapeutics, typically docetaxel, with ADT and/or antiandrogens (Hotte & Saad 2010). 
Several therapies targeting the AR pathway, such as abiraterone acetate and enzalutamide 
(Section 1.4.5), have entered the clinic because it is well accepted that androgen signalling 
drives CRPC.  However, still no treatment could cure this stage of prostate cancer and the 
current regimens are only palliative.  
Multiple mechanisms have been proposed to explain how AR signalling drives CRPC, 
including AR amplification and mutations, modifications of AR coregulator expression 
(leading to enhancement of AR signal transduction), protein kinase alterations, steroid 
metabolism perturbations, and crosstalk with other signalling axes with the AR pathway 
(Heinlein & Chang 2004; Chang 2007; Mostaghel et al. 2010). Previous studies have 
demonstrated that mutations of the AR, common in CRPC, result in reduced ligand specificity 
allowing the receptor to be activated in response to other ligands, including antiandrogens and 
other hormones ( Heinlein & Chang 2004; Brooke & Bevan 2009). More recently, it has been 
also demonstrated that constitutively active AR splice variants (AR-Vs) are up-regulated in 
CRPC. These variants lack the ligand binding domain and are therefore able to circumvent 
antiandrogenic agents (Cao et al. 2014). The failure of current treatments for CRPC has led to 
a large volume of research on the subject, to understand different factors and pathways that 
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regulate and lead to tumour progression.  
1.5.1! Molecular pathways that could be essential for prostate cancer progression 
Many pathways have been suggested to enhance PCa proliferation and migration. 
Several of these pathways, as mentioned before, are AR-regulated and others are AR 
independent oncogenic and tumour suppressor pathways. For example, the PI3K-Akt-mTOR 
pathway promotes PCa survival, growth, migration, metabolism, angiogenesis, and 
differentiation (Bitting & Armstrong 2013). This pathway is often constitutively active in PCa 
as a result of inactivation of its negative regulator PTEN (Phin et al. 2013). However, targeting 
this pathway with single agents was not found to result in significant clinical activity in 
castration resistant disease, and hence it has been proposed that dual targeting will improve 
efficacy (Saad & Eisenberger 2014). The TP53 tumour suppressor gene is also commonly 
mutated in PCa, however the frequency of this alteration is still low in the disease (5 % of PCa 
patients) compared to its existence in other cancers.  Further, alterations in TP53 do not clearly 
correlate with disease grading and staging (Ecke et al. 2010; Kluth et al. 2014). 
There is significant evidence to suggest that CRPC proliferation is still under the 
regulation of AR or via cross-talk with androgen signalling (Hoang et al. 2017). One such 
pathway is Wnt/"-catenin and genomic alterations of this pathway have been detected in CRPC 
but not in hormone naïve prostate cancer. Further, Hoang et al. (2017) demonstrated that "-
catenin is found to colocalise with the nuclear AR more commonly in CRPC than in primary 
PCa. This data suggest that AR and "-catenin interact and may cooperate to control the 
expression of target genes in CRPC, promoting survival and drug resistance (Yokoyama et al. 
2014). 
The mentioned signalling pathways form only the most common alterations found in 
PCa. However, none of the pathways were frequently altered to the extent that could suggest 
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they are major causes of PCa. The heterogeneity of the molecular alterations in PCa suggests 
that targeting a common downstream signalling pathway (e.g. metabolic signalling) could be a 
viable strategy to treat CRPC. 
1.5.2! Chemotherapies 
The majority of patients will respond to ADT and antiandrogens, however these 
therapies will invariably fail and the tumours will progress to CRPC (Deshayes et al. 2017). 
Since the 1990s, several chemotherapeutics have been introduced for the treatment of CRPC. 
Mitoxantrone was approved by the United States Food and Drug Administration (FDA) for 
CRPC in 1999, although other drugs like 5-fluorouracil and cyclophosphamide were already 
established and shown to have a palliative effect on CRPC patients (Sundararajan & Vogelzang 
2014). Several randomized trials using mitoxantrone in combination with other treatments 
(such as prednisone and hydrocortisone) have shown that this chemo-drug has a palliative effect 
on patients (mainly reduced bone pain), however it did not show any enhancement on overall 
survival ( Tannock et al. 1996; Kantoff et al. 1999; Berry et al. 2002). This drug is not currently 
in common use as it has been replaced with newer agents that show better efficacy in CRPC 
patients.  However, it might be used as a third or fourth-line treatment when other drugs such 
as Radium-223, docetaxel, and cabazitaxel have failed/cannot be administered (Sundararajan 
& Vogelzang 2014).  
The first taxane agent introduced for CRPC was paclitaxel, which was introduced in the 
early 1990s. It is believed that taxanes block cell cycle progression due to their effect on 
microtubule disassembly, leading to cell cycle arrest in G2/M phase (Schiff & Horwitz 1980; 
Caplows et al. 1994). Taxanes are also proposed to deactivate the anti-apoptotic activity of Bcl2 
proteins, consequently inducing apoptosis (Li et al. 2004). These drugs have been shown to 
reduce PSA levels, improve symptoms, and increase survival time (Dayyani et al. 2011).  
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Paclitaxel (taxol) was initially reported in a randomized phase 2 trial study; using a 24-
infusion doses of 135-170 mg/m2 every three weeks, which was found to be ineffective as a 
treatment for CRPC (Roth et al. 1993). A following trial study using weekly treatment of 24-
hour infusion taxol at a dose of 150 mg/m2 showed that 39 % of patients exhibited a decline in 
their PSA levels, but toxicity was also high (35%) (Trivedi et al. 2000). Several other phase 1 
and 2 trial studies combined paclitaxel with estramustine (an antitumor agent which also affects 
microtubules assembly leading to growth inhibition) and concluded that the addition of 
microtubules targeted agents enhanced PSA response, quality of life, and somewhat prolonged 
survival time (Hudes et al. 1997; Smith et al. 1999; Haas et al. 2001; Kelly et al. 2001). 
However, the small number of patients included in these studies made it difficult to draw a final 
conclusions and again, the treatment regime was associated with significant side-effect 
including fatigue, diarrhoea, hepatotoxicity, anaemia, leukopenia, nausea, fluid retention, 
hyperglycaemia, hypophosphatemia, leukopenia, thrombocytopenia, and peripheral 
neurotrophy (Hudes et al. 1997; Smith et al. 1999; Haas et al. 2001; Kelly et al. 2001). 
Docetaxel was subsequently found to show better efficacy compared to paclitaxel, as confirmed 
by cell culture studies (Kreis et al. 1997), and in xenograft tumours in nude mice (Vanhoefer et 
al. 1997). In addition, it is demonstrated that docetaxel is twice as effective as paclitaxel in 
microtubules destabilisation (Williams et al. 2000). Several randomized trials were conducted 
using docetaxel as a single agent or in combinations as shown in Tables 1.3 and 1.4. Overall, 
docetaxel, with or without other agents, is moderately tolerated by patients in phase 1 and 2 
studies at doses of less than 80 mg/m2, but a greater decrease in PSA levels were seen in the 
combination studies (Table 1.4). Docetaxel as a single agent and in combined treatments was 
also reported to enhance survival and provide symptomatic relief (Beer et al. 2001; Berry et al. 
2001; Berthold et al. 2008). Toxicity was mostly mild to moderate in these studies and included 
hematologic and non-hematologic toxicities. Hematologic toxicities like neutropenia, anaemia  
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Table 1.3 Docetaxel-Based Treatment of Castration Resistance Prostate Cancer: A 
Summary of Single-Agent studies. D = docetaxel, NR=not reported. 
Reference No. of patients 
Study 
Phase Doses and timing 
>50 % 
PSA 
decline 
(%) 
survival 
(Months) 
(Beer et al. 
2001) 25 II 
D 36 mg/m2 x 6 weeks. 46 9 
(Picus & 
Schultz 1999) 35 II 
D 75 mg/m2 /3weeks. 
46 12 
(Friedland et 
al. 1999) 21 II 
D 75 mg/m2 /3weeks. 38 NR 
(Gravis et al. 
2003) 30 II 
D 35 mg/m2/week for 24 
weeks, 2 weeks intervals 
every 6 weeks. 
48 20 
(Berry et al. 
2001) 60 II 
D 36 mg/m2 /week for 6 
weeks, 3 cycles with 2 
weeks intervals between 
each. 
41 9.4 
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Table 1.4 Docetaxel-Based Treatment of Castration Resistance Prostate Cancer: A 
Summary of combination studies. D=docetaxel, E=Estramustine, H=hydrocortisone, 
NR=not reported. 
Reference No. of patients 
Study 
Phase Doses and timing 
>50 % 
PSA 
decline 
(%) 
survival 
(Months) 
      
(Petrylak et 
al. 1999)  34 I 
E 280 mg 1- 5 days + D 40 
or 80 mg/m2 on day2. 
Repeated every 3 weeks. 
63 NR 
(Kreis et al. 
1999) 17 I 
D 40-80 mg/m2 /3weeks + E 
14 mg/kg/ dpo. 82 NR 
(Oh et al. 
2005) 
 
 
30 I 
D ≤ 34 mg/m2 on days 2,6,9 
of 28-day cycles + E 140 
mg 3x/day on days 1-5,8-12, 
& 15-19+ C on day2. 
63 14.6 
(Chittoor et 
al. 2006) 58 II 
D 25 mg/m2 on days 2,9,16 
of 28-dyas cycles + E 140 
mg 2x/day on days 1-3, 8-
10, & 15-17. 
68 5.3 
(Savarese et 
al. 2001) 47 II 
D 70 mg/m2 on 
days2/3weeks + E 10 
mg/kg/dpo days 1-5 + H 40 
mg/day. 
68 20 
(Sinibaldi et 
al. 2002) 40 II 
D 70 mg/m2 + E 280 
mg/6hours/3 weeks up to 6 
cycles. 
45 13.5 
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(Picus & Schultz 1999; Savarese et al. 2001; Gravis et al. 2003), grade 3/4 granulocytopenia 
(Petrylak et al. 1999; Savarese et al. 2001), and grade 3 and 4 myelosuppression (Sinibaldi et 
al. 2002; Oh et al. 2005) were reported. Other adverse effects reported in the phase1 and 2 trials 
included hyperglycaemia, grade 1 or 2!hypocalcaemia, hypophosphatemia, dermatitis, myalgia, 
nausea, emesis, fatigue, edema, diarrhoea , anorexia, myalgias, and mild alopecia (Kreis et al. 
1997; Picus & Schultz 1999; Savarese et al. 2001;  Sinibaldi et al. 2002; Gravis et al. 2003). 
Due to the side-effects associated with these therapies, the docetaxel regimens are only now 
applied to patients with CRPC (Puente et al. 2017). 
The current standard treatment of CRPC consists of a combination of docetaxel 
chemotherapy (75 mg/m2 every three weeks) with continued androgens suppression plus 10 
mg/day of prednisone (Delongchamps 2014). The latter is a corticosteroid that is administrated 
to manage the excessive mineralocorticoids-related side effects which arise because of 
CYP17A1 inhibition (Vasaitis et al. 2011). A study demonstrated by Sweeney et al. (2015) 
followed 790 patients with CRPC and showed that the combination of docetaxel (75 mg/m2) 
every three weeks with ADT treatment significantly prolonged the survival of patients by 13.6 
months compared with ADT alone, and the median time of biochemical, symptomatic or 
radiographic progression was 20.2 months in the combination group and only 11.8 months in 
ADT-alone group. In addition, the docetaxel plus ADT treatment group exhibited 27.7 % 
decrease in PSA levels to less than 0.2 ng/mL compared to 16.8 % in the ADT only group 
(Sweeney et al. 2015).  
As discussed by Sundararajan and Vogelzang (2014), several subsequent phase 3 
studies were conducted using docetaxel in combination with other agents, such as immune 
modulators, vascular endothelial growth factor receptor inhibitors, monoclonal antibodies, and 
tyrosine kinase inhibitors, none of which showed any improvement in the overall survival rates 
compared to the standard treatment using docetaxel and prednisone. One of these studies was 
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conducted by treating 1059 patients with docetaxel and prednisone in combination with 
lenalidomide or placebo (NCT00988208), the addition of lenalidomide did not demonstrate any 
improvement in overall survival and led to greater toxicity levels (Sundararajan & Vogelzang 
2014).  
The standard treatment used to treat patients with progressed CRPC after docetaxel 
treatment is cabazitaxel (25 mg/m2 every 3 weeks) in combination with ADT agents such as 
abiraterone acetate or enzalutamide (Nakouzi et al. 2015; Omlin et al. 2014; Sonpavde et al. 
2015). This second-generation taxane was proven by phase 1 and 2 trials that it has anti- 
tumour activity and increases overall survival, although toxicity is still considerable.  Many 
patients required the cabazitaxel dose to less than 25 mg/m2 in the trials (Pivot et al. 2008; Mita 
et al. 2009; Massard et al. 2017). De Bono et al. (2010), in a randomized phase 3 study 
comparing prednisone plus cabazitaxel to mitoxantrone in 755 males, demonstrated that overall 
survival was longer in cabazitaxel treated group than the mitoxantrone arm. However, the study 
also demonstrated that 82% of cabazitaxel treated males exhibited neutropenia compared to 
53% in the other group (de Bono et al. 2010). These results demonstrated the efficacy of 
cabazitaxel but at the price of increased levels of toxicity and adverse side effects compared to 
other agents and combinations. CRPC is still regarded as incurable and toxicity associated with 
chemotherapy agents results in poor quality of life (Hotte & Saad 2010). These reasons stress 
the urgent need for alternative approaches to treat PCa that confer less toxicity and more 
efficacy than chemotherapy drugs. 
1.6! Novel and targeted therapies 
 
Improvements in our biological and molecular knowledge of prostate cancer 
progression have transformed the way CRPC is managed, improving survival times and 
reducing unwanted side-effects (Macfarlane & Chi 2010).  
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1.6.1! Androgen-targeted new therapies 
CRPC is believed to be still driven by AR signalling and hence targeting this axis 
remains an important window for new therapies. For example, previous in situ hybridisation 
studies reported that 20–30% of  androgen-independent prostatic tumours exhibit AR gene 
amplification (Koivisto et al. 1997; Linja et al. 2001) and most of which showed an average 
of 6-fold higher expression than that of androgen-dependent tumours or BPH (Linja et al. 2001). 
This is thought to hypersensitise the pathway to the residual low levels of androgens that are 
synthesised by the adrenal gland and intra-tumoural steroid production (Osanto & Van 
Poppel 2012). For this reason, several AR targeting agents are in clinical use for the treatment 
of CRPC.  For example, CYP17 inhibitors (inhibition of adrenal androgen production, Table 
1.2 and 1.5) have been shown to be effective in CRPC (Sternberg 2012). Abiraterone acetate, 
for instance, has been demonstrated to improve the survival of CRPC patients that had 
experienced docetaxel failure (Altavilla et al. 2012). This family of inhibitors (e.g. abiraterone 
acetate and Orteronel) are still under investigation and on-going clinical trials are assessing 
their efficacy in combination with chemotherapies (Yoo et al. 2016).  
Orteronel inhibits the 17,20 lyase activity of the enzyme CYP17A1, which forms an 
important step of androgen synthesis in the testes, adrenal glands and prostate cancer cells (Van 
Hook et al. 2014). Orteronel possess greater specificity for 17,20 lyase over 17 hydroxylase and 
therefore appears to be more specific compared to abiraterone acetate (Alex et al. 2016). Phase 
3 studies have shown that this inhibitor increases progression-free survival (PFS) and reduces 
PSA levels, however, it did not enhance the overall survival when combined with 
chemotherapeutics (Fizazi et al. 2015).  
Other examples of newly developed ADT agents are Seviteronel (VT464) and 
Galeterone (Imamura & Sadar 2016). Seviteronel is a novel non-steroidal CYP17 inhibitor and 
AR-antagonist, it targets 17,20 lyase over 17α hydroxylase and blocks the AR variants F877L  
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Table 1.5 Novel androgens targeted dugs. 
Drug name Mechanism of action 
 
Status 
 
Abiraterone acetate Irreversible inhibitor of CYP17. 
Under clinical phase II 
study with apalutamide 
(NCT03360721). 
Orteronel (TAK-700) 
 
Inhibits the 17,20 lyase 
activity of the enzyme 
CYP17A1. 
Phase III double blind 
study with prednisone 
was completed in 2016 
(NCT01193244). 
Seviteronel (VT464) 
CYP17 inhibitor, AR 
antagonist, and reduces the 
intratumoral androgen levels. 
Multiple phase I/II and II 
studies. (NCT02012920), 
(NCT02445976), 
(NCT02130700). 
Galeteron (VN/124-1, TOK-
001) 
 
CYP17 inhibitor, AR 
antagonist, and decreases 
intratumoral androgen levels. 
 
Phase III compared to 
enzalutamide was 
terminated 2017 
(NCT02438007). 
Apalutamide (ARN-509) 
 
AR antagonist targets the AR 
ligand-binding domain and 
prevents AR nuclear 
translocation. 
 
Under clinical phase II 
with abiraterone acetate 
(NCT03360721). 
CFG920 CYP17A1 inhibitor.  
I/II phase studies 
completed, no further 
studies. 
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and T878A, which were shown to be correlated with resistance to enzalutamide and abiraterone 
acetate, respectively (Alex et al. 2016). Galeterone exerts a similar mechanism of action as 
Seviteronel, both have no inhibitory effect on 17α hydroxylase and hence have reduced side 
effects (Imamura & Sadar 2016). These and other ADP-based newly developed drugs are still 
under investigations and clinical trials, and they might be approved in future by FDA (Table 
1.5). 
In addition to new ADTs, new antiandrogens are also being developed.  AR-antagonists 
such as apalutamide and PAY1841788 (ODM-201) are new AR-targeting drugs that bind to  
the ligand binding domain of the AR and inhibit is nuclear translocation and hence halt the 
transcription of AR-target genes (Yoo et al. 2016). These new AR-antagonists were shown to 
have a good safety profile, antitumour activity and to reduce PSA levels (Smith et al. 2016; 
Shore 2017). These drugs are currently in clinical trials to elucidate their efficacy for CRPC. 
1.6.2! Cytotoxic and pathway-based agents 
ADT agents and third generation antiandrogens have proved to be effective for CRPC; 
however, resistance will occur in most cases ( Madan et al. 2011; Karantanos et al. 2013). For 
this reason, novel therapeutic strategies that do not target the AR pathway are needed. These 
include immunologic/vaccine therapies such as sipuleucel-T, ipilimumab and Prostvac, 
antiangiogenic molecules such as cabozantinib and tasquinimod, and cytotoxic agents such as 
platinum-based drugs (Mehta & Armstrong 2016). 
1.6.2.1! Novel vaccines and immunotherapies 
Vaccines and immunotherapies aim to utilise the hosts immune system to recognize and 
destroy cancer cells (Schweizer & Drake 2014). For example, the recently approved (2010) 
sipuleucel-T targets antigen-presenting cells (dendritic cells, APCs), on the basis of stimulating 
a T-cell immune response targeted against prostatic acid phosphatase (PAP), an antigen that is 
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highly expressed in most prostate cancer cells (Anassi & Ndefo 2011). Sipuleucel-T is 
specifically used to treated asymptomatic or minimally symptomatic CRPC without visceral 
metastasis, and several on-going clinical trials are investigating the efficacy of Sipuleucel-T 
with other agents (Wei et al. 2015). For example, an on-going phase 2 clinical study is 
investigating sipuleucel-T in combination with R223 for the treatment of asymptomatic or 
minimally symptomatic CRPC (NCT02463799). Sipuleucel-T-based therapy was found to 
increase the median survival by 4.1 months in  non-visceral CRPC patients when compared to 
placebo (Nussbaum et al. 2016). This is currently the only vaccine for PCa approved by the 
FDA, however an additional vaccine is also under development. The Prostvac vaccine is 
composed of vectors containing PSA and other T-cell stimulatory molecules (Singh et al. 2015) 
and it is in phase 3 clinical trials (Table 1.6).  
Immune checkpoint inhibitors, such as ipilimumab (an IgG antibody that binds to 
cytotoxic T-lymphocyte antigen 4 (CTLA-4) and increases anti-tumour T-cell responses 
(Festino et al. 2018)) have also been trialled in PCa.  Ipilimumab was shown to improve 
progression-free survival and reduce PSA levels, however it did not meet the endpoint of 
improved overall survival rates (Beer et al. 2017). Therefore, some phase 3 studies of 
ipilimumab were recently terminated (CA184095). 
1.6.2.2! Targeted alpha and beta-particle therapies 
Radioisotopes or radionuclides are particles emitting energy that can cause damage, so 
they are delivered to tumour cells to enhance their destruction (Waldmann 2003). Antibodies 
have been utilized to deliver alpha and beta-emitting isotopes specifically to tumour tissues 
(Brechbiel 2007). Targeted alpha and beta-particle therapies form the new era of radio-
immunotherapies for the treatment of PCa and other cancers. Wild et al (2011) discussed that 
several antibodies labelled with beta-emitting isotopes have been evaluated in PCa and limited 
success rates were reported. Due to lower energy and high travelling distances, more  
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Table 1.6 On-going PROSTVAC phase III clinical studies. 
Phase study code Drug name Study design 
 
Status 
 
NCT01322490 PROSTVAC 
Double blinded phase III of 
Prostvac -/+ GMC-SF in 
CRPC. 
Completed December 
2017, no results 
released. 
NCT02326805 PROSTVAC 
Phase II Randomised, 
Placebo-controlled trial of 
Prostvac. 
Not recruiting yet. 
NCT02933255 PROSTVAC 
phase II/I of Prostvac -/+ 
Nivolumab. 
Recruiting. 
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damaging/cytotoxic effects occur when a beta-emitter is used. Therefore, alpha-emitters have 
been recognised as a better alternative due to advantages such as higher linear energy transfer, 
minimum dependence on oxygen availability in tumour tissues, their shorter path length and 
ability to overcome radio-and chemo-resistance (Wild et al. 2011). 
 Several alpha-emitters have emerged over last few decades (Kozempel et al. 2018). A 
radioactive isotope called radium-223 dichloride (R223) is an example of an alpha-emitter. 
R223 was recently approved (2013) by the FDA for its benefit in increasing the overall survival 
of CRPC patients in the ALSYMPCA study (Hoskin et al. 2014). R223 is a calcium mimetic 
absorbed by bones that emits radiation to adjacent tissues and hence it is used to kill tumour 
cells in bone metastasises (Deshayes et al. 2017). The beneficial effect of this alpha-therapy 
was established by phase I, II, and III trial studies (Vogelzang 2017) and R223 was shown to 
enhance CRPC survival regardless of prior docetaxel use (Hoskin et al. 2014).  
1.6.2.3! Cytotoxic chemotherapies 
Since docetaxel’s introduction in 2004, research has aimed to improve the efficacy of 
chemotherapeutics for the treatment of PCa. Several cytotoxic chemotherapeutics emerged and 
are currently under clinical investigations (Yoo et al. 2016). Cytotoxic agents like carboplatin 
(a platinum-based drug) have been under clinical investigation. Carboplatin is an analogue of 
cisplatin which is suggested to act by inducing DNA damage through interaction with purine 
bases of the DNA, and hence stimulate apoptosis (Dasari & Tchounwou 2014). This drug was 
shown to led to a decrease in PSA levels, in 18% of patients, when combined with docetaxel in 
tumours that progressed after prior docetaxel treatment (Ross et al. 2007). However, elevated 
toxicity was also reported when carboplatin was combined with docetaxel in other studies 
(Bouman-Wammes et al. 2017). Minimal clinical efficacy was obtained when carboplatin was 
used in combination with the mTOR inhibitor everolimus in a phase II study (Vaishampayan et 
al. 2015). Other studies are currently on-going (NCT02311764, NCT01505868, and 
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NCT02598895) to evaluate its efficacious and anti-tumoural profile as a single and combined 
therapy. 
Another novel cytotoxic drug is osteodex (ODX), which is a bone-targeting  
polybisphosphonate used against metastatic CRPC. ODX was shown to have well tolerated  
toxicity and promising efficacy levels (Thellenberg-Karlsson et al. 2016). This drug is also 
under clinical phase 2 studies for further investigations of its efficacious properties and 
tolerability (NCT02825628). 
1.6.2.4! Gene-based and personalised therapies 
The anatomy of the prostate, the natural history of the disease, and the increased 
volume of knowledge in relation to the molecular basis of prostate cancer rendered it an 
attractive target for gene-based therapy (Patel et al. 2004). Several genes, that have been 
found to be up/down-regulated or mutated in prostate cancer cell lines and tumour tissues, 
are regarded as potential therapeutic targets for alternative novel therapies. An example of 
these is the gene TP53 which was found to be mutated in a subgroup of PCa patients 
(Heidenberg et al. 1995). The potent tumour suppressor activity of TP53 has made 
restoration of the wild-type function a promising anti-tumour approach for various cancers 
(Martinez 2010). Chen et al. (2014) discussed that several clinical trials were conducted 
using restoration of TP53 function and utilised a recombinant human serotype5 adenovirus 
to insert the wild-type TP53 gene to tumour cells. Gendicine was the first vector-based agent 
(Avp53) approved for clinical use of this strategy. These studies were carried out in several 
inactivated TP53 cancers and demonstrated that ectopic expression of TP53 wild-type led to 
induction of cell death and cell cycle arrest (Chen et al. 2014). In addition to TP53, a large 
number of other suppressor/activator mutations were associated with prostate cancer 
progression and could offer various strategies for novel therapeutics (Robbins et al. 2011; 
Taylor et al. 2010; Kan et al. 2010). 
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1.6.2.5! Alternative targets and pathways 
As mentioned above, inhibitors are being developed to target AR-independent pathways 
that have been shown to be critical for PCa progression. For example, antiangiogenic molecules 
such as cabozantinib and tasquinimod (Brower 2016; Patnaik et al. 2017), and signal 
transduction targeted agents such as everolimus (an mTOR inhibitor) (Templeton et al. 2013), 
are being developed. mTOR (target of rapamycin) is a serine-threonine kinase down-stream of 
PI3K (Laplante & Sabatini 2012; Soliman 2013). mTOR is implicated in signalling of protein 
synthesis, cell growth, proliferation, angiogenesis, and survival through the action of its 
complexes including mTORC1 and mTORC2 (Kaur & Sharma 2017). This signalling pathway 
is believed to be upregulated in CRPC and is hence a potential therapeutic target for progressive 
prostate cancer (Bitting & Armstrong 2013). However, inhibition of this pathway with 
everolimus was found to have a minimal effect on CRPC and led to an upregulation of AR-
signalling. For this reason, everolimus was subsequently combined with ADT/antiandrogens 
(Wang et al. 2008). For example, combination of this everolimus with the AR-antagonist 
bicalutamide, in a phase 2 study in bicalutamide-naïve CRPC patients, led to a significant PSA 
decrease ( $  50%) in 62.5% of patients with a median overall survival of 28 months, but adverse 
grade 3 and 4 events such as anaemia, hyperglycaemia, anorexia, abdominal pain, and nausea 
were reported in 58% of the patients (Chow et al. 2016). Combination of everolimus with 
docetaxel and bevacizumab was found to have similar outcomes to the bicalutamide study; the 
PSA decrease ($ 50%) was detected in 74 % of patients, overall survival was 21.9 months and 
adverse side effects were reported (Gross et al. 2018). The overall survival is higher in the latter 
combination study compared to docetaxel monotherapy (17-19 months) as shown in a separate 
study (Tannock et al. 2004).  
Tasquinimod is another therapeutic that is being developed for the treatment of PCa that 
has a unique mechanism of action. Tasquinimod targets  specific immunosuppressive and pro-
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angiogenic cells called the myeloid-derived suppressor cells (MDSCs) and inhibits their 
immune and angiogenic properties (Mehta & Armstrong 2016). This therapeutic inhibits the 
immunosuppressive properties of the tumour microenvironment by modulating specific 
interactions between MDCSs and the tumour cells (reviewed in (Raymond et al. 2014)). The 
preclinical studies of this agent demonstrated its success in exerting immunomodulatory and 
anti-angiogenic activity against CRPC, hence it has been in the final stages of clinical 
development for the treatment of this disease (Gupta et al. 2014). A double blinded global phase 
III study of this agent compared to placebo demonstrated improved progression-free survival 
(PFS) (median of 7 months and 4.4 months, respectively) in chemotherapy-naïve men with 
metastatic CRPC, however no benefit in overall survival was observed and significant side-
effects were again described (Sternberg et al. 2016).  
Cabozantinib is a tyrosine kinase inhibitor and regarded as a novel anti-angiogenic agent 
for CRPC that is currently still under investigation (Patnaik et al. 2017). This drug blocks 
several growth associated kinases, including hepatocyte growth factor receptor (HGF) and 
vascular endothelial growth factor (VEGF), that were demonstrated to be associated with PCa 
progression and bone metastasis (Fay et al. 2015). This novel approach of inhibiting these 
signalling pathways is based on the rationale that therapy resistance in metastatic cancer induces 
hypoxia, which in turn upregulates HGF and VEGF levels resulting in angiogenesis and 
stimulation of invasion (Vaishampayan 2014). Phase II trial studies in CRPC patients 
demonstrated that cabozantinib enhanced PFS and showed other encouraging anti-tumoural 
activity (Smith et al. 2013; Smith et al. 2014). However, a recent phase III study investigating 
the efficacy of this agent in chemotherapy-naïve CRPC patients demonstrated that the agent 
improved PFS but did not improve the PSA decline or overall survival in comparison with 
prednisone (Smith et al. 2016). Another phase III study of this agent combined with docetaxel 
and prednisone is on-going (NCT01683994). 
 
 
73 
More recently, a new poly-adenosine diphosphate-ribose polymerase (PARP)- 
inhibitor called olaparib, which was approved by FDA for certain ovarian and breast cancers 
with BRCA1/2 mutations (DNA repair aberrations) (Kim et al. 2015; Robson et al. 2017), 
have been in phase II/III clinical trials (NCT0347135, NCT0239893917, NCT02987543) to 
evaluate its anti-tumour activity in metastatic CRPC. A recent study by Meteo et al. (2015) 
showed that this agent induced a high response rate (33 %) in CRPC patients, and next-
generation sequencing demonstrated that this response was associated with deleterious 
mutations in the BRCA1/2 genes. These results are promising as this gene-targeted therapeutic 
approach could offer sustained responses for the right subgroup of patients, according to their 
genetic profiling, but this approach would be made more beneficial if incorporated with precise 
biomarkers that can identify such genetic alterations (Mateo et al. 2015).  
1.7! Metabolism of cancer as a therapeutic window 
 
An emerging field for novel cancer treatment strategies is tumour metabolism which is 
regarded as a hallmark of cancer ( Kroemer & Pouyssegur 2008; Deberardinis et al. 2008; 
Hanahan & Weinberg 2011;  Ros et al. 2012; Vander Heiden 2013; The Deberardinis 2014; 
Yizhak et al. 2014). The survival of cancer cells can be linked directly to altered metabolism 
for example by increasing aerobic glycolysis and lipogenesis (Costello & Franklin 2000; 
Benedettini et al. 2008; Ward & Thompson 2012; Wu et al. 2014). Several decades ago Otto 
Warburg observed that cancer cells convert pyruvate into lactic acid even in the presence of 
oxygen (termed the Warburg effect) (Warburg 1956). This switch to aerobic glycolysis sustains 
high energy levels in cancer cells as it makes 100 times more ATP than mitochondrial 
respiration, but this is associated with higher glucose consumption (Valvona et al. 2016). 
Oxidative phosphorylation generate 36 ATP molecules per one molecule of glucose, whereas 
aerobic glycolysis generates two ATP molecules per one glucose molecule (Vander Heiden et 
al. 2009). Such metabolic alterations could be seen as  consequences of the genetic aberrations 
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that arise sporadically or as a result of harsh tumour microenvironment conditions such as 
hypoxia and poor nutrient availability (Cutruzzolà et al. 2017). Understanding the basis of 
metabolic alterations in relation to tumorigenesis and metastasis have made cancer metabolism 
an attractive area of research in cancer biology and drug discovery. Generally, how metabolic 
reprograming occurs, which pathways are altered, and how they can be exploited for the 
invention of novel and beneficial cancer therapeutics form the main questions in the current 
research. 
Drugs targeting altered cellular metabolism in cancer is not a new approach.  Many 
metabolic reprograming strategies have been translated into successful treatment regimens. For 
example, asparaginase, an enzyme that converts asparagine to aspartic acid and degrades 
glutamine (DeBerardinis & Chandel 2016),  is a therapeutic target for lymphoblastic leukaemia 
(LL) and other types of lymphomas (Salzer et al. 2017). Inhibitors of this enzyme have been 
shown to improve event-free survival in children with ALL, which relies on asparagine for its 
high rate of protein synthesis and growth (Clavell et al. 1986).  
1.7.1! Metabolism in normal and tumour cells 
Metabolism has been an attractive axis to treat cancers because metabolic pathways are 
significantly altered in tumours to suit tumour growth and survival (Figure 1.12) (Vander 
Heiden 2013). However, cancer cell metabolism is altered in a heterogeneous manner according 
to several factors including tumour type, conditions inside the tumour, and nutrients available 
(Vander Heiden 2011). Therefore, therapeutics that target a metabolic pathway in one cancer 
may not work in others. Normal non-replicating cells maintain low ATP production via 
glycolysis (oxidative phosphorylation) to sustain homeostatic processes, however, proliferating 
cells would require energy not only for the replication process but further to support the 
anabolic requirements for macromolecule biosynthesis as well as to maintain cellular redox 
homeostasis to neutralize the toxic effect of reactive oxygen species (ROS) generated  
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Figure 1.12 Metabolism of normal cell versus cancer cell. 
Schematic shows the metabolic remodelling of cancer cells to maintain their growth and survival. 
Normal cells (blue) usually perform complete breakdown of glucose in presence of oxygen (O2) into 
acetyl-CoA that enters the mitochondria for the respiratory cycle and ATP synthesis. Cancer cells (red) 
attenuate the conversion of pyruvate into acetyl-CoA in presence and absence of oxygen and instead 
produce lactate. Cancer cells use other sources for biosynthetic precursors such as glutamine, fatty acids, 
and other non-essential amino acids to maintain the tricarboxylic acid (TCA) cycle for ATP and 
macromolecule synthesis.  
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(Cantor & Sabatini 2012).  
One of the best-known modifications in cancer metabolism, observed in 1920 by 
Warburg, is aerobic glycolysis (DeBerardinis & Chandel 2016). Aerobic glycolysis is 
associated with increased lactate production, regardless of the amount of oxygen available, 
which normally only occurs in hypoxic conditions in normal cells (Koppenol et al. 2011). 
Tumour cells convert glucose to lactate despite the fact that this process is far less efficient in 
energy production (ATP) compared to typical oxidation of glucose to pyruvate (Vander Heiden 
et al. 2009). The glycolytic use of glucose provides cancer cells with essential glycolytic 
intermediates that feed the metabolic demands of tumours (Lunt & Vander Heiden 2011). 
Glycolysis is induced to meet the ATP required by cancer cells, and glycolysis’ carbon 
forms the main resource of building blocks for fatty acid and nucleotide biosynthesis (Romero-
Garcia et al. 2011). Therefore, the switch of cancer cells to fermentative metabolism of glucose 
was suggested to predominantly support the accumulation of biomass and maintenance of redox 
state (Cantor & Sabatini 2012). 
Reprogramming of glucose metabolism is not sufficient to explain all of the alterations 
required for cancer cell survival and growth. For example, increased glutamine metabolism and 
elevated fatty acids synthesis are additional alterations associated with tumour metabolic 
reprogramming (Zhao et al. 2013). Cancer cells utilise nitrogen derived from glutamine to 
generate nucleotides, non-essential amino acids, and hexoamines (Zhu et al. 2017). Further, as 
the tricarboxylic acid (TCA) cycle provides several intermediates that can be redirected to 
biosynthetic and NDPH-generating pathways, proliferating cells are able to utilise these 
intermediates and maintain TCA through glutamine anaplerosis (Wise & Thompson 2010). The 
latter occurs through either glutamine conversion to glutamate which enters TCA cycle as a-
ketoglutarate (a-KG) or via the carboxylation of pyruvate derived from glycolysis into 
oxaloacetate (Figure 1.11) (Cantor & Sabatini 2012; DeBerardinis & Chandel 2016).  
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An increase in metabolite flux in tumours can occur as a result of the oncogenic 
activation or loss of several suppressors of specific genes, especially those affecting glucose 
and glutamine uptake and catabolism, including mutations in MYC, HIF1a, TP53, the Ras-
related oncogenes, and the LKB1-AMP kinase (AMPK), and PI3 kinase (PI3K) signalling 
pathways (Wu et al. 2015; Boroughs & DeBerardinis 2015). One of the most important 
signalling pathways associated with metabolism is the PI3K-Akt-mTOR pathway, which is 
frequently altered in malignancies (Dienstmann et al. 2014). This pathway is triggered by 
growth factors that stimulate PI3K (phosphatidylinositol 3-kinase) and downstream Akt (Alpha 
Serine-Thrionine Kinase) and mTOR (mammalian target of rapamycin) pathways, which in 
turn initiate anabolic processes including increased glycolytic flux and fatty acid production 
following activation of HIF-1 (hypoxia-inducible factor–1) and SREBP (sterol regulatory 
element–binding protein), respectively (Dibble & Manning 2013). The PI3K-Akt-mTOR 
pathway is vital for cell survival in stress conditions, and as cancer cells emerge under such 
conditions, this pathway appears crucial for metabolic reprogramming in tumours (Porta et al. 
2014). Activation of this cascade has been found to enhance the expression of GLUT1, a glucose 
transporter, and translocation of its encoded protein to the plasma membrane (Wieman et al. 
2007). In addition, Akt also promotes the activity of hexokinases (HK) which phosphorylate 
glucose to abrogate its extracellular efflux (Elstrom et al. 2004; Engelman et al. 2006; Porta et 
al. 2014). Further, exogenous expression of constitutively active Akt was found to promote cell 
survival and maintain growth and homeostasis in growth factor deprived medium (Plas et al. 
2001). 
1.7.2! Metabolic pathways as novel therapeutic targets 
As described above, metabolism is known to be distorted in malignant cells and 
therefore suggested to be a novel therapeutic approach to inhibit cancer cell proliferation with 
minimal effects upon normal cells. Inhibitors for several metabolic pathways are already in  
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development/clinical trials. 
1.7.2.1! Targeting glucose and glutamine  
Metabolic alterations are heterogeneous and occur according to the tumour 
microenvironment and nutrient availability. However, there are some common metabolic 
features shared between most cancers such as the alterations in glucose, glutamine, and 
mitochondrial metabolism (Kishton & Rathmell 2015). These hallmarks may provide targeting 
strategies to halt cancer proliferation and survival. Cancer genes can drive metabolic 
reprogramming in malignant cells, also several essential enzymes/proteins that regulate these 
metabolic pathways are found to be overexpressed/mutated in such cells (Dang 2012). For 
example, the glucose transporters GLUT1 and GLUT3 are found to be oncogenically mutated 
to allow high glucose uptake for cancer cells (Ganapathy-Kanniappan 2013), and other factors, 
such as those in the PI3K-Akt-mTOR pathway, are also mutated to further stimulate glucose 
consumption in malignant cells (Chen et al. 2016). Importantly, inhibition of factors involved 
in glucose or glutamine metabolism does attenuate the proliferation of cancer cells (Liu et al. 
2012).  
Various glutamine metabolism targeting agents have been investigated, however, 
similar to glycolysis inhibitors, the majority of compounds were found to have significant 
effects upon non-tumorigenic cells and hence only preclinical testing was performed 
(Ganapathy-Kanniappan 2013; Altman et al. 2016). Despite this, many other metabolic 
inhibitors have been approved for cancer treatment or are under clinical trials. For example, the 
glutamine metabolism inhibitor CB-839 (targeting the glutaminase enzyme which converts 
glutamine to glutamate) has been shown to have anti-tumour activity in several cancers (Gross 
et al. 2014; Jacque et al. 2015; Biancur et al. 2017), and is under clinical trials for further 
validation for solid tumours, lymphoid, and myeloid malignancies (NCT02071862, 
NCT02071888 and NCT02071927) (Fung & Chan 2017). 
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1.7.2.2! Targeting macromolecules synthesis and specific genetic alterations 
Apart from targeting glucose and glutamine, other metabolic targeting strategies include 
inhibition of macromolecule synthesis, such as inhibition of nucleotide and fatty acid synthesis 
(Nishi et al. 2016; Shuvalov et al. 2017). Nucleotide synthesis forms an important part of cell 
division and proliferation, hence it gained interest as a potential novel strategy to halt cancer 
growth. The inhibition of enzymes implicated in nucleotide base synthesis by small molecules 
that mimic nucleotide metabolites (antimetabolites) has been a successful strategy to treat 
cancer for many years (Farber et al. 1948). Recent examples of such antimetabolite molecules 
are gemcitabine and cytarabine, which inhibit DNA-polymerase activity and these are currently 
being utilized to treat several cancers (Luengo et al. 2017). 
An example of successful inhibitors that halt fatty acid synthesis is the fatty acid 
synthase (FASN)-inhibitor (TVB-2640) that is currently under clinical trials (NCT02980029, 
NCT03032484, NCT03179904) (Alwarawrah et al. 2016). FASN is over-expressed in cancer 
and its inhibition selectively induced apoptosis and abrogated growth and viability in xenograft 
tumour models (Heuer et al. 2017).  In addition to these therapeutics, mitochondrial complex, 
asparagine synthesis and glutamine synthesis inhibitors are also under investigation (Luengo et 
al. 2017).  
1.7.3!  The potential side-effects of metabolism inhibition 
Most of the currently used chemotherapeutics and radiation-based therapies result in 
cytotoxicity to normal cells as well as to cancer cells (Kalyanaraman 2017), which results in 
acute side effects that affect the patient’s quality of life. This highlights the need for therapeutics 
that are selective for cancer cells with minimal effects on normal tissues. Using metabolic 
inhibition as strategy to treat cancers has proven to be effective, however toxicity is common 
with such agents because of the shared pathways and signalling between cancer and normal 
tissues (DeBerardinis & Chandel 2016). For example, inhibition of Pyruvate Dehydrogenase 
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Kinase 1 (PDK1), an enzyme commonly activated in solid tumours that deactivates the 
mitochondrial pyruvate dehydrogenase complex and thereby decreases the flow of pyruvate 
used by the TCA cycle, by the PDK-inhibitor dichloroacetate (DCA), was demonstrated to 
have good therapeutic activity against some cases of brain cancer.  However, nerve toxicity 
was reported in some studies and the use of the therapy has therefore been restricted to 
selected patients (Muñoz-Pinedo et al. 2012).  
Another example is L-asparaginase, which resulted in significant toxicity when it was 
used to treat pancreatic cancer patients (Lessner et al. 1980). Glutamine inhibition also 
exhibited a toxicity profile. For example, phase I study on relapsed leukaemia patients 
demonstrated that the glutaminase inhibitor CB-839, that shows a potent anti-tumour activity 
as indicated earlier, is associated with grade 1 and 2 toxicities such as transaminitis, 
thrombocytopenia, gastrointestinal events, and fatigue and one third of patients showed grade 
3/4 toxicities like hematologic cytopenia (Wang et al. 2015). However, CB-839 combination 
with paclitaxel showed tolerable side effects in triple negative breast cancer patients (Fung & 
Chan 2017).  
In addition, several agents that target the Warburg effect/glycolysis and lipogenesis 
have been established but none have reached the clinic due to their off-target effects. These 
side-effects including significant weight loss and were also found to have reduced efficacy in 
vivo (Muñoz-Pinedo et al. 2012). It was discussed by Pelicano et al.  (2006) that it has proved 
difficult to predict the side-effects of glycolytic inhibitors especially in tissues that rely upon 
glucose as a main energy source such as the brain, testis, and retinae. The utilization of 
alternative sources such as amino acids and fatty acids by such tissues when glycolytic pathway 
is impaired remains unknown and warrants further investigation (Pelicano et al. 2006). 
Therefore, the specificity of the chosen pathways to be inhibited should be restricted to those 
that are crucial for the proliferation of cancer cells but not normal cells. This can be challenging 
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as different tumours and different foci of the same tumour can have different adaptations to suit 
their survival.  
Minimisation of side-effects might be achieved through the use of combinational 
therapeutic strategies; the standard therapy (chemotherapy) plus metabolic inhibition might 
form an important rational to maximize efficacy of such treatments and minimize the associated 
toxicity to normal cells (Kalyanaraman 2017). In addition, the heterogeneity in genetic and 
epigenetic changes that occur in the tumour cell population, which changes over time because 
of genetic instability, also provides a rationale for targeting multiple genes/pathways found to 
be altered in a given tumour (Pelicano et al. 2006). It is therefore important that customized 
treatments regimens, adjusted according to the type and the stage of the tumour and the common 
genetic/pathways reprograming to eradicate all malignant cells with minimum off-target 
effects, are developed.  
1.7.4! Metabolism of normal prostate  
Typically, in normal mammalian cells, the complete oxidation of glucose or fats occurs 
by generating citrate that enters the Krebs cycle for ATP synthesis and this is coupled to the 
generation of various Krebs cycle intermediates which are employed in biosynthetic pathways 
(Costello & Franklin 2000). In prostate tissues (especially epithelial cells in the peripheral zone) 
this is different. Prostate epithelial cells synthesise citrate and do not oxidise it; instead 
accumulation of citrate take place in these cells as high citrate levels are a constituent of semen 
(Dakubo et al. 2006). The increased levels of citrate is also accompanied with zinc accumulation 
(Figure 1.12) (Costello et al. 2004). Zinc is transported to the cells from the extracellular space 
by the ZIP family of plasma membrane transporters, and distributed to different organelles via 
the ZnT (slc30A) intracellular transporters (Costello & Franklin 2016).  
The accumulation of zinc in prostatic tissues have an essential role in inhibiting the 
enzyme aconitase that catalyses the oxidation of citrate into isocitrate to complete the Krebs 
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cycle energy production process (Figure 1.12) (Eidelman et al. 2017). However, as discussed 
by Costello and Franklin (2000) the cells of the central zone of the prostate do not accumulate 
zinc and still carry out the citrate-oxidation like other mammalian cells.  
In other mammalian cells, enzymes such as phosphofructokinase (PFK) are inhibited by 
high concentrations of citrate and hence glycolysis is halted in a negative feedback loop.  
However, this is also different in the prostatic glandular cells, which retain high citrate levels 
but still demonstrate high glycolysis levels (Costello & Franklin 2000). This may be explained 
by the utilization of aerobic glycolysis (Figure 1.13) (Wu et al. 2014). Costello and Franklin 
(2016) indicated that citrate and zinc levels in prostatic epithelial tissues are significantly 
greater than other soft tissues, 30-80 and 10-20-fold respectively. The synthesis of citrate and  
zinc does occur in all other types of cells, however citrate is predominantly produced in 
mitochondria and used in the Krebs cycle or delivered to the cytosol and converted to acetyl-
CoA for lipid synthesis, but accumulations of these ions are only seen in prostatic tissues 
(Costello & Franklin 2016). More interestingly, the peripheral zone where citrate and zinc are 
accumulated is where prostatic cancers usually develop (Sinnott et al. 2015; Wernert et al. 
2011). These observations demonstrate that the prostatic tissues harbour unique  
metabolic modifications to maintain their secretory functions, however the role of citrate in 
prostatic cells and prostatic secretions is not completely understood. 
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Figure 1.13 Regulation and maintenance of specific metabolic signalling in normal/benign 
prostatic cells. 
The secretory function of epithelial cells in the peripheral zone requires adaptive metabolic modification 
to suit their roles. The citrate formed in Krebs cycle is not completely oxidised and instead it is 
accumulated and secreted into cytosol to be used in lipogenesis or to be a part of the prostatic fluids. 
This is regulated by increased zinc concentrations which deactivate acotinase enzyme that perform 
citrate oxidation in the Krebs cycle.  
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1.7.5! Metabolic alterations in prostate cancer 
1.7.5.1! Citrate metabolism and aerobic glycolysis in prostatic carcinomas 
As discussed, prostatic epithelial cells in the peripheral zone of the prostate accumulate 
zinc and citrate. However, in prostate cancer it is reported that zinc levels are reduced, and this 
is associated with citrate oxidation and Krebs cycle progression to supply malignant cells with 
energy (Franz et al. 2013). The expression of zinc transporters (e.g. ZIP1) are also down-
regulated in prostatic adenocarcinomas compared to intact prostatic issues (Franklin et al. 2005; 
Costello et al. 2011). This phenotype (citrate complete oxidation through the Krebs cycle and 
a reduction of zinc levels) is seen in prostate cancer cells, especially in the early stages, rather 
than the Warburg effect ( Zadra et al. 2013; Sadeghi et al. 2015; Twum-Ampofo et al. 2016) 
which is present in most other cancers (Ganapathy-Kanniappan & Geschwind 2013; 
Deberardinis 2014; Kishton & Rathmell 2015). Therefore, most early prostatic cancers do not 
rely on aerobic glycolysis for energy and biomass production, instead they use citrate oxidation 
in the Krebs cycle and resumed oxidative phosphorylation as well as fatty acids and protein 
catabolism, however, late stages of PCa, when large numbers of mutations and modifications 
take place, utilise the Warburg effect (aerobic glycolysis) (Eidelman et al. 2017).   
1.7.5.2! Amino acids in prostate cancer 
As discussed above, glutamine forms an essential fuel for many cancers and PCa is 
known to utilise amino acids for ATP and macromolecule biosynthesis. Further, the expression 
of glutaminase-1, an enzyme that carries out glutaminolysis, is found to correlate with PCa 
progression (Pan et al. 2015). The glutamine transporter ASCT2 (Alanine, serine, cysteine-
preferring transporter 2) is also over-expressed in PCa, and the inhibition of this protein was 
associated with reduction of glutamine intake and cell cycle progression in vitro and decreased 
PC-3 xenografts growth and metastasis in vivo (Wang et al. 2015). In addition, other amino 
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acids might be important for PCa growth. For example, arginine was proposed as a potential 
target for the treatment of PCa since this strategy had been shown to be effective in inhibiting 
other cancers (Eidelman et al. 2017). However, its depletion did not show a significant 
induction of apoptosis in PCa cell lines (Kang et al. 2000; Hsueh et al. 2012). This is may be 
explained by the fact that these cell lines express argininosuccinate synthetase (ASS), which 
carries out the de novo conversion of citrulline into arginine. Hence, arginine depletion might 
be more effective in tumours lacking ASS expression (Feun et al. 2008). In addition, 
transporters of amino acids such as L-type amino acids transporters (LATs) are over-expressed 
in all stages of PCa and their knockdown inhibits cell growth, cell cycle progression, and 
metastasis in vivo (Wang et al. 2013). This suggests the importance of the alteration of amino 
acid metabolism in PCa progression.  
1.7.5.3! Lipids metabolism and prostate cancer progression 
Another essential cellular energy source utilized by PCa cells is lipids. PCa cells 
regulate lipids synthesis and/or uptake by androgens (Butler et al. 2016). However, at some 
stages (CRPC) PCa cells are able to synthesize lipids independently from androgens probably 
through the reactivation of AR-signalling by elevated expression of AR splice variants (Han et 
al. 2018). The latter is linked to poor prognosis in prostatic carcinomas and other cancers (Butler 
et al. 2016). De novo lipid synthesis is correlated with the over-expression of certain lipogenic 
enzymes (probably due to oncogenic aberrations) such as fatty acid synthase (FASN) and α-
methylacyl-CoA racemase (AMACR), which convert long branched fatty acids to a form that 
facilitates "-oxidation (Wu et al. 2014). In addition, androgens are suggested to enhance fatty 
acid synthesis by increasing the activity of lipogenic enzymes (Swinnen et al. 1997). It was also 
found that the expression of multiple factors involved in lipid synthesis (ATP citrate lyase 
(ACLY), acetyl-CoA carboxylase α (ACACA), FASN, long chain fatty acyl-CoA synthetases 
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1, 3 and 5 (ACSL1, ACSL3, ACSL5) and sterol regulatory binding protein 1 (SREBP1)) are 
increased in PCa (Wu et al. 2014).  
Alterations in the synthesis and metabolism of lipids can occur as a consequence of 
several oncogenic events including deactivation or loss of PTEN, Akt activation, loss or 
mutation of TP53 or BRCA1, steroid hormone action, and intra-tumoural hypoxic conditions 
(Butler et al. 2016). Lipids in PCa cells undergo "-oxidation for energy production, stored as 
intracellular lipid droplets, or form phospholipids for membrane synthesis supporting cell 
growth and survival (Butler et al. 2016). 
An important type of lipid for prostatic cell growth is cholesterol, which is an essential 
precursor of androgens synthesis as well. The accumulation of cholesterol has also been linked 
to the aggressiveness of PCa (Pelton et al. 2012). For example, Yue et al. (2014) found that 
high-grade PCa cells were found to have an increase in lipid droplets consisting of esterified 
cholesterol and this increase was linked to stimulation of the PI3K-Akt pathway and loss of 
PTEN activity; the latter is a tumour suppressor found to be commonly deleted/mutated in PCa 
and is associated with disease progression and poor prognosis (Geybels et al. 2017). 
Additionally, the depletion of esterified cholesterol led to a reduction in cell proliferation, 
invasion and the growth of mouse tumour models (Yue et al. 2014). These data suggest that 
lipids including cholesterol and fatty acids form an important energetic source for PCa (Liu 
2006) suggesting that they might be good targets for novel therapies and many may be useful 
prognostic biomarkers. 
1.7.6! Targeting novel metabolic reprograming in CRPC 
Several attempts have been made to target metabolic signalling in advanced prostate 
cancer. For instance, fatty acids synthesis factors were targeted to enhance the sensitivity of 
PCa to conventional therapies such as AR-antagonism. An example is a study conducted by 
Shah et al. (2016) which demonstrated that inhibition of ATP-citrate lyse (ACTL), an enzyme 
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implicated in fatty acids synthesis, decreased AR levels, inhibited proliferation, and promoted 
apoptosis of PCa cells when used with AR-antagonists. More recently, a model of invasive and 
metastatic PCa cells (PC3) was used to measure the accumulation and metabolism of long chain 
fatty acids. The study showed that these cells had enhanced metabolism and transport of the 
long chain fatty acids into the mitochondria. Further, inhibition of this transportation into the 
mitochondria inhibited PC3 proliferation (Marín de Mas et al. 2018).  
Apart from targeting lipids biosynthesis, amino acids essential for PCa such as 
glutamine are also still under investigation. A recent study demonstrated that inhibition of the 
glutamine transporter ASTC2 led to glutamine uptake inhibition, mTOR pathway deactivation, 
and growth inhibition of PC3 xenografts (Wang et al. 2014). This suggests that metabolism of 
fatty acids, amino acids and other metabolic factors are potential therapeutic targets for CRPC 
that warrant further investigation.   
1.8! Induction of tumour cell death  
 
Targeted therapies for the treatment of cancer usually arise from the investigation of the 
molecular pathways implicated in cell growth and cell death (Ricci & Zong 2006). Tumours 
are treated with agents that enhance cell death, and the mechanism by which cancer cells die 
does not strictly mean apoptosis or programmed cell death. Chemotherapeutics, for example, 
can promote cell death through several mechanisms including necrosis, autophagy, and mitotic 
catastrophe (Ricci & Zong 2006). In normal cells, the decision on which of these cell death 
pathways will be used is linked to many factors such as the type of tissue, physiological nature, 
developmental stage and the type of death signal (Elmore 2007). However, in the case of cancer, 
apoptosis is defective and therefore unfavoured conditions such as metabolic stress or hypoxia 
often cannot induce the apoptotic cascade. This can therefore lead to therapy resistance (Jin et 
al. 2007). Inhibition of apoptotic pathways is a general phenomenon by which most cancers 
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promote their survival, and targeting pro-apoptotic factors is a strategy to overcome tumour cell 
survival and resistance to anti-cancer drugs (Rivera et al. 2017).  
1.8.1! Defective apoptosis and cancer 
Apoptosis is a well characterised form of programmed cell death (Rastogi et al. 2009). 
The process can be defined as a series of events that result in phenotypical changes including 
cell membrane blebbing, cell shrinkage, chromatin condensation, DNA fragmentation, loss of 
adhesion to other cells or the extracellular matrix and finally formation of apoptotic bodies 
which are engulfed by macrophages or neighbouring cells (Ouyang et al. 2012). There are two 
pathways that can induce apoptosis: the intrinsic and extrinsic pathways (Figure 1.14). The 
former take place as a result of intracellular stimuli, such as DNA damage and oxidative stress, 
where pro-apoptotic bcl2 factors (such as Bax, Bak, and Bid) initiate the permeabilisation of 
mitochondrial membranes which in turn results in the release of apoptotic proteins including 
cytochrome c, Smac/DIABLO, Omi/HtrA2, apoptosis-inducing factor (AIF) and endonuclease 
G. The latter proteins induce either caspase-dependent or caspase-independent cell death 
effectors (Fulda & Debatin 2006).  
In the case of caspase-dependent apoptosis, caspase 3 is activated by the formation of 
the cytochrome c/ABAF-1/caspase 9 apoptosome complex, which subsequently cleaves several 
substrates leading to apoptotic cell death (Figure 1.14). Saelens et al. (2004) stated that the 
caspase-independent pathway occurs through the nuclear translocation of AIF and 
endonuclease G, which mediate DNA-fragmentation. SMAC/Diablo and Omi/HtrA2 are 
suggested to play roles in caspase-dependent apoptosis, and may induce caspase-independent 
cell death (Saelens et al. 2004). SMAC/Diablo is found to be released under conditions that 
induce apoptosis which suggests that it is required in this cell death modality (Maycotte et al. 
2008). It is a positive regulator of apoptosis by activating caspases and by inhibiting IAPs. A 
recent work by Paul et al. (2017) demonstrated that SMAC/Diablo has implicated in lipid  
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Figure 1.14 Intrinsic and extrinsic apoptosis pathways. 
Apoptosis can occur in two ways according to the type of stimuli. Intrinsic pathway is initiated by 
intracellular stimuli like DNA damage which triggers TP53 apoptotic activity and caspase cascade take 
place. The other type of apoptotic pathways is the extrinsic cascade which is stimulated upon death 
signal that enhance ligands to bind to death receptors leading to recruit adaptor molecules such as Fas-
associated death domain (FADD) followed by caspase 8 and caspase 3 cleavage and activation. 
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biosynthesis when silenced by siRNAs, it led to reduction of phospholipids and next generation 
sequencing analysis of SMAC/Diablo silenced tumour tissues was associated with altered 
expression of genes related to cellular membrane and extracellular matrix of genes associated 
with lipid, metabolite, and ion transport. These findings suggested non-apoptotic functions for 
SMAC/Diablo; it is essential for lipid biosynthesis and cancer cell progression which also could 
explain its overexpression profile in tumours (Paul et al. 2017). 
Extrinsic apoptosis (Figure 1.14), as explained by Fluda and Debatin (2006), is induced 
by extracellular stimuli such as tumour necrotic factor-a (TNFa), first-apoptotic signal receptors 
(FasR) ligands e.g. CD95/APO1, or TRAIL (TNF related apoptosis inducing ligand) which 
bind to death receptors of the tumour necrotic factor receptors (TNFR) superfamily. TNFR, 
following ligand binding, form dimers activating the death domains, which in turn recruit 
adaptor molecules such as Fas-associated death domain (FADD) (Su et al. 2015). The latter 
then recruits procaspase-8/10 to form the death inducing signalling complex (DISC) leading to 
caspase-8 activation which in turn cleaves caspase-3 and the rest of apoptotic pathway (Fulda 
& Debatin 2006). 
Genetic aberrations in several pro-apoptotic or anti-apoptotic factors is a hallmark of 
carcinogenesis (Fernald & Kurokawa 2013), for example mutations in TP53 (Lowe & Lin 
2000). It was explained by Fridman and Lowe (2003) that cellular stresses such as DNA 
damage, hypoxia, or aberrant oncogene expression promote TP53 activity which can block 
cell-cycle progression and promote DNA repair, cellular senescence, or apoptosis according 
to the damage level. Therefore, defective TP53 can result in checkpoint defects, genomic 
instability and abnormal survival, resulting in the uncontrolled proliferation and evasion of 
apoptosis (Fridman & Lowe 2003). TP53 regulates the transcriptional activity of a number 
of pro-apoptotic factors including Puma, Noxa, Bim, Bid, Bik, Bak, Bax, Apaf-1, Bmf, Hrk, 
Pag608, Drs, Fas and Gadd45, and is therefore directly linked to the activation of 
 
 
91 
mitochondrial membranes to release apoptotic factors and hence induce apoptosis (Rastogi 
et al. 2009; Miyashita et al. 1994). 
Genetic alterations resulting in over-expression of anti-apoptotic proteins or down-
regulation of pro-apoptotic factors are also directly related to impaired apoptosis (Placzek et 
al. 2010; Ionov et al. 2000). The anti-apoptotic phenotype of tumours then can be a result of 
the deregulation of apoptotic gene expression which might occur downstream of cell 
checkpoints like TP53 or other genes that could induce the release of these factors by 
affecting mitochondrial membrane integrity (Rastogi et al. 2009). These genetic alterations 
affect cell fate not only in the development of neoplastic cell populations but also in drug-
resistance phenotypes. 
1.8.2! Non-apoptotic cell death pathways  
Necrosis is a non-apoptotic form of cell death that occurs as a result of irreversible injury 
as a consequence of pathogens or extreme conditions such as hypoxia, heat, or radiation 
(Adigun & Bhimji 2017). Necrosis manifests phenotypic changes that include cytoplasmic 
swelling, irreversible plasma membrane injury, organelle damage and random degradation of 
DNA (Festjens et al. 2006). This type of cell death is usually accompanied with the release of 
the cells contents together with cytokines, resulting in inflammation (Kanduc et al. 2002). 
Importantly, it has been suggested that necrotic cell death could be exploited as a therapeutic 
strategy to kill cancer cells when apoptotic cascades are deactivated (Festjens et al. 2006).  
Necrosis is known to be caspase-independent because treatment of cells with TNF%, a 
cytokine produced by macrophages that induces apoptosis, resulted in necrosis induction when 
caspases were inhibited in embryonic fibroblasts (Lin et al. 2004). Similarly, inhibition of 
caspases also enhanced TNF%-induced necrosis in L929 fibrosarcoma cells (Vercammen et al. 
1998). Further, FasR ligand in caspase 8 deficient Jurkat cells also promoted necrosis 
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(Kawahara et al. 1998). Therefore, death receptors (like TNFR, FasR, and TRAILR) have been 
demonstrated to regulate necrosis (Nikoletopoulou et al. 2013). However, it has now become 
clear that multiple non-apoptotic pathways exist such as necroptosis, autophagy, and pyroptosis 
(Tait et al. 2014). Furthermore, programmed cell death does not strictly mean apoptosis and 
cross-talk between cell death pathways has been described (Figure 1.15) (Conrad et al. 2016).  
Necrosis has recently been proposed to occur in a controlled and regulated manner and 
it has been suggested that the term should encompass all forms of caspase-independent death 
pathways including necroptosis, parthanatos, ferroptosis or oxytosis mitochondrial 
permeability transition (MPT)-dependent necrosis, pyroptosis and pyronecrosis, and cell death 
associated with the release of (neutrophil) extracellular traps, that is defined as NETosis or 
ETosis (Pasparakis & Vandenabeele 2015). However, some non-apoptotic cell death 
mechanisms such as pyroptosis and autophagy lack the clear necrotic phenotypic characteristics 
associated with necrosis (Conrad et al. 2016). Among all these mechanisms (reviewed in 
(Pasparakis & Vandenabeele 2015)) necroptosis is the most characterised mechanism of 
caspase-independent cell death.  
The process of necroptosis (Figure 1.15) as described by Vanlangenakker et al. (2011) 
occurs upon ligand (TNF/TNFa) binding to death receptors (TNFR) which leads to the 
recruitment of several factors, including TNFR-associated death domain (TRADD), receptor 
interacting protein-1 (RIP1), cellular inhibitor of apoptosis 1 (cIAP1), cIAP2, TNFR-associated 
factor 2 (TRAF2) and TRAF5, to the cytoplasmic part of the receptor dimers and this big 
structure is termed as complex I. At this point several signalling pathways including NF-κB 
signalling, cell survival signals, and cell-death-inducing cascades are initiated as a result of 
ubiquitylation and deubiquitylation (Conrad et al. 2016).The polyubiquitination of RIP1 by 
cIAP2 activates NF-κB pathways through TRAF2/5 and promoting cell survival. NF-κB 
signalling also leads to FLIP (FLICE inhibitory protein) inhibition of caspase 8 cleavage and  
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Figure 1.15 The signalling pathways of cell survival, apoptosis, and necroptosis 
(interconnection between cell death pathways). 
Caspase-dependant and independent pathways are believed to cross-talk through tumour necrotic factor 
(TNF) or death receptor pathways. Death receptor activation results in the recruitment of several factors 
including TRADD, RIP1, TRAF2/5, and cAIP1. Ubiquitination of RIP1 by cAIP1 promotes cell 
survival, while its deubiquitination by CYLD results in the recruitment of FADD, RIP3, and caspase 8 
to the TRADD complex to form complex II or DISC.  The latter activates caspase 8 cleavage and leads 
to apoptosis. Necroptosis is believed to occur as a result of deletion or depletion of caspase 8. 
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apoptosis therefore promoting cell survival (Micheau & Tschopp 2003; Vanlangenakker et al. 
2011). In contrast, the deubiquitination of RIP1 by cylindromatosis (CYLD) promotes the 
formation of complex II, or cytosolic death-inducing signalling complex (DISC), which 
consists of TRADD, FADD (Fas-associated protein with death domain), RIP1, RIP3, and 
caspase-8. This complex induces apoptotic cell death, but in the case of deletion or depletion 
of caspase 8 complex II will lead to necrosome complex formation leading to necroptotic cell 
death (Figure 1.15) (Micheau & Tschopp 2003). 
1.9! Novel drug targets identification 
Target identification attempts to find factors which significantly induce or inhibit 
disease progression (Lindsay 2003). A drug target can be defined as a specific molecule or 
binding site, which plays an important role in signalling pathways or metabolism of a particular 
disease, in which a drug can bind and exerts its activity in vivo (Chen & Du 2007). In spite of 
developments in the pharmaceutical industry, as a result of e.g. advancements in molecular 
biology and the completion of human genome project, the rate of new drug approvals has 
remained relatively constant.  In 2017, there were 46 new drugs approvals by FDA which is 
still not exceed the record of 53 approvals in 1996 (U.S. Food and Drug Administration 2017).  
Novel target identification is an important step in the drug discovery process and can be 
carried out by different methods including phenotypic approaches which are associated with 
the examination of the expression of mRNA/protein levels and whether their expression is 
linked to disease progression. A second method is the use of bioinformatic approaches which 
utilise available data sources including patients information, genomics, proteomics, transgenic 
phenotyping and compound profiling (Sioud 2007). Another method is the use of genetic 
associations, for example, determining whether the presence of a particular polymorphism or 
mutation is correlated with disease development and progression (Hughes et al. 2011). All of 
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these approaches have resulted in a significant increase in the number of targets that have been 
identified. 
1.9.1! Drug target screening using RNA interference 
Various techniques can be applied to identify targets; these generally include forward 
and reverse genetic approaches. Forward genetics looks initially at the phenotype and then 
works out its genotype by genetic mapping, while reverse genetics deals with the manipulation 
of a particular gene expression and observing its resulted phenotype (Desselberger 2017). 
Reverse genetics through RNA interference (RNAi) has become a promising tool in the drug 
discovery process because it gives direct insights into the role of individual genes (Kroenke et 
al. 2004). RNAi was initially characterized in the nematode worm Caenorhabditis elegans by 
Fire and colleagues, who found that double stranded RNAs (dsRNAs) are more efficient in 
introducing sequence-specific silencing of a particular mRNA than a single stranded antisense 
RNA, which were originally used for target knockdowns (Fire et al. 1998; Sledz & Williams 
2005). However, RNAi was originally defined in plants as an immune response to viral 
infection in 1928 (Sledz & Williams 2005). The upper leaves of a tobacco plant which was 
infected with ringspot virus showed resistance to the viral infection and this correlated with 
activation of RNAi machinery.  More specifically, the dsRNA intermediates produced during 
the viral infection, led to silencing of the complementary viral genes (Ratcliff et al. 1997; Covey 
et al. 1997).  
 RNAi-based gene silencing is an evolutionary process which depends on using small 
double-stranded RNA molecules (20-25 base pairs with two nucleotide 3’ overhangs) 
complementary to the targeted mRNA sequence, these RNAs then bind to the mRNA and cause 
its degradation hence reducing target protein levels inside the cell (Figure 1.16) (Kroenke et al. 
2004). The siRNA approach works through the association of the antisense strand of the siRNA  
 
 
96 
 
Figure 1.16 The mechanism of siRNA gene knockdown in mammalian cells. 
The mechanism of siRNA gene silencing is initiated by the presence of double stranded (ds)-RNAs that 
are cleaved with an enzyme called dicer forming 21-23 fragments of siRNAs. The latter unwinds and 
the antisense strand associates with protein components of the RNA-Induced Silencing Complex 
(RISC). The activated complex of RNA-RISC binds to the complementary mRNA inducing its 
degradation. 
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with the protein components of the RNA-Induced Silencing Complex (RISC). The RNA/RISC 
binds to the complementary mRNA region, resulting in its degradation and hence a subsequent 
decrease in the level of the corresponding protein (Zeng & Cullen 2002; Kroenke et al. 2004; 
Sledz & Williams 2005; Singh et al. 2016). 
For research purposes, siRNA libraries are now available that target the whole genome 
or a particular subset of genes; such as kinases, metabolic factors, or phosphatases, allowing 
large-scale phenotypic screening (Campeau & Gobeil 2011). Therefore, RNAi-based gene 
silencing has facilitated the identification of a large number of therapeutic targets (Perrimon et 
al. 2010). After targets are identified by screening, further validation and characterization can 
follow. If a target is validated, then it can be tested further to determine whether it can be bound 
by drug molecules or not; small molecule library screens can then be  performed to identify 
leads that exhibit activity upon the target protein (Hughes et al. 2011). 
1.9.2! Targets characterization/validation  
The validation of targets that harbour potential therapeutic characteristics is a crucial 
step in the discovery of new drugs (Chen & Du 2007), and several methods can be used to 
obtain adequate information to validate the importance of a target to disease development and 
progression (Chen & Du 2007). RNAi can be also be used to validate targets, e.g. as a direct 
method to study a target’s role in proliferation using live cell line models or transgenic animals 
(Hughes et al. 2011). However, the off-target effects of approaches such as RNAi can lead to 
false-positive results and limit the confidence needed for validation. The application of inactive 
derivatives as negative controls will enhance the confidence that the associated phenotypic 
changes are not due to nonspecific effects (Jones 2016). 
The design of experiments to elucidate the biological activity of a target will depend on 
what the target does (Chen & Du 2007). Phenotypic investigations of a drug target in patient-
derived cell-line models, representing the disease state, are seen as a valid method to provide 
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confidence of the association of the target or pathway with disease progression and the results 
can be translated into clinical studies (Vincent et al. 2015). However, such models are limited 
due to the lack of e.g. the tumour micro-environment which is known to have a significant 
impact upon tumours (Goodspeed et al. 2016). Therefore, the use of cell-lines models for 
screening and validation proposes forms only a step into the drug discovery process as further 
preclinical investigations, for example using transgenic animals, will follow such studies 
(Kanade et al. 2011). 
1.10!Aims of the project 
Therapies for non-organ confined PCa usually target the AR signalling pathway.  These 
are initially successful in the majority of patients, but invariably fail and the tumour progresses 
to CRPC.  Few options exist for this stage of the disease and hence there is a great need to 
identify novel therapeutic targets. It is well known that metabolism is altered in cancer and is 
seen as its Achilles’ heel.  The hypothesis of this study was that metabolic factors are potential 
therapeutic targets for prostate cancer and I therefore sought to identify metabolic 
vulnerabilities in prostate cancer, which could be exploited for therapeutic gain. A flow diagram 
summarising the study is provided in Figure 1.17.  
Aims: 
i. to carry out an siRNA screen targeting 217 metabolic and cell traffic factors, and study the 
effect of knocking down each factor on PCa cell proliferation and migration to identify novel 
metabolic genes and pathways that play critical roles in PCa progression. 
ii. to validate potential targets across a range of prostate cancer cell lines using different 
functional assays. 
iii. to further characterise and validate UROS as a novel therapeutic target for the treatment of 
PCa. 
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Figure 1.17 Schematic illustration to show the aim, methods used and general outcomes 
of this study. 
siRNA screening was conducted to identify metabolic factors that affect cell growth and migration using 
crystal violet (CV) proliferation assay and single cell tracking assays respectively. Potential hits were 
identified using statistical analysis. Hits were further assessed to elucidate their role in PCa and to 
validate them as drug targets for PCa. 
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2! Chapter 2: Material and methods 
2.1! siRNAs, Reagents and Buffers 
2.1.1! Reagents and kits 
The siRNA library used in this work was kindly provided by Dr Greg Brooke (Sigma-
Aldrich, Cat. No SI10100-1SET). The library consisted of 3 individual siRNA duplexes against 
each target gene (217 genes), and all were designed by Rosetta Inpharmatics′ design algorithm. 
The siRNAs are 21 nucleotides duplexes with dTdT overhangs.  
The siRNA sequences were supplied dry with a final quantity of 1 nmol per duplex in 
96-well microplates with 80 duplexes per plate. Positive control sequences were included in all 
plates. Plate maps, target genes list and full siRNA sequences information were included.   
The details of all other reagents and kits used in this work are in the following table 
(Table 2.1), otherwise stated accordingly in the text.  
Table 2.1 Reagents and commercially available kits. 
Reagent/kit                 Supplier                        
Acrylamide Sigma-Aldrich 
Agar  Fisher Scientific 
Agarose Fisher Scientific 
APS (Ammonium persulfate) Sigma-Aldrich 
Bleomycin Sulfate (BLM) Sigma-Aldrich (Cat. No. B1141000) 
Bovine serum albumin (BSA) Sigma-Aldrich 
Crystal violet (CV) stain Sigma-Aldrich 
DC assay kit Bio-Rad 
DiCO6(3) (3,3’-Dihexyloxacarbocyanine 
Iodide). 
Sigma-Aldrich 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Docetaxel Sigma-Aldrich 
DNA-FreeTM Kit  Thermo Scientific, Leicestershire, UK 
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EDTA Sigma-Aldrich 
Ethidium bromide Sigma-Aldrich 
Fast Ion TM Plasmid Midi Advanced Kit RBCBiosciences (Cat. No. YPMI-25) 
Fetal bovine serum, FBS  SLS (Cat. No. HYC85) 
GeneJET Gel Extraction Kit Thermo-Fisher Scientific 
GeneJET Miniprep Kit  Thermo-Fisher Scientific 
Glucose Thermo-Fisher Scientific 
Glycine Thermo-Fisher Scientific 
Glycogen blue Thermo-Fisher Scientific 
Halt TM phosphate inhibitor cocktail    Thermo-Fisher Scientific 
Hydrogen peroxide (30%) solution Sigma-Aldrich 
IPTG (Isopropyl-B-D-thiogalalctoside) Sigma-Aldrich 
Kanamycin Sigma-Aldrich 
L-Ascorbic acid Sigma-Aldrich (Cat. No. A92902) 
Lipofectamine® RNAiMAX Transfection 
Reagent 
Thermo-Fisher Scientific (Cat. No. 
13778075) 
Luria Broth (LB) (Lennox, larger granules, Fisher 
Scientific) 
Luria Broth (LB) Agar Sigma-Aldrich 
NaCl Sigma-Aldrich 
Opti-MEM I reduced serum medium Thermo-Fisher Scientific 
PageRulerTM Plus Prestained Protein Ladder Thermo-Fisher Scientific 
Penicillin-Streptomycin-Glutamine (PSG)  Sigma-Aldrich 
Phenol red-free RPMI-1640 SLS  
phosphate-buffered saline (PBS) tablets Sigma-Aldrich 
PMSF (Phenylmethylsulfonyl fluoride) Sigma-Aldrich 
Propodeum iodide (PI) 1 mg/ml staining 
solution 
Sigma Aldrich (Cat. No. P4864-10ML) 
PureLink TM RNase A (20 mg/mL) Thermo-Fisher Scientific 
(Cat.No.12091021) 
REDTaq ReadyMix TM PCR Reaction Mix Sigma-Aldrich 
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RPMI-1640 SLS (Cat. No. LZBE04-558F) 
Sodium citrate Sigma-Aldrich 
Sodium deoxycholate Sigma-Aldrich 
Specta/Por Dialysis Membrane6MW CO:2000 Sigma-Aldrich 
SYPR-Green  Bio-Rad 
TEMED (Tetramethylethylenediamine) Sigma-Aldrich 
Transcriptor First Strand cDNA synthesis kit  Roche 
Succinylacetone (SA) Sigma-Aldrich 
Tris Sigma-Aldrich 
TRI-Sure reagent  Bioline, Taunton, MA 
Triton X-100 Sigma-Aldrich 
Trypsin/EDTA  Sigma-Aldrich 
Tryptone Oxoid 
Tween®"20 Sigma-Aldrich 
Xgal Sigma-Aldrich 
Yeast extract Oxoid 
4X Laemmili loading buffer  Bio-Rad 
Sodium dodecyl sulphate (SDS) Fisher Scientific 
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2.1.2! Solutions and buffers 
The details of all buffers and solutions used in this study are provided in the following 
table (Table 2.2). 
Table 2.2 Buffers and solutions used. 
Name Description                           Sterilization and storage 
  
Western blotting 
 
 
RIPA 
(Radioimmunoprecipitation) 
cell lysis buffer 
 
0.5 ml of 1 mM Tris-Cl (pH 8.0), 1 mM 
of EDTA (20 mg), 1% Triton X-100 (0.0 
ml), 0.1% sodium deoxycholate (50 mg), 
0.1% SDS, 140 mM NaCl, protease 
inhibitors (added in time of experiment). 
 
Autoclaved and stored 
at 4 °C. 
 
10x Running buffer 
 
30.3g of Tris, 144g of Glycine, 100 ml of 
10% SDS, ddH2O to make up 1000 ml. 
 
Autoclaved and stored 
at room temperature. 
 
1x Running buffer 
 
100 ml of 10x running buffer, 900 ml of 
ddH2O. 
 
Autoclaved and stored 
at 4 °C. 
 
Transfer Buffer 
 
22.52g of Glycine, 4.88g of Tris, 400ml 
of methanol, made up to 2 L by ddH2O. 
 
Autoclaved and stored 
at room temperature. 
 
10% acrylamide gel 
 
3.3ml of acrylamide, 2.5ml of 1.5M Tris 
pH 8.9, 4ml of ddH2O, 100µl of 10% 
SDS, 100µl of 10% APS, 10µl TEMED 
(Tetramethylethylenediamine). 
 
 
Prepared fresh every 
time. 
 
Stacking Gel 
 
0.85ml acrylamide, 1.25ml of 1.5M Tris 
pH 6.8, 2.8ml of ddH2O, 50µl of 10% 
SDS, 50µl of 10% APS, 5µl of TEMED. 
 
Prepared fresh every 
time. 
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10 % SDS 
50 g of SDS dissolved in a total of 500 
mL ddH2O. 
Stored at RT. 
 
Cloning 
 
 
Luria Broth (LB) 10 g of LB dissolved in 500 ml of ddH2O 
and autoclaved prior to use; 50 µg/ml of 
Kanamycin added if needed. 
Autoclaved and stored at room 
temperature. 
 
Luria Broth Agar 
(LB Agar) 
35 g of   LB agar added to 1 L of ddH2O. 
Stock was then autoclaved, warmed, and 
supplemented with antibiotics (50 µg/ml 
of ampicillin or kanamycin) before 
pouring into plates.  
4 µL IPTG (200 mg/mL) and 40 µL Xgal 
(20 mg/mL) were spread on the surface 
of each plate before use.  
 
Autoclaved and stored at room 
temperature, antibiotics and 
Xgal/IPTG mix added before use. 
 
Super Optimal 
broth with 
Catabolite 
repression (SOC) 
Medium 
  
2% tryptone, 0.5% yeast extract, 10 
mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 
10 mM MgSO4, and 20 mM glucose, 
made up in 1 L of ddH2O. 
 
 
Autoclaved and stored at room 
temperature. 
 
Agarose Gel (1%) 
1 g agarose was added to 100 ml of Tris 
acetic acid EDTA (TAE) (1x) buffer 
and heated until boiling. 5µl of 
ethidium bromide (10 mg/ml) were 
added to the gel solution. 
 
Stored at room temperature. 
 
Tris acetic acid 
EDTA (TAE) (1x) 
buffer  
 
40 mM Tris base, 1.114 mL glacial 
acetic acid, and 1 mM EDTA in a total 
of 1 L ddH2O. 
 
Autoclaved and stored at room 
temperature. 
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Flow cytometry (FACS) buffers 
 
Nicolletti buffer 
 
10 g of Sodium citrate, 10 ml triton 
(100x), diluted to 1000 ml of ddH2O. 
 
Stored at 4 °C. 
PI staining solution 
for apoptosis 
measurements 
200µl PI (1 mg/ml), 5ml Nicolletti 
buffer. 
Stored at 4 °C. 
PI staining solution 
for cell cycle 
measurements 
1ml PBS, 20µl RNase (10 mg/ml), 
10µl PI (1 mg/ml in ). 
Freshly prepared. 
 
Drugs 
Docetaxel (Doc) Dissolved in DMSO. 
 
Kept at -20 °C.  
Succinylacetone 
(SA) 
Dissolved in ddH2O,0.5 mM stocks. Kept at -20 °C. 
Bleomycin (BLM) Dissolved in DMSO, 20 mM stocks. Kept at -20 °C. 
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2.2! Cell culture 
Human prostate cancer cells (PC3, LNCaP, DU145, 22RV1, C42, and C42B) and the 
benign normal prostatic cell lines (BPH1, PNT1A) (Table 2.3), were all provided by Dr. Greg 
N Brooke, University of Essex. They were maintained in 1640 RPMI supplemented with 10 % 
fetal bovine serum (FBS). The RPMI media was also supplemented with Penicillin-
Streptomycin-Glutamine (PSG); 5 ml PSG per 500 ml RPMI. Cell culture was performed using 
standard tissue culture techniques under sterile conditions and cells were incubated in 
humidified air containing 5% CO2 at 37 °C. 
2.2.1! Passaging cells 
Cells were passaged every time they reach 70-80% confluency by removing the old 
medium and washing cells for few minutes with PBS. Cells then were incubated for 3-5 minutes 
with trypsin/EDTA to detach them. Trypsinized cells were resuspended with 4.5 or 9.5 ml of 
fresh RPMI depending on flask size, and the desired volume was transferred into a new flask 
containing warm 10 % FBS-RPMI, normally 1 x 10 5 cells/75 cm2 flasks or 0.5 x 10 5 
cells/25cm2 flasks (Nunclon TM Delta Surface, Thermo Scientific).  
2.2.2! Cell counting and plating 
To count cells, 10 µl of cell suspension; 1:10 dilution from the main flask, was placed 
in a haemocytometer and 10 squares were counted and averaged. The number of cells in the 
whole flask was estimated by making the number x106. To find number of cells per ml, it was 
further divided by the volume of RPMI used to resuspend cells (10 or 5 ml). Normally, 1 x 105 
cells/ml stocks were prepared to allow further dilution of cells for plating according to plate 
size and experimental design. 
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Table 2.3 Mammalian cell line models used in this study. 
CELL LINE DESCRIPTION MEDIA 
PC3 an androgen-independent cell line model that was 
established from a human PCa metastatic to the bone. 
 
RPMI-1640 
PC3-GFP PC3 cell that were stably transfected with GFP.  
 
RPMI-1640 
LNCAP A hormone-sensitive cell line originated from a metastatic 
lesion of PCa grew in a lymph node of a patient that 
developed CRPC after ADT. 
 
RPMI-1640 
DU145 A model of castration resistant prostate cancer (like PC3) 
that derived from a central nervous system metastasis. 
 
RPMI-1640 
C42 A metastatic cell line derived from LNCaP-C4 sub-cell 
line that was co-injected with fibroblasts into castrated 
mice. 
 
RPMI-1640 
C42B A bone metastatic cell line derived after injecting the sub-
cell line C42 into castrated mice.  
 
RPMI-1640 
22RV1 Derived from an androgen-dependent PCa xenograft line 
(CWR22R). 
RPMI-1640 
BPH1 A benign hyperplastic prostatic epithelial cell line.  
 
RPMI-1640 
PNTA1 Normal prostatic epithelial cells that were immortalised 
with SV40.  
RPMI-1640 
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2.2.3! Defrosting/freezing cells 
For defrosting cells that have been stored in liquid nitrogen, stocks were firstly kept on 
dry ice and rapidly defrosted using a warm water bath. Cell suspensions were transferred to a 
flask containing 10 ml of fresh 10 % FBS-RPMI and left overnight in the incubator. The 
following day medium was aspirated, and cells were washed once with warm PBS. 20 ml of 
RPMI was added to the cells and allowed to reach confluency. Fresh cells were passaged at 
least twice before using in experiments. 
To freeze down cells, confluent cultures were detached by trypsin as described in 
Section 2.2.1. Cells suspensions was then collected in 15 ml tubes and centrifuged at 1500 rpm 
for 3-5 minutes. Media was aspirated off and pellets were resuspended in freezing medium; 
10% Dimethyl Sulphoxide (DMSO) and 90 % FBS. Cell suspension was transferred to a 
cryotube (1.5-2 ml each), wrapped in insulating material and stored at -80 °C at least 24 hours 
before transferring into liquid nitrogen. 
2.3! Transfection by siRNAs 
 
Cells were transfected 24 hours post seeding using about 11-17 nM of siRNAs diluted 
in Opti-MEM reduced serum medium and mixed with Lipofectamine RNAiMAX transfection 
reagent as indicated in Table 2.4. The siRNA-lipid complex solutions were incubated for 5 
minutes before applying to the cells. 10-15 hours post treatments culture medium was replaced 
with fresh RPMI-1640 medium, cells were then incubated for 72 hours for transfection process, 
and phenotype quantification was followed as required. Details of cell numbers and plate types 
used depended on each experiment, and they are generally as indicated in Table 2.4 or 
accordingly in the following methods sections if different. 
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Table 2.4 siRNA transfection reagents volumes and concentrations.  
Component 
 
96-well 
 
12-well 
 
6-well 
 
Number of cells per well 
 1-6x10
3 1 x105 2-4 x105 
Opti-MEM 
 24.8125 µl 100 µl 150 µl 
Lipofectamine 
RNAMAX 0.1875 µl 3 µl 4.5 µl 
Opti-MEM 
 24.5 µl 100 µl 150 µl 
siRNA (10 µM) 
 0.5 µl 2 µl 3 µl 
Diluted Lipofectamine 
iRNAMAX 25 µl 103 µl 154.5 µl 
Diluted siRNA 
 25 µl 102 µl 153 µl 
Final transfection mix 
volume 50 µl 205 307.5 µl 
Volume of siRNA-lipid 
complex per well 20 µl 125 µl 250 µl 
siRNA concentration 
per well &17 nM &11 nM &11 nM 
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2.3.1! Proliferation assay for siRNA screening  
Crystal violet staining (CV) was used as a main experiment to determine the effect of 
siRNA transfections and drugs treatments on cell proliferation of PCa cells. The dye works by 
staining the protein content and DNA of all cells; viable and dead cells equally. Using the fact 
that dead cells will lose their adherence, only viable adherent cells will stay reducing the 
staining levels in treated cells compared to controls which in theory should maintain all cells 
(Feoktistova et al. 2016).  
Cells were seeded in 96 well plates in complete RPMI-1640 at a final volume of 100 µl 
(1.0 -2.0 x 103 cell/ well for PC3 and DU145, 6.0 x 103 cell/well for LNCaP, and 6.0-8.0x103 
cell/well for BPH1) and maintained at 37 °C for 24 hours prior to treatments. The medium was 
refreshed 10-15 hours post-treatment and left to grow 6 days for screening plates or as indicated 
for drug treatments, explained later in this chapter. After treatments incubations, 100 µl of 4% 
paraformaldehyde (PFA) was added to each well and incubated at room temperature (RT) for 
one hour. Plates then were washed three times using phosphate-buffered saline (PBS) and left 
to dry at RT. Cells then were incubated for one hour in 50 µl of 0.04 % crystal violet stain, 
washed three times with distilled H2O and allowed to dry. Finally, 100 µl of acetic acid (10 %) 
was added to all wells and left for one hour on a shaker. Plates were read using 
spectrophotometer microplate reader (FLUOstar Omrega, BMG LABTECH, UK) at 490 nm 
wavelength.  
2.3.2! Migration assay for siRNA screening 
GFP-tagged PC3 cells were seeded on 96-well plates (500-1,000 cell/well) 24 hours 
prior to treatments. Treatment with siRNAs was followed and incubated for 72 hours. Media 
was replaced with phenol red-free RPMI (5% SFCS, Charcoal Stripped Foetal Calf Serum) 10-
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15 hours after treatments; to reduce cell growth as cell density is an important factor when 
tacking images. Media then switched back to 10 % FBS RPMI 1640 24 hours before imaging.  
2.3.2.1! Single cell tracking and image acquisition by widefield microscopy 
Widefield microscope (Eclipse Ti; Nikon) with a motorized stage and humidified 
chamber (Model: H301, OkoLab, Italy), 37 oC in 5 % CO2 conditions, was set to acquire images 
using 10X 0.3 N.A objective lens using 20-30 % illumination and 3-5 seconds exposure. GFP 
was excited using blue light 470 nm via a CoolLED pE excitation system. Two-dimensional 
(2D) time series frames were captured with an Andor camera (Model: Luca-R DL-626, Andor 
Technology, UK) using NIS-Elements AR 4.13.04 (Build 925) software every 15 minutes for 
24 hours in multiple locations in every well, 3-4 fields minimum per well. Resulted image 
sequences were pre-processed and analysed as described in the following section. 
2.3.2.2! Image pre-processing and automated quantification of PC3 cell speed 
High resolution time-lapse image sequences were captured and used to analyse the 
trajectories and the speed of single PC3 cells. Analysis was carried out by a semi-automated 
method using the ADAPT algorithm (Barry et al. 2015). For cell segmentation, multiple manual 
processing steps were required to make the objects in a form that ADAPT algorithm can easily 
and precisely detect and track. The pre-processing steps were background subtraction, contrast 
adjusting and thresholding (Figure 2.1). These steps are labour intensive when dealing with 
large sets of images as in this study. Therefore, the pre-processing steps were gathered in one 
macro using existing ImageJ plugins in a batch process to accelerate the pre-processing of 
image datasets. The Macro used to convert ICS files into TIFF files is as the following: 
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Figure 2.1 Illustration for the processing steps applied for cell segmentation of time-lapse 
sequences. 
The background of the original image (A) was firstly subtracted (B), contrast was then adjusted (C) and 
finally images were thresholded manually to the point that cells are clear enough for the detection 
process (D). 
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macro'"tracking'images'preprocessing"'{ 
'dir1'='getDirectory("Choose'Source'Directory'");'
''dir2'='getDirectory("Choose'Destination'Directory'");'
''images'='getFileList(dir1);''
setBatchMode(true);'
for(i=0;'i<images.length;'i++)'{'
open(dir1'+'images[i]);'
run("8Cbit");'
saveAs("Tiff",'dir2'+'images[i]);'
''''close();'
''''''''''}''
}!
 
The routine used to pre-process the images in a batch mode is: 
macro'"tracking'images'preprocessing"'{'
'dir1'='getDirectory("Choose'Source'Directory'");'
''dir2'='getDirectory("Choose'Destination'Directory'");'
''images'='getFileList(dir1);''
setBatchMode(true);'
for(i=0;'i<images.length;'i++)'{'
open(dir1'+'images[i]);'
'
run("Subtract'Background...",'"rolling=50'stack");'
setAutoThreshold("Default'dark");'
//run("Threshold...");'
setAutoThreshold("Default'dark");'
run("Convert'to'Mask",'"method=Default'background=Default");'
'saveAs("Tiff",'dir2'+'images[i]);'
''''close();'
''''''''''}''
}'
'
2.3.3! Statistical analysis 
One-way ANOVA was used to determine the statistical difference between treated cells 
and negative control (NTC) experiments including proliferation assays and wound healing 
migration assays. For proliferation screen, all 3 siRNA treatments for each target were 
combined and compared to NTC-siRNA transfection control using ANOVA followed by 
Fisher’s LSD (least significance difference) post hoc. Validation growth assays and wound 
healing assays were analysed by ANOVA using Dunnett’s post hoc test.  
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Non-parametric Kruskal-Wallis test using Dunn’s post hoc test was applied to for single 
cells migration screen comparisons where each siRNA was compared individually to NTC and 
targets with all three significant siRNA results were marked as hits and showed in the heat map.  
A P value of < 0.01 (95 % confidence interval) was used to decide on significance. 
2.3.4! Wound healing assays after siRNA knockdowns 
 1.0-2.0 x 105 cells/well or 2.0-4.0 x 10 5 cells/well of PC3 were seeded in 12 or 6 well 
plates, respectively, 24 hours prior to siRNA based transfections. 10-15 hours after siRNA 
treatments (as indicated in Table 2.4), media was changed to fresh 10 % FBS RPMI and cells 
left to reach required confluency. Cells were left 72 hours in total after transfection, and 24 
hours before making scratches medium was switched to 5% SFCS phenol red-free RPMI (1% 
Penicillin- Streptomycin-Glutamine) to minimize cell proliferation that can interfere with 
population cell migration. Monolayers were then wounded using 200 μl pipette tip; the tip was 
used to make multiple scratches in each well by gently removing a patch of cells (Figure 2.2). 
After wounding, cells were gently washed twice with PBS to remove cell debris, fresh medium 
was applied, and imaging was followed as in the next section. 
2.3.4.1! Imaging scratch assays using widefield Ti Nikon microscope 
Nikon Eclipse Ti widefield microscope was used to capture large scale images of the 
whole plates. Images were captured at the start of the experiment (zero hour) and at different 
time intervals to determine the time point which allow seeing the difference in the closure speed 
between the treated and untreated cells. Large scale images of the whole plate were taken by 
brightfield using 2X objective without binning. Uneven illumination (Figure 2.3) was the main 
problem when using smaller well plates because of the meniscus effect of the liquid which  
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Figure 2.2 The main method of performing scratches on cell monolayers. 
Taken from: Bise et al. (2011). 
 
 
 
 
 
    
Figure 2.3 Meniscus effect on imaging cells in 96-well plate using 2 x objectives on Nikon 
Ti widefield microscope. 
Left: Light is diffracted when it gets close well edges as surface is not flat. Right: The small size of the 
wells of 96-well plate cause to further increase the meniscus of residual medium which in turn increase 
the shading effect (dark regions, arrow). 
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results in shaded areas of the well, and hence wider wells-plates, which display less meniscus 
effect, were preferred to perform the assay. Also, binning of pixels, combining signals from 
adjacent pixels together, when taking the image increases signal to noise ratio and reduces 
image-acquisition time in the cost of spatial resolution; which is not critical in scratch imaging 
that does not seek cells details. Uneven illumination can also be further reduced by simply 
acquiring a bright image of an empty field, then divide the original image by this image or by 
convolving the image with  a low pass filter such as Gaussian (Leong et al. 2003), also other 
specialized algorithms for shading correction are available in most software packages like 
ImageJ (Bolte & Cordelières 2006). 
2.3.4.2! Semi-automated quantification of scratch assay images 
Image analysis of scratches was carried out using NIS-elements software (Nikon). The 
rate of scratch closure was found by calculating the difference between the open area of each 
scratch at 0 hours and at 24 hours. The area of each wound was determined using a method 
similar to that presented by Treloar & co-workers (2013) (Figure 2.4) which depends mainly 
on using an edge detection algorithm called Sobel that convolves images with horizontal and 
vertical edge detection kernels and results in increasing the contrast between dark and bright 
areas which makes the area’s detection easy and concise (Treloar & Simpson 2013). More 
sharpening was also used to further increase the brightness difference along the edges in the 
image. 
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Figure 2.4 Sobel filter was used to find and enhance the scratch edges. 
Sobel filter was used to find and enhance the scratch edges which then can be sharpened to increase the 
contrast between the dark and white areas. This method helps to easily detect the wound area. However, 
some randomly moved cells in the open area of scratches could not be detected precisely.  
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2.4! Heme depletion and heme-synthesis inhibition 
As our lead target (UROS) is implicated in heme-synthesis pathway, we decided to 
abolish heme from the medium and further halt the intracellular production of heme by using 
succinylacetone (SA) inhibitor, which targets the ALAD gene that works upstream of UROS 
gene. The next sections explain the recipe of how heme content was reduced from the serum 
and the dose-based SA treatments used to stop the de novo heme biosynthesis in PCa cell lines. 
2.4.1! Heme-depleted media preparation 
To remove heme from FBS, the initial absorbance (A) of the serum was measured as 
405 nm. Then, ascorbic acid was added to the FBS at a concentration of 10 mM and serum was 
placed in a water path (37 °C). Absorbance was recorded every 60 minutes intervals until it 
reached half of the initial reading. FBS was then placed in a dialysis bag (Specta/Por Dialysis 
Membrane 6 MWCO:2000) under sterile conditions and dialyzed against 10 times the volume 
of PBS for 3-4 hours. Then, PBS was changed and dialyzed overnight. The next day, again PBS 
was changed and dialyzed for 3-4 hour. All dialysis was carried out with continuous stirring of 
PBS at 4 °C, and then serum was filtered in the tissue culture hood and stored the aliquots in -
20 °C. This serum was then added to RPMI media at 5 % concentration to form heme-depleted 
RPMI medium for use as required in experiments. 
2.4.2! Succinylacetone dose-treatments for proliferation assays  
For heme biosynthesis inhibition, SA inhibitor was used as doses between 0 and 
1000 µM. PC3, DU145, LNCaP, and BPH1 cells were seeded in 96 well plates (1000, 2000, 
6000, and 6000-8000 cell/well, respectively) using 5% heme-depleted or 5% typical FBS 24 
hours prior to the SA dose-treatments. Cells were left for either 2, 4, or 6 days to allow growth. 
CV growth assays as explained in Section 2.3.1 was carried out to determine the effect of SA 
doses on proliferation of PCa cell lines.  At 2 and 4 days, there was an initial effect of the 
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inhibitor doses on PC3 cell growth, but the effect was clearer at 6 days’ treatments. Therefore, 
the 6 days’ dose treatment was extended to other experiments.  
2.4.3! Succinylacetone dose treatment for cells migration assays 
To investigate if SA doses inhibits PC3 cell migration, cells were seeded in 5 % RPMI 
at either 96 well plates (500 cell/well) or 12 well plates (100,000 cell /well) 24 hours before SA 
doses addition. Cells in 96 well plates were left 3 days, and on day 4 images were acquired as 
explained above (Section 2.3.2.1) using widefield Nikon microscope every 20 minutes over 24 
hours. Images were analysed as in Section 2.3.2.2. 
12 well plates were also left 3 days to allow them to form a confluent monolayer. On 
day 4, cells were washed once with PBS and media was changed to fresh 5 % SFCS phenol 
red-free RMPI. 6 hours later, wounds were introduced as explained before and cells washed 
with PBS to remove cell debris. Fresh 5 % SFCS phenol red-free RMPI was added and cells 
were retreated with SA doses. A big scale image of the whole plate was acquired using widefield 
inverted microscope via brightfield and 2x objectives (no binning was needed, and objective 
calibration was applied before imaging). 24 hours another image was acquired similarly, and 
scratch analysis was carried out as explained in Section 2.3.4.2.  
2.5! Combinations of heme biosynthesis inhibition with chemotherapeutics and 
ROS enhancing agents 
To investigate if cellular stress brought about by heme biosynthesis inhibition will have 
additive effects to the existing chemotherapeutics and whether the reactive oxygen species 
(ROS) generated by SA sensitise PCa cells to other treatments, the inhibitor in low doses was 
combined with other drugs including docetaxel (DOC) and bleomycin (BLM). In addition, 
doses of fresh H2O2 were applied as an artificial ROS that is proposed to be generated by cancer 
cells when under great amount of stress. The following sections explains methods of these 
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combinations in details. Cell numbers of 1.0 -2.0 x 103 cell/ well for PC3 and DU145, 6.0 x 103 
cell/well for LNCaP, and 6.0-8.0x103 cell/well for BPH1 were used for all experiments. All 
experiments were conducted 24 hours post-seeding. 
2.5.1! Treatments of cells with succinylacetone and docetaxel 
1 nM of DOC was added to PC3, DU145, LNCaP and BPH1 that were initially treated 
with SA doses (0-1000 µM) in 96 well plates. Cells were allowed to grow over 6 days and on 
day 7 they were fixed, CV assay was followed and absorbance was read at 490 nm.  
2.5.2! Treatments of cells with succinylacetone and bleomycin sulfate (BLM) doses 
Cells were treated with a sub-lethal concentration of SA (50 µM) 24 hours post-seeding. 
Few hours after SA treatment, cells were treated with BLM doses (0-10 nM) and allowed to 
grow for 6 days. Then, cell fixation and CV staining were followed, and absorbance was read 
at 490 nm. 
2.5.3! Treatments of cells with succinylacetone and hydrogen peroxide doses 
PCa cell lines and PBH1 cells were seeded 24 hours before treatments in correct 
numbers as indicated before. For each cell line, cells were either treated or untreated with 50 µM 
or 500 µM of SA inhibitor and left to grow over 5 days. On day 6, cells were treated with H2O2 
doses of 100-500 µM and left 24 hours. Control cells that were untreated, only SA treated, or 
only H2O2 treated were included in all experiments. Cells were then fixed with 4% PFA and 
CV assays was followed to determine cell viability (Section 2.3.1).  
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2.6! Flow cytometric assays 
2.6.1! Treatments 
 
For siRNA knockdowns assays, cells were seeded in either 6 or 12 well plates and 
treated as presented in Table 2.4. Cells were left 72 hours and harvested on day 4 for 
corresponding flow cytometric analysis as explained in the next sections. 
For SA flow cytometric experiments, in 12 well plates, 1 x 104, 2 x 104, 4 x 104 and 5 x 
104 cell/well of PC3, DU145, LNCaP, and BPH, respectively, were seeded 24 hours prior to 
treatments. Cells then were either treated with SA doses and incubated for 6 days or treated 
with a single dose of SA (50 or 500 µM) and incubated for 5 days followed by H2O2 dose 
treatments that lasts for 24 hours.  
For the experiment included the caspase inhibitor, PC3 cells were treated with 10 µM 
of the caspase inhibitor ZVAD-FMK 20 minutes prior to SA treatments. H2O2 was added on 
day 5 and left 24 hours before analysis. 
After incubations cells were trypsinised and collected for flow cytometric analysis. 
Most experiments included a minimum of 10,000 cells per sample in the analysis except the 
apoptotic measurements which included 1000 cells per sample.   
2.6.2! Flow Cytometric Measurement of Apoptotic and Necrotic Cells 
For apoptosis measurements, control and treated cells were harvested by collecting 
medium in 1.5 ml tubes, cells then were washed with 500 µl of PBS which was transferred to 
the same tube. 100 µl of trypsin was then added to cells and incubated for few minutes to allow 
cells dissociation. 500 µl of the collected media and PBS mixture was added to cells and 
pipetted gently up and down and transferred to the corresponding tube. Cell suspensions were 
centrifuged for 2 minutes at 5000 rpm. Pellets were then suspended in 200 µl of PI (Propodeum 
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iodide) staining buffer; Section 2.1.2. Percentage of apoptotic cells were analysed and measured 
by flow cytometry using Accuri C6 software.  
Necrosis was determined by measuring the number of PI positive cells using flow 
cytometry. Briefly, cells harvested with its medium, stained with 20 µg/ml of PI and 
immediately assessed by flow cytometry after a gentle vortex. Percentage of necrotic cells were 
then measured by flow cytometry using Accuri C6.  
2.6.3! Flow cytometric analysis of cell cycle 
Media was collected in clean 2 ml tube and cells were washed with 500 µl of PBS which 
then was transferred to the same tube. 100 µl of trypsin was added to cells and incubated for a 
few minutes to allow cell dissociation. 500 µl of the collected media and PBS mixture was 
added to cells and pipetted up and down. Cell suspension was transferred back to the 2 ml tube 
and centrifuged at 5500 rpm for 5 minutes. Media was discarded, and pellets were resuspended 
in 50 µl PBS. Cells were fixed by dropwise addition of 500 µl of 70 % ethanol with gentle 
vortex. Cells were stored at 4 oC. In analysis time, cells were pelleted at 5500 rpm for 5 minutes 
and ethanol was aspirated off. Pellets were resuspended in 200 µl of PI staining solution 
containing RNase A, Section 2.1.2. 10,000 cells per sample were analysed and quantified by 
Accuri C6. 
2.6.4! Flow cytometric analysis of mitochondrial membrane potential 
In 12 well plates, 10,000, 20,000, 40,000 and 50,000 cell/well of PC3, DU145, LNCaP, 
and BPH1, respectively, were seeded 24 hours before treatments. Cells were treated 
with/without SA (50 µM or100 µM) and incubated. On day 3, cells were treated with/without 
300 µM H2O2 and left 24 hours. On days 4, cells were harvested and washed with pre-warmed 
PBS, then labelled with 40 nM DIOC6(3) at 37 oC for 15 minutes. The mitochondrial 
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membrane depolarisation was measured using flow cytometric analysis using Accuri C6. A 
minimum of 10,000 cells per sample were acquired and analysed.  
2.7! Measurement of Cellular Heme Content 
In 6 well plates, 20,000, 40,000, 80,000 and 60,000 cell/well of PC3, DU145, LNCaP, 
and BPH1, respectively, were seeded 24 hours before treatments. Cells were treated with 0-
1000 µM doses of SA and left for 6 days. Cells then were harvested and counted, and the same 
number of cells was pelleted in 1.5 tubes; the number of cells was made relative to the control 
sample in each single experiment. The protocol presented by Sinclair et al. (2001) was followed 
for heme content analysis. Briefly, pellets were resuspended in 2M solution of oxalic acid and 
kept 30 minutes in a heating block at 100 OC. Controls of unheated suspensions of pellets were 
included for blank readings in order to subtract the background fluorescence. 200 µl of each 
sample was loaded into a white polystyrene flat-bottom microplate (Sigma Aldrich) and the 
fluorescence of porphyrin was read at 400 nm excitation and 662 nm emission by plate reader 
(CLARIOstar, BMG LABTECH, UK). Data was made relative to untreated control cells. 
2.8! Real-Time Quantitative PCR 
Quantitative PCR (qPCR) has been employed in this work to quantify the efficiency of 
targets knockdowns by siRNA transfections as well as to assess the transcript levels of UROS 
and ALDOA in different cell lines. Validation of targets knockdowns was performed by 
comparing the levels of transcripts of interest in treated samples with mock transfected and 
NTC-treated control samples. The principle behind qPCR is briefly the detection of florescence 
produced by the SYPR-Green dye when it binds to the double stranded DNA produced during 
the amplification time. SYPER-Green dye conformation changes when it binds to double helix 
DNA and produces more fluorescence that is collected by a detector and displayed in real time. 
Melt curves displayed will give an overview of the amplification efficiently of the target DNA. 
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2.8.1! Cells preparations 
After transfections or required treatments, cells were firstly washed with cold PBS; 1 ml 
of cold PBS was added and pipetted up and down to detach cells with help of a scrapper. Cells 
were transferred into pre-chilled 1.5 ml tubes, then pelleted at 4 oC (5000 rpm) for 5 minutes 
and kept on ice. PBS was discarded, and pellets were either snap frozen (in dry ice ethanol path) 
and stored at -80 oC or proceeded directly into RNA extraction (Section 2.8.2). 
2.8.2! RNA extraction 
RNA extraction was performed in a fume hood and only filtered tips were used to avoid 
any spontaneous contamination. Cell pellets were lysed in 1 ml of TRI-Sure reagent and 
incubated for 5 minutes at RT. 200 µl of chloroform was added, and tubes were vortexed for 
15 second and kept at RT for 5 minutes. Centrifugation at 4 oC and maximum speed for 15 
minutes was followed and the aqueous clear part (contains RNAs) was transferred into fresh 
1.5 ml tubes. 500 µl of isopropanol and 1 µl of Glycoblue (Ambion) was added, mixed by 
inversion, and incubated 5 minutes at RT. Tubes were then centrifuged at full speed for 15 
minutes at 4oC and carefully the supernatant was removed by pipetting. A pulse spin was 
followed to ensure that all liquid was removed. 1 ml of 75 % ethanol was added and tubes 
vortexed and centrifuged at 7500 g at 4oC for 5-10 minutes. Supernatants were removed with 
pipetting and pellets were air-dried for 10 minutes. Dry pellets were finally resuspended in 30 
µl of sterile RNase-Free water and kept on ice. RNAs concentration was measured using 
NanoDrop® ND-1000 UV/VIS Spectrophotometer (Nanodrop, Thermo Scientific). 
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2.8.3! DNase treatment of RNAs and cDNA synthesis  
A DNase step was performed before cDNA synthesis to remove any DNA 
contaminations in RNA stocks. DNA-FreeTM Kit was used according to manufacturer’s 
instructions. T100 Thermal Cycler (Bio-Rad) was employed to perform reverse transcription to 
generate cDNAs from RNA templates by PCR Transcriptor First Strand cDNA synthesis kit 
(Roche) according to the manufacturer’s protocol. The concentrations of cDNAs were 
quantified using NanoDrop® ND-1000 UV/VIS Spectrophotometer (Nanodrop, Thermo 
Scientific). All samples were stored at -20 until the qPCR experiment time.  
2.8.4! Real time QPCR  
Roche LightCycler 96, Roche, was used to quantify alterations in gene of interest 
expression using SYPR-Green. All cDNA stocks were diluted using 60 µl of RNase-free water 
before using. QPCR mix consists from 2 µl of cDNA, 5 µl SYPR-Green, 0.5 µl of forward 
primer, F (10 µM), 0.5 µl of reverse primer, R (10 µM) and 2 µl RNase-free. Gene expression 
was normalised by the RPL19 ribosomal protein (L19) reference gene. Primers used in this 
study were all purchased from Sigma-Aldrich (Table 2.5). 
2.9! Protein immunoblotting 
Protein immunoblotting is a basic technique that allows the semi-quantification and 
analysis of proteins levels in tissues and cells. An antibody will bind specifically to the protein 
of interest which then is conjugated to a secondary antibody that carries a fluorophore; which 
in turn will allow detection. The detection was through the measurement of chemiluminescence 
using Fusion FX (VILBER LOURMAT). Protein immunoblotting was employed in this work 
to validate the knockdowns efficiency at protein levels as well as to access lead targets proteins 
levels in PCa cell lines.  
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Table 2.5 Sequences of primers used to amplify targets’ DNA sequences by QPCR. 
Primer Name Sequence 
L19_F GCAGCCGGCGCAAA 
L19_R GCGGAAGGGTACAGCCAAT 
RDX _F (Radixin) TATGCTGTCCAAGCCAAGTATG 
RDX_R (Radixin) CGCTGGGGTAGGAGTCTATCA 
UROS_var2F GTCCTCAGCACTGCCTCTTC 
UROS_var2R TGGGTGTGCAACTGTCTGAT 
ALDOA_F ATGCCCTACCAATATCCAGCA   
ALDOA_R  GCTCCCAGTGGACTCATCTG 
FDPS_F CCAAGAAAAGCAGGATTTCG 
FDPS_R TCCCGGAATGCTACTACCAC 
LARS_F GCGACACCATAGCACGGTT 
LARS_R TGTGGATGTAGATTCCTCTCGAC 
!
!
!
!
!
!
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2.9.1! Preparing cell lysate and protein quantification 
After treatments and incubations as required, cells were washed in PBS and harvested 
by cell scraping. Cells were then pelleted at 1200 rpm for 4 min, lysed by sonicating (2 cycles 
on ‘high’ of 30 secs on and 30 secs off using Biorupter® Plus, Diagenode) in RIPA buffer 
containing protease inhibitors (10 µl Halt phosphate inhibitor cocktail, 5 µl PMSF per 1 ml of 
RIPA buffer, Section 2.1.2). Lysates were centrifuged at maximum speed for 10 minutes at 4 
oC. Clear supernatants were transferred to clean microcentrifuge tubes and kept on ice or - 80 
oC until further analysis. Proteins concentrations were determined using Protein Detergent 
Compatible (DC) assay kit according to manufacturer’s instructions. Briefly, 5 µl of each 
sample was used against a series of standard concentrations of BSA as a reference. Protein 
concentrations were detected at absorbance (A) of 750 nm using the FLUOstar Omega plate 
reader (BMG LABTECH). Protein volumes were made equal in each experiment; 10 µg per 
10 µl of each sample, by diluting them accordingly with the lysis buffer (RIPA). 
2.9.2! SDS polyacrylamide gel electrophoresis 
10 % SDS polyacrylamide gel was prepared briefly by pouring 4-5 ml of 10% 
acrylamide gel (Section 2.1.2) between a sandwich of two glass plates and was topped up with 
1 ml of H2O and left to set before adding the stacking buffer (Section 2.1.2). Proteins stocks 
were heated to 95 oC for 5-10 minutes. Samples then were immediately placed on ice for 2 
minutes and then mixed up with 4x Laemmili loading buffer containing Beta-mercaptoethanol 
(B-Me). A total of 25-30 µg of proteins were loaded together with 5 µl of PageRulerTM Plus 
Prestained Protein Ladder (Bio-Rad) and run in 1x running buffer (Section 2.1.2) at 120 V for 
1.5-2.0 hours.  
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2.9.3! Immunoblotting 
Gels then were hydrated with 100 % methanol (Sigma-Aldrich) and then washed with 
pre-made transfer buffer (Section 2.1.2). Proteins were transferred into a soaked polyvinylidene 
fluoride (PVDF) membrane (Sigma Aldrich) over two hours (15 mA, and 100 V) using semi-
dry electro blotting apparatus (Bio-Rad). Membranes were then washed with PBS and blocked 
with 5% Milk PBS-T (0.1% Tween) on rotator for 30 minutes. Membranes were then incubated 
with the required primary antibodies (1o) diluted in 5% Milk PBS-T for one hour at RM or 
overnight at 4 oC with rotation.  Antibodies and concentration details used to probe the 
membranes are shown in Table 2.6. After primary antibody incubation, membranes were 
washed quickly 2 times with PBS-T followed with 3 washes with PBS-T for 5 minutes each 
with rotation. Re-blocking with Milk- PBS-T for 15 minutes was followed and respective 
secondary antibodies (2o) diluted in Milk- PBS-T (1:2000) were added and incubated for an 
hour at RT with rotation. Protein bands were visualized by LuminataTM Forte Western HRP 
Substrate (Millipore) using Fusion FX (VILBER LOURMAT) equipped with Fusion analysis 
software. The molecular weights of the proteins were estimated in respect to PageRulerTM Plus 
Prestained Protein Ladder used. 
2.10!Cloning DNA sites of lead targets 
DNA sites of lead targets were cloned for further investigation into their localization to 
give more indications into their related signalling and functions. DNA sites were firstly 
amplified by PCR, digested and ligated into pGEM as it has more efficiency. They were then 
cut and re-ligated into pEGFP-C1 vector and transit transfection was used to allow their GFP 
signal visualization by widefield microscope.  
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Table 2.6 Antibodies. 
(a)!Immunoblotting 
 
 
Protein 
 
Primary antibody Secondary antibody 
Radixin anti-Radixin (Abcam, ab52495), 1:500 dilution. 
Anti-Rabbit IgG (whole 
molecule)-Peroxidase 
(Sigma-Aldrich, 1:2000 
dilution) 
UROS anti-UROS (Sigma-Aldrich, HPA044038) 1:100 dilution. 
Anti-Rabbit IgG (whole 
molecule)-Peroxidase 
(Sigma-Aldrich), 1:2000 
dilution. 
ALDOA 
anti-ALDOA (Abnova, 
H00000226-MO2), anti-
ALDOA (Santa Cruz 
Biotechnology, sc390733)  
1:500 dilution. 
Anti-Mouse IgG (whole 
molecule)-Peroxidase 
(Sigma-Aldrich), 1:2000 
dilution. 
a-Tubulin 
anti-a-Tubulin (Sigma 
Aldrich, T5168), 1:1000 
dilution. 
Anti-Mouse IgG (whole 
molecule)-Peroxidase 
(Sigma-Aldrich), 1:2000 
dilution. 
 
(b)!Confocal microscopy 
 
 
Protein 
 
Primary antibody Secondary antibody 
UROS 
anti-UROS (Santa Cruz 
Biotechnology, sc-365120), 
1:50 dilution. 
Goat anti-Mouse IgG H&L 
(Alexa Fluor® 568), 1:1000 
dilution. 
ALDOA 
anti-ALDOA (Santa Cruz 
Biotechnology, sc390733), 
1:200 dilution. 
Goat anti-Mouse IgG H&L 
(Alexa Fluor® 488), 1:1000 
dilution. 
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2.10.1!PCR amplification and gel extraction DNA sites 
For the amplification DNA sites of UROS and ALDOA, REDTaq® ReadyMix™ PCR 
Reaction Mix (Sigma-Aldrich) was used and primers were designed to add Bglll and EcoRl 
restriction sites as shown below in Table 2.6. Each reaction consisted of 5 µl of both primers 
(forward and reverse), 2 µl of cDNA, 25 µl of RedTaq and 13 µl of ddH2O. The cDNAs used 
were generated from untreated PC3-GFP cells as explained in Section 2.8.3. Several PCR 
reactions were run at a series of temperatures and amplified DNAs were all run on 1 % agarose 
gel in 1x TAE buffer (Section 2.1.2) to access their quality and lengths. Gels were visualized 
using the AlphaImager EP MultiImage I system (Alpha Innotech).  
For gel extraction of DNAs, bands were visualized using a UV box to help cut them 
precisely. The cut bands were placed in 1.5 ml tubes. DNA was extracted using GeneJET Gel 
Extraction Kit by following the manufacturer’s protocol. 
2.10.2!Ligation into pGEM T-easy vector and transformation 
DNA fragments were ligated into pGEM T-easy vector (Promega) (Figure 2.5) 
according to the kit’s guidelines. The reaction consisted of 1 µl (50 ng) of pGEM vector, 2 µl 
of DNA, 2 µl of 10x Ligase buffer, 14 µl of ddH2O and 1 µl of Ligase enzyme. The reaction 
was incubated overnight at 4 oC. 
Vectors were then transformed into Escherichia coli XL-1 competent cells (Promega). 
In brief, 1 µl of the ligation reaction was added to 50 µl of competent cells that has been 
defrosted on ice. Reactions were incubated for 30 minutes on ice before heat shocking them for 
45 seconds at 42 oC. Reactions were then placed on ice for 2 minutes and 450 µl of SOC 
medium (Section 2.1.2) was added and left shaking for 1 hour at 37 oC. In a fume hood, 200 µl 
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Table 2.7 Primers’ sequences used to amplify studied DNA sites and add restriction 
sites. 
Primer Name Sequence (5’-3’) 
ALDOAFBglll AGATCTATGCCCTACCAATATCCAGC 
ALDOAREcoRl GAATTCTTAATAGGCGTGGTTAGAGACGA 
UROSFBglll AGATCTATGAAGGTTCTTTTACTGAAGGATG 
UROSREcoRl GAATTCTCAGCAGCAGCCATGG 
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Figure 2.5 Map of pGEM-T Easy vector. Taken from: Promega.co.uk 
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of the reaction was spread on a LB agar plate supplemented with 50 µg/ml ampicillin (Sigma-
Aldrich) on which a mixture of 4 µl IPTG (Isopropyl-B-D-thiogalalctoside) and 40 µl Xgal was 
spread on the surface. Plates were left overnight at 37 oC. After incubating plates overnight for 
white-blue colonies screening, single white colonies were picked carefully each by a sterile tip 
and inoculated into 5 ml of LB broth containing 50 µg/ml ampicillin (Table 2.2). Cultures were 
incubated at 37 oC overnight in a shaking incubator. 4.5 ml of each culture was centrifuged at 
8000 rpm for 1 minute at RT, pellets were used for the following plasmid extraction. 
2.10.3!Plasmid DNA extraction and sequencing 
Pellets from the previous section were used to extract the plasmid DNAs using GeneJET 
Miniprep Kit (Themo Scientific) by following the manufacturer’s guidelines. DNA yield was 
measured using a NanoDrop® ND-1000 UV/VIS Spectrophotometer (Nanodrop, Thermo 
Scientific). Samples were digested using Bglll and EcoRl and run on 1% agarose gel together 
with uncut pGEM vector containing the corresponding DNA insert for size conformation. 
Sequencing (Biosciences) confirmed that all sequences were efficiently ligated into the pGEM 
vector. Primers used are shown in Table 2.8. 
2.10.4!Re-cloning into pEGFP-c1 vector 
After cloning the sites efficiently into pGEM T-easy vector, digestion with the 
corresponding restriction enzymes was followed and samples were separated on 1 % agarose 
gel together with pEGFP-c1 vector sample (Figure 2.6). Gel extraction of DNA, ligation, and 
transformation steps were followed as explained in cloning into pGEM T-easy vector above. 
Colonies were grown on a larger scale by adding 500 µl of grown competent cells to 200 ml of 
LB broth containing 50 µl/ml kanamycin (Sigma-Aldrich). Cultures were left to grow overnight 
in a shaking incubator at 37 oC and harvested by centrifugation at 6000 rpm at 4 oC for 15  
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Table 2.8 Primers used for sequencing of UROS and ALDOA inserts. 
Description Sequence 
pGEM F GTAAAACGACGGCCAGT 
pGEM R CATGGTCATAGCTGTTTCC 
EGFP-C F CATGGTCCTGCTGGAGTTCGTG 
EGFP-C R GTTCAGGGGGAGGTGTG 
 
 
 
 
Figure 2.6 Plasmid map of pEGFP-C1 vector (designed by SnapGene software). 
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minutes.  
Plasmid DNA was extracted using Fast Ion TM Plasmid Midi Advanced Kit 
(RBCBiosciences) according to manufacturer’s standard protocol. DNA concentrations were 
measured NanoDrop® ND-1000 UV/VIS Spectrophotometer (Nanodrop, Thermo Scientific). 
Digested an un-digested pEGFP-C1 samples were separated on 1% agarose and were also 
sequenced (primers used are shown in Table 2.8), 100 ng/µl. UROS and ALDOA sequences 
were compared to that available in the National Centre for Biotechnology Information (NCBI). 
2.10.5!DNA transient transfection of UROS and ALDOA containing pEGFP-C1 
vectors into PC3 cells 
TurboFect Transfection Reagent (Thermo Fisher) was used to transfect cells with 
plasmid DNAs. Briefly, 5 x 104 cells/well were seeded in 24 well plated and left overnight to 
adhere. 1 µg of the corresponding plasmid DNA was diluted in 100 µl of serum-free RPMI and 
2 µl of the transfection reagent was added. They were mixed by pipetting and incubated for 20 
minutes at RT. 100 µl of the transfection reagent/DNA mixture was added dropwise to each 
well and incubated for 24 hours. Transfection efficiency was confirmed by imaging cells using  
NikonTi wiedfiled microscope; blue light 470 nm via a CoolLED pE excitation system. 
For confocal microscopy, transient transfection was carried out using cells grown on glass 
coverslips. After 24 hours, cells were fixed with 4% paraformaldehyde (PFA) and coverslips 
were mounted onto glass slides in 4',6-diamidino-2-phenylindole (DAPI)-containing 
Vectashield mounting media. Coverslips were sealed using Marabu Fixogum rubber cement 
(Marabuwerke GmbH & Co.KG, Tamm, Germany) and left to dry before imaging. 
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2.11!Cell fixation and immunofluorescent probing  
For immunofluorescence labelling, untreated PC3 cells were firstly washed 3 times with 
warm PBS each for 5 minutes and then fixed with 4% PFA at room temperature for 15 minutes 
and then with absolute ethanol for 10 minutes at -20 oC. Cells were then permeabilised for 10 
minutes using 0.1% triton (x100) in PBS followed by three washes for 5 minutes with BPS. 
Cells were then blocked with 1% BSA in PBS-T (0.1% Tween) for 30 minutes. The fixed cells 
were then incubated for 1 hour with diluted primary antibody (1o) using either anti-UROS or 
anti-ALDOA in 1% BSA (Table 2.6). Cells then were washed three times with PBS each for 5 
minutes on a rocker to remove any excess antibody. Cells were then probed for 1 hour with a 
1:1000 dilution of corresponding secondary antibody (2o) in 1% BSA in PBS-T in dark; Goat 
anti-mouse IgG (Alexa Fluor® 568 or Alexa Fluor® 488; Table 2.6) (Abcam). Excess 
secondary antibodies were removed by washing three times with PBS and the cover slips were 
mounted onto glass slides in 4',6-diamidino-2-phenylindole (DAPI)-containing Vectashield 
mounting media and sealed using Marabu Fixogum rubber cement (Marabuwerke GmbH & 
Co.KG, Tamm, Germany).  
2.11.1!Laser scanning confocal microscopy for proteins localization 
Cells were imaged by Nikon A1R confocal microscope using an- apochromatic violet 
corrected (VC) 1.4 Numerical Aperture (N.A.) 60x oil- immersion objective and Nikon A1plus 
camera at a Refractive Index (RI) of 1.515. A laser power of 12 arbitrary units (AU) was used 
for the excitation of DAPI at a wavelength of 405 nm, and the emission was collected using a 
PMT gain of 100 AU at 450/50nm. Alexa Fluor 488 (GFP, green fluorescent protein) was 
excited using a laser power of 5.8 AU at 488 nm, and emission was collected using 120 AU 
gain at 525/50 nm. Alexa Fluor 568 (red signal) was excited at 561 nm using a laser power of 
2.3 AU and signal collected at 120 AU gain at 595/50 nm. 3D images were obtained using z-
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steps of 1.0 µm, and images were reconstructed by maximum intensity using NIS-Elements 
software (Nikon).      
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3 Chapter 3 Results I 
3! Screening for novel therapeutic targets that regulate prostate cancer 
proliferation and migration 
Regardless of the fact that some prostatic tumours are not AR-driven, most preserve 
elevated levels of AR which maintains their survival and progression into CRPC (Hodgson et 
al. 2012; Jernberg et al. 2017). Therefore, first line therapies, for non-organ confined disease, 
target this axis. Although initially successful, these therapies invariably fail, and the disease 
progresses to the aggressive castrate resistant stage, for which few therapeutic options exist. 
There is therefore a great need to identify novel therapeutic targets for the treatment of the 
disease. Altered metabolism is a common feature of tumorigenesis, however the metabolic 
changes present in prostate cancer differ to that seen in other cancers.  For example, early 
disease does not rely on the Warburg effect or high glucose uptake as other cancers do 
(Eidelman et al. 2017). Prostate tumours, especially in early stages are more dependent upon 
other molecules such as lipids and citrate oxidation through TCA cycle for energy production 
(Sadeghi et al. 2015).  
Generally, metabolism of malignant cells differs from that of normal cells. Cancer cells 
tend to not follow the orderly metabolic machinery that normal cell use, which allows a 
controlled proliferation that will be inhibited by cellular contact or signals of errors like DNA 
damage (Kalyanaraman 2017). These regulatory manners are lacked in tumours, cancer cells 
continuously grow regardless of the contact inhibition, poor-nutrient conditions, and other anti-
proliferative factors. Therefore, they require adaptive pathways to make more energy to meet 
their higher demand for prolonged survival. The metabolic reprogramming has been linked to 
the oncogenic stimulation of key metabolic pathways (Michalopoulou et al. 2016). For 
example, alteration in the phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target 
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of rapamycin (mTOR),PI3K/Akt/mTOR metabolic cascades result in changes that make the 
cell have intensified ability to uptake glucose (and other nutrients) and synthesize building 
blocks especially proteins (Plas et al. 2001; Thompson 2011; Pavlova & Thompson 2016). The 
oncogenic mutations directly and indirectly alter the metabolism of cells, which renders normal 
and cancer metabolic signalling to be far different from each other (Pavlova & Thompson 
2016). This difference allows a therapeutic window and novel approaches to target cancer 
metabolism. This study was therefore designed to carry out a phenotypic screen, targeting 
metabolic and cell traffic signalling, in a cell line model of castrate resistant disease (PC3).  The 
first aim of this project was to investigate the effect of siRNA depletion of metabolic and cell 
traffic factors upon proliferation and migration of the PC3 cell line model.  
3.1! Identification of metabolic factors affecting PCa cell proliferation  
3.1.1! Screening for metabolic factors that regulate PC3 proliferation 
To identify novel metabolic targets involved in prostate cancer growth, a semi-high-
throughput screen was carried out using an siRNA library targeting 217 metabolic and cell 
traffic factors.  The library consists of three different siRNA oligonucleotides for each factor to 
reduce false-positives; which could result from the off-target effects. siRNA knockdown was 
performed in PC3 cell line, which is an androgen-independent cell line model that was 
established from a human prostatic adenocarcinoma metastatic to the bone (Kaighn et al. 1979). 
The screening was carried out in triplicates and the effect upon proliferation was measured 
using crystal violet (CV) staining on day 6 post-transfections (Figure 3.1).  
The analysis identified 40 targets that significantly affected PC3 proliferation compared 
to NTC (Figure 3.2) (P < 0.05; LSD post hoc test). From the heat map, it can be seen that more 
factors were enhanced (26 targets) than inhibited (14 targets) PC3 proliferation.  The genes 
found to have the most significant inhibitory effects upon proliferation following depletion were 
uroporphyrinogen III synthase  
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Figure 3.1 An siRNA screen to evaluate the impact of depletion of metabolic and cell 
traffic factors on PC3 growth. 
PC3 cells were seeded at 1000 cells per well in a 96 well plates 24 hours before transfection. All siRNA 
transfections were performed in triplicate and all plates included the necessary controls. The medium 
was replaced 10-15 hours after the treatment, and cells left to grow for further 6 days. Cells were fixed, 
stained with crystal violet, and absorbance was read using a spectrophotometer microplate reader 
(FLUOstar Omrega) at a wavelength of 490 nm. Each data point represents the average cell growth 
(three individual siRNAs per gene in triplicate) relative to non-targeting control (NTC). The blue line 
indicates NTC and the red circle is a positive control knockdown (polo-like kinase 1, PLK1).  
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Figure 3.2 A Heat map representing the fold change of PC3 cell proliferation when 
transfected against 40 metabolic related factors by siRNA. 
PC3 were transfected with siRNA targeting proteins involved in metabolism and cellular trafficking. 6 
days after transfection, cells were fixed and stained with crystal violet.  A heat map was generated for 
the genes found to significantly affect PC3 proliferation compared to NTC-siRNA transfection. NTC = 
non-targeting control.  Positive control = polo-like kinase 1, PLK1. 
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(UROS), Glycine C-acetyltransferase (2-amino-3-ketobutyrate coenzyme A ligase) (GCAT), 
and Aldolase A, fructose-bisphosphate A (ALDOA) (82, 81 and 78 % inhibition of growth 
compared to NTC, respectively) (Table 3.1). Table 3.1 summarises the list of lead targets, gene 
description, the pathways that they are involved in, and the associated inhibition of proliferation 
rate. Targets that significantly elevated PC3 proliferation are listed in Table 7.1 (Appendix). 
3.1.2! Validation of lead targets implicated in PCa proliferation 
To validate the 14 hits that showed an inhibitory effect on PCa proliferation, further 
proliferation assays were performed using PC3 and other PCa cell lines including LNCaP, 
which is a hormone-sensitive cell line that was originated from a metastatic lesion of prostatic 
adenocarcinoma grew in a lymph node of a patient that developed hormone-refractory disease 
after ADT (Horoszewicz et al. 1980; Horoszewicz et al. 1983), and DU145, which is a model 
of castration resistant prostate cancer (like PC3) that derived from a brain metastatic 
adenocarcinoma (Stone et al. 1978). The data shown represent the average effect of three 
siRNAs for each target, and it was made relative to NTC (non-targeting control) (Figure 3.3) 
(P < 0.05, Dunnett’s comparison test).  Knockdown of all of the targets resulted in a significant 
reduction in the proliferation of PC3 and LNCaP.  siRNA depletion of the hits also significantly 
inhibited DU145 proliferation, with the exception of GCLC (Glutamate-cysteine ligase 
catalytic subunit) and MARS (Methionyl-tRNA synthetase). Data demonstrated that nearly all 
hits reduced proliferation to a similar level in the three PCa cell lines (Figure 3.3). The 
knockdown of these hits in the Benign Prostatic Hyperplasia-1 cells (BPH1), non-transformed 
human prostate epithelial cells derived from a patient with BPH disease (Hayward et al. 1995), 
demonstrated no significant changes apart from ALDOA and GCLIC knockdowns which 
resulted in some significant decrease in the proliferation of these cells (Figure 3.3). 
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Table 3.1 Summary of the lead targets identified in the siRNA screen to reduce 
proliferation. 
Symbol 
(symbol 
in screen) 
Gene Description    Pathways Inhibition of Relative 
Proliferation 
P-value 
UROS Uroporphyrinogen 
III synthase  
Catalyzes the fourth step of 
porphyrin biosynthesis in the 
heme biosynthetic pathway. 
 
82% < 0.0001 
GCAT Glycine C-
acetyltransferase (2-
amino-3-
ketobutyrate 
coenzyme A ligase) 
Implicated in the degradiation 
of L-threonine to glycine. 
 
82% < 0.0001 
ALDOA Aldolase A, 
fructose-
bisphosphate A 
Reversible conversion of 
fructose-1,6-bisphosphate to 
glyceraldehyde 3-phosphate 
and dihydroxyacetone 
phosphate. 
 
78% 0.0241 
NOS3 Nitric oxide 
synthase 3 
Serves as a biologic mediator 
in neurotransmission and 
antimicrobial and anti-
tumoral activities. 
 
73% 0.0001 
TYMS Thymidylate 
synthetase 
Catalyzes methylation of     
deoxyuridylate to 
deoxythymidylate. 
 
70% 0.0032 
PAFAH2 Platelet activating 
factor 
acetylhydrolase 2 
 
Catalyzes the removal of the 
acetyl group at the SN-2 
position of platelet-activating 
factor. 
 
65% 0.0363 
FDPS Farnesyl 
diphosphate 
synthase 
Catalyzes the production of 
geranyl pyrophosphate and 
farnesyl pyrophosphate from 
isopentenyl pyrophosphate. 
 
63% 0.0036 
ACSM1 Acyl-CoA 
synthetase medium 
chain family 
member 
 
Unkwon. 62% 0.0227 
MARS 
 
Methionyl-tRNA 
synthetase 
Protein biosynthesis. 57% 0.0339 
ACACA 
 
Acetyl-CoA 
carboxylase alpha 
Fatty acid synthesis. 53% 0.0310 
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SLC27A1 Solute carrier family 
27 
 member 1 
Translocation of long-chain 
fatty acids (LFCA) across the 
plasma membrane. 
 
53% 0.0037 
HAS3 
 
 
Hyaluronan synthase 
3 
Hyaluronic acid synthesis. 53% 0.0477 
GART Glycinamide 
ribonucleotide 
transformylase 
  
Purine biosynthesis. 
 
44% 0.0386 
GCLC Glutamate-cysteine 
ligase catalytic 
subunit, gamma-
glutamylcysteine 
synthetase! 
 
The rate-limiting enzyme of 
glutathione synthesis. 
42% 0.0458 
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Figure 3.3 Validation growth assays of 14 hits in prostate cancer (PC) cell lines and BPH1 
cells. 
Cells were transfected with siRNAs against metabolic hit targets (as indicated on the graphs). Three 
siRNAs were used individually to knockdown every target and the effect upon proliferation was assessed 
using crystal violet assays. Data was made relative to the negative control (NTC) and it represents 
mean±1SD of 3 repeats of 3 individual siRNAs. ANOVA via Dunnett’s comparison test was used to 
quantify the statistical significance (*P <0.05, **P <0.01, ***P < 0.001, ****P < 0.0001).                                                                                                                                                                                                       
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3.2! Identification of metabolic factors affecting PCa migration 
Metastasis is a hallmark of cancers. The treatment of localised prostate cancer with ADT 
showed good long-term clinical outcomes, although 10-50 % of patients will experience relapse 
and will demonstrate metastasis (Shelley et al. 2008). Prostate cancer tumours tend to spread to 
bones forming secondary tumours which are incurable, bony metastasis gives rise to the high 
rates of the disease-specific morbidity and  mortality (Manca et al. 2017). The migration ability 
of cancer cells is an important aspect and research have focused on the alterations that could 
supress the migratory potential of malignant cells. Therefore, blocking prostate cancer cell 
motility in respect to metabolic signalling was of interest. 
The aim of this part was to screen for novel metabolic targets and pathways that 
contribute to migration and metastatic properties of PCa cells. Therefore, the siRNA screen was 
repeated in PC3-GFP cell line (PC3 cells stably transfected with empty GFP) (Chapter 2, 
Section 2.3.2). Changes in single cell motility (single cell speed) of siRNA-transfected PC3 
cells was quantified using tracking analysis of cells that have been imaged in time-lapse image 
sequences. Images were acquired over 24 hours using a widefield microscope (Eclipse Ti; 
Nikon) equipped with a motorized stage and incubator chamber.  
3.2.1! Optimization of single cell tracking  
Prior to the screen, the procedure was optimised using negative (siRNA-non-targeting 
control, NTC) and positive controls (siRNA-radixin).  Radixin is one of ezrin/radixin/moesin 
(ERM) family proteins that are implicated in the linkage of plasma membrane receptors and 
actin cytoskeleton (Tsukita & Yonemura 1997). In addition, ERM proteins function in 
signalling pathways that regulate cell migration and cell polarity (Fehon et al. 2010). A previous 
work by Valderrama et al. (2012) found that radixin regulates migration and adhesion of PC3 
cells. The depletion of Radixin in by siRNA transient transfection in PC3 cells demonstrated a 
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significant reduction (62%) of PC3 single cell speed (Valderrama et al. 2012). Therefore, the 
siRNA transfection against radixin was employed as a positive control.  
To confirm successful knockdown of radixin, prior to screening, GFP-PC3 cells were 
seeded in 6 well plates and transfected with either NTC or radixin-siRNA.  Cells were incubated 
for 3 days, harvested and the effect upon radixin expression analysed using qPCR and 
immunoblotting. Figure 3.4 (a) and (b) shows that radixin knockdown was successful both at 
the RNA and protein levels, with expression reduced by more than 90 % compared to NTC. 
3.2.2! The effect of Radixin knockdown on motility  
For the screen, I developed a live cell-based semi-high throughput protocol that can be 
performed in 96-well plates. Cells were seeded sparsely (500-700 cell per well) to avoid cells 
becoming too confluent, which would have had an impact upon cell motility. Time-lapse 
microscopy was employed to take images of the chosen fields of view every 15 minutes, 72 
hours after transfection. Before applying a tracking algorithm to follow single-cell trajectories, 
time-lapse images needed to be pre-processed in order to segment objects (cells in this case) 
from the background (Chapter 2 (2.3.2.2), Figure 2.1). Thresholding was subsequently applied 
to label anything above the intensity threshold as an object and the rest as background 
(Meijering et al. 2012). The Trackmate module in ImageJ was initially employed to analyse the 
tracks and cell motility (Tinevez et al. 2017). Figure 3.5 shows a graphical example of the 
Trackmate output of PC3-GFP cells transfected with siRNA-NTC and -radixin. 355 trajectories 
for each phenotype were analysed using the Trackmate algorithm and cells that appeared in less 
than 50 frames were excluded from the analysis for accuracy (Figure 3.6).  
Radixin-depleted cells were relatively static compared to controls which appeared to be 
more motile, Figure 3.6 (a), and analysis confirmed that this gene knockdown significantly 
reduced PC3 cell speed (micron/minute) compared to NTC and mock transfected cells. Control 
cells demonstrated a speed of 0.48-0.58 µm/min, while radixin-siRNA transfected PC3 cells 
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Figure 3.4 Confirmation of radixin knockdown at the RNA and protein levels. 
PC3-GFP were transfected with siRNA-NTC or -radixin and incubated for 72 hours. (a): Cells were 
harvested, RNA extracted and cDNA synthesised. Radixin expression was subsequently quantified 
using qPCR. Data represent mean±1SD of three independent repeats. ANOVA by Dunnett’s post hoc 
comparison test, ****P < 0.0001. (b): Cells were harvested, and proteins separated using SDS-PAGE. 
Immunoblotting was subsequently performed using antibodies specific for radixin or %-tubulin (loading 
control).  
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Figure 3.5 Mean velocity (micron/frame) of cells following depletion of radixin. 
PC3-GFP were transfected with siRNA-NTC or -radixin and incubated for 72 hours, and on day 4 
imaging was performed by widefield microscope. Images of Radixin-depleted and control cells were 
acquired every 15 minutes over 24 hours, time-lapse sequences were then used to calculate mean of cell 
speed (µm/frame) by a semi-automated method. Images show the mean speed of tracks of NTC-siRNA 
transfected versus Radx (Radixin)-siRNA transfected PC3 cells. These data graphs were made by 
Trackmate plugin in ImageJ. 
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Figure 3.6 Quantification of PC3-GFP motility using a semi-automated algorithm 
(Trackmate). 
Images of Radixin-depleted and control cells were acquired every 15 minutes over 24 hours and time-
lapse sequences were used to calculate cell speed (µm/min).  (a): shows images of tracks of radixin-
depleted cells compared to control (NTC-transfected) cell tracks. (b): Bar chart of mean cell speed per 
minute (micron/minute). Data is mean±1SD of more than 100 trajectories, three independent repeats. 
Kruskal-Wallis (Dunn’s post hoc test).  ****P < 0.0001. 
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migrated at a mean speed of 0.19 µm/min or less Figure 3.6 (b). 
3.2.3! Tracking analysis automation 
Processing of large image-based datasets can be streamlined through the use of 
automation. In the case of this study, hundreds of individual transfections were performed with 
a minimum of 4 images per repeat. Therefore, further work was required to simplify the data 
analysis. Quantification of image sequences required multiple steps, including image pre-
processing (background subtraction and thresholding), tracking, and statistical analysis. To 
streamline this process, two macros using existing ImageJ plugins were created to automatically 
pre-process the image sequences (Methods Chapter, Section 2.3.2.2). The first macro converted 
the ICS files to TIF files prior to image pre-processing. Both steps were further automated by 
adding a batch routine which makes the macro automatically pre-process a group of images at 
once by only selecting the input and output directory. Batch analysis using ADAPT plugin 
available in ImageJ (Barry et al. 2015) was then run automatically and data was extracted as 
Excel files for the rest of the analysis. This algorithm was chosen over Trackmate because the 
latter does not allow batch mode analysis, and it requires further processing of the output to 
calculate cell speed, while ADAPT automatically allows entering image parameters into the 
graphical user interface (GUI) and gives cell speed in micron/min. In addition, ADAPT was 
more efficient in cell detection and linking objects between frames. In other words, ADAPT 
tracks most cells to the end frame while Trackmate often loses cells between frames and detects 
and follows them as new objects resulting in a high number of short tracks. 
The same dataset used in Figure 3.6 was reanalysed using the ADAPT algorithm (Figure 
3.7).  The results of the ADAPT analysis (Figure 3.7 b) gave a similar trend as when Trackmate 
was applied (Figure 3.7 a), with radixin knockdown significantly decreasing PC3 motility 
compared to controls. However, there is a slight difference in the mean speed values when 
comparing the two methods, and this can be explained by the mentioned drawbacks of  
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Figure 3.7 Quantification of PC3-GFP cell speed using batch mode based pre-processing 
macros and an automated tracking algorithm (ADAPT) versus results of the semi-
automated method. 
Images of Radixin-depleted and control cells were acquired every 15 minutes over 24 hours. The time-
lapse sequences were used to calculate cell speed per minute. (a) cell speed was quantified by semi-
automated method (Trackmate), and (b) shows cell velocity quantified using automated method 
(ADAPT).  Data represent mean±1SD of at least 100 cells for each phenotype obtained from at least 3 
independent experiments. Kruskal-Wallis (Dunn’s post hoc test), ****P < 0.0001. 
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Trackmate over ADAPT. 
3.2.4! Screening for the identification of metabolic targets regulating prostate 
cancer motility 
Single cell tracking analysis following siRNA knockdown of 217 targets was performed 
with the aim of identifying novel therapeutic targets that block cell motility (Figure 3.8).  
Depletion of more than 100 targets significantly affected cell motility relative to NTC control 
(P< 0.05, Dunn’s test); statistical analysis performed by using all 3 siRNAs data together for 
each target compared to NTC. To be more stringent, a cut-off was used to reduce the list of 
targets. The cut-off included only targets that their knockdowns led to an average cell speed of 
greater than 1.25 µm/min or less than 0.65 µm/min (relative to NTC). Therefore, the resulted 
list included only 55 targets and 3 of which increased PC3 cell speed compared to NTC-
transfection (Figure 3.9). Knockdown of UROS led to the most significant reduction in PC3 
migration; 67% reduction in motility compared to NCT control data. Interestingly, knockdown 
of UROS resulted in a greater inhibition of PC3 motility compared to the positive control 
Radixin. Knockdown of other targets, including Nitric oxide synthase 3(NOS3), Ferrochelatase 
(FECH), scribble cell polarity complex component (LLGL2), ALDOA, and sphingomyelin 
synthase 2 (MGC26963) also led to a decrease in cell motility by more than 50 % (Table 3.2).  
Several targets identified to inhibit motility were also found to have a significant effect upon 
PC3 proliferation. UROS, NOS3, ALDOA, hyaluronan synthase 3 (HAS3), platelet activating 
factor acetylhydrolase 2 (PAFAH2), and Farnesyl diphosphate synthase (FDPS) demonstrated 
a considerable reduction of PC3 cell proliferation as reported previously in this work (Figure 
3.3 and Table 3.1). Table 3.2 exhibits information about 18 targets of interest that demonstrated 
a significant effect upon PC3 motility by each of the 3 siRNAs used (P < 0.01, Dunn’s test). 
The other 37 targets that were identified by the cut-off are shown in Figure 7.2 (Appendix). 
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Figure 3.8 An siRNA screen to identify metabolic and cell traffic factors that affect cell 
motility. 
PC3 were transfected with siRNA targeting 217 metabolic and cell traffic factors (3 siRNA per gene). 
Single cell motility was measured by automated analysis of time-lapse sequences acquired 4 days post 
transfection (10X objective of Nikon Eclipse Ti widefield microscope, 24 hours of imaging). The data 
plotted represents the average speed of three siRNA transfections of each target (each siRNA treatment 
included a minimum of 30 cells) and error bars are the standard deviations (SD). Data was made relative 
to the NTC (line) present in every run. The green circles highlight the targets’ knockdowns that were 
chosen according to the used cut-off, 1.25 > average speed (!µm/min) < 0.65. The red circle represents 
the positive control (Radixin knockdown) and the blue line represents the speed of NTC-siRNA 
transfected PC3 cells. 
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Figure 3.9 Heat map of lead targets affecting PC3 cell migration. 
The heat map shows the knockdowns that led to significant reduction of PC3 cell migration (µm/min) 
relative to NTC according to the used cut-off of 1.25 > average speed (µm/min) < 0.65. The plotted 
data is of 55 targets where almost each of the three siRNAs used resulted in a significant reduction of 
cell speed of PC3 in comparison with NTC-siRNA treated cells. The individual effect of used siRNAs 
is shown as well as the average effect of the three siRNAs. Positive control = RDX (Radixin). 
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Table 3.2 Summary of the lead targets identified in the siRNA screen to significantly 
reduce cell motility. 
Symbol 
(symbol in 
screen) 
Gene Description    Pathways Inhibition of 
Motility (%) 
UROS uroporphyrinogen III synthase  Catalyzes the fourth step of 
porphyrin biosynthesis in 
the heme biosynthetic 
pathway. 
 
67.3% 
NOS3 
 
Nitric oxide synthase 3 
 
Afree radical implicated 
in processes including 
neurotransmission and 
antimicrobial and anti-
tumoral activities. 
 
59.3% 
FECH Ferrochelatase 
 
Catalyses the insertion of 
the ferrous form of iron into 
protoporphyrin IX in the 
heme synthesis pathway. 
 
59% 
LLGL2 
 
scribble cell polarity complex 
component 
 
The encoded protein is 
similar to the lethal (2) giant 
larvae of Drosophila, which 
functions in asymmetric cell 
division, epithelial cell 
polarity, and cell migration.  
 
 
58% 
ALDOA Aldolase A, fructose-
bisphosphate A 
Reversible conversion of 
fructose-1,6-bisphosphate to 
glyceraldehyde 3-phosphate 
and dihydroxyacetone 
phosphate. 
 
56% 
MGC26963 sphingomyelin synthase 2 
 
Essential for cell growth. 
Catalyses the transfer of 
phosphocholine from 
phosphatidylcholine  
onto ceramide to make 
Sphingomyelin, a major 
component of cell and Golgi 
membranes.  
 
51% 
siRNA1 siRNA3 siRNA2 Average 
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TXNDC13 TMX4,!thioredoxin related 
transmembrane protein 4 
 
A member of the disulfide 
isomerase (PDI) family of 
endoplasmic reticulum (ER) 
proteins that play roles 
in protein folding and  
thiol-disulfide interchange 
reactions. 
 
48% 
FKBP11 FK506 binding protein 11 
 
Implicated in the catalysis 
of the folding of proline-
containing polypeptides. 
 
48% 
HMGCS2 3-hydroxy-3-methylglutaryl-CoA 
synthase 2 
 
It is a mitochondrial enzyme 
that catalyses the first 
reaction of ketogenesis, a 
metabolic pathway that 
makes lipid-derived energy 
for various organs when 
required. 
 
47% 
STX1A 
 
syntaxin 1A 
 
Syntaxins are nervous 
system-specific proteins 
which function in the 
docking of synaptic vesicles 
with the presynaptic plasma 
membrane.  
 
46% 
HAS3 hyaluronan synthase 3 
 
Involved in the synthesis of 
the unbranched 
glycosaminoglycan 
hyaluronan, or hyaluronic 
acid, which is a major 
constituent of the 
extracellular matrix. 
 
46% 
FKBP9L FK506 binding protein 9 
pseudogene 1 
 
Unknown. 46% 
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PAFAH2 platelet activating factor 
acetylhydrolase 2 
 
The encoded enzyme 
catalyses the removal of the 
acetyl group at the SN-2 
position of platelet 
activating factor. 
 
45% 
LARS2  leucyl-tRNA synthetase 2 
 
This gene encodes a 
mitochondrial leucyl-tRNA 
synthetase which implicates 
in catalysis of the 
aminoacylation of a specific 
tRNA. 
 
44% 
OTOP3 otopetrin 3 
 
Unknown. 42% 
FASN fatty acid synthase 
 
The encoded enzyme mainly 
catalyses the synthesis of 
palmitate from acetyl-CoA 
and malonyl-CoA into long-
chain saturated fatty acids. 
 
42% 
SLC27A5 solute carrier family 27  
member 5 
 
Activation of very long-
chain fatty-acids containing 
24- and 26-carbon. 
 
42% 
FDPS Farnesyl diphosphate synthase Catalyzes the production of 
geranyl pyrophosphate and 
farnesyl pyrophosphate from 
isopentenyl pyrophosphate. 
 
40% 
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3.2.5! Validating targets that significantly affect PCa cell migration 
Only 10 hits, that showed the most significant reduction of PC3 cell speed (Table 3.2), 
were selected for validations. As for the siRNA screen, each factor was depleted using three 
individual siRNAs and cells left for 72 hours prior to imaging for 24 hours. The experiments 
were repeated at least 3 times and 3-4 images of each siRNA transfection were acquired each 
time. The analysis included tracks of more than 100 cells for each siRNA and demonstrated 
that depletion of the majority of factors significantly reduced PC3 cells motility (Figure 3.10-
3.19). The only exception was HMGCS2 which exhibited no significant change in PC3 motility 
for two of the siRNAs tested (Figure 3.19).  
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Figure 3.10 Quantification of the effect of ALDOA knockdown upon single cell tracking 
in GFP-PC3 cells. 
Cells were transfected with 3 individual siRNAs targeting ALDOA, or positive and negative control 
siRNA (Radx and NTC). Images were acquired every 15 minutes using a Nikon Eclipse Ti widefield 
microscope. A: a panel of representative images of cell tracks after knockdowns. Images were generated 
using Trackmate (ImageJ) using LoG detector and nearest neighbour search tracker. B: A scatter dot 
plot of mean±1SD of cell speed (three independent repeats, a minimum of 30 cells per mean) Kruskal-
Wallis (Dunn’s post hoc test), ****P < 0.0001. 
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Figure 3.11 Quantification of the effect of UROS knockdown upon single cell tracking in 
GFP-PC3 cells. 
Cells were transfected with 3 individual siRNAs targeting UROS, or positive and negative control 
siRNA (Radx and NTC). Images were acquired every 15 minutes using a Nikon Eclipse Ti widefield 
microscope. A: a panel of representative images of cell tracks after knockdowns. Images were generated 
using Trackmate (ImageJ) using LoG detector and nearest neighbour search tracker. B: A scatter dot 
plot of mean±1SD of cell speed (three independent repeats, a minimum of 30 cells per mean) Kruskal-
Wallis (Dunn’s post hoc test), ****P < 0.0001. 
NT
C-
siR
NA
Ra
dx
-si
RN
A
UR
OS
-si
RN
A1
UR
OS
-si
RN
A2
UR
OS
-si
RN
A3
0.0
0.1
0.2
0.3
0.4
0.5
C
el
l s
pe
ed
 (u
m
/m
in
)
****
****
****
****
B
NTCDsiRNA RadxDsiRNA 
UROSDsiRNA1 UROSDsiRNA2 UROSDsiRNA3 
A 
 
 
162 
 
                                 
Figure 3.12 Quantification of the effect of FDPS knockdown upon single cell tracking in 
GFP-PC3 cells. 
Cells were transfected with 3 individual siRNAs targeting FDP, or positive and negative control siRNA 
(Radx and NTC). Images were acquired every 15 minutes using a Nikon Eclipse Ti widefield 
microscope. A: a panel of representative images of cell tracks after knockdowns. Images were generated 
using Trackmate (ImageJ) using LoG detector and nearest neighbour search tracker. B: A scatter dot 
plot of mean±1SD of cell speed (three independent repeats, a minimum of 30 cells per mean) Kruskal-
Wallis (Dunn’s post hoc test), ****P < 0.0001. 
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Figure 3.13 Quantification of the effect of FECH knockdown upon single cell tracking in 
GFP-PC3 cells. 
Cells were transfected with 3 individual siRNAs targeting FECH, or positive and negative control 
siRNA (Radx and NTC). Images were acquired every 15 minutes using a Nikon Eclipse Ti widefield 
microscope. A: a panel of representative images of cell tracks after knockdowns. Images were generated 
using Trackmate (ImageJ) using LoG detector and nearest neighbour search tracker. B: A scatter dot 
plot of mean±1SD of cell speed (three independent repeats, a minimum of 30 cells per mean) Kruskal-
Wallis (Dunn’s post hoc test), ****P < 0.0001. 
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Figure 3.14 Quantification of the effect of NOS3 knockdown upon single cell tracking in 
GFP-PC3 cells. 
Cells were transfected with 3 individual siRNAs targeting NOS3, or positive and negative control 
siRNA (Radx and NTC). Images were acquired every 15 minutes using a Nikon Eclipse Ti widefield 
microscope. A: a panel of representative images of cell tracks after knockdowns. Images were generated 
using Trackmate (ImageJ) using LoG detector and nearest neighbour search tracker. B: A scatter dot 
plot of mean±1SD of cell speed (three independent repeats, a minimum of 30 cells per mean) Kruskal-
Wallis (Dunn’s post hoc test), ****P < 0.0001. 
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Figure 3.15 Quantification of the effect of FKBP11 knockdown upon single cell tracking 
in GFP-PC3 cells. 
Cells were transfected with 3 individual siRNAs targeting FKBP11, or positive and negative control 
siRNA (Radx and NTC). Images were acquired every 15 minutes using a Nikon Eclipse Ti widefield 
microscope. A: a panel of representative images of cell tracks after knockdowns. Images were generated 
using Trackmate (ImageJ) using LoG detector and nearest neighbour search tracker. B: A scatter dot 
plot of mean±1SD of cell speed (three independent repeats, a minimum of 30 cells per mean) Kruskal-
Wallis (Dunn’s post hoc test), ****P < 0.0001. 
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Figure 3.16 Quantification of the effect of MGC26963 knockdown upon single cell 
tracking in GFP-PC3 cells. 
Cells were transfected with 3 individual siRNAs targeting MGC26963, or positive and negative control 
siRNA (Radx and NTC). Images were acquired every 15 minutes using a Nikon Eclipse Ti widefield 
microscope. A: a panel of representative images of cell tracks after knockdowns. Images were generated 
using Trackmate (ImageJ) using LoG detector and nearest neighbour search tracker. B: A scatter dot 
plot of mean±1SD of cell speed (three independent repeats, a minimum of 30 cells per mean) Kruskal-
Wallis (Dunn’s post hoc test), ****P < 0.0001. 
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Figure 3.17 Quantification of the effect of LLGL2 knockdown upon single cell tracking in 
GFP-PC3 cells. 
Cells were transfected with 3 individual siRNAs targeting LLGL2, or positive and negative control 
siRNA (Radx and NTC). Images were acquired every 15 minutes using a Nikon Eclipse Ti widefield 
microscope. A: a panel of representative images of cell tracks after knockdowns. Images were generated 
using Trackmate (ImageJ) using LoG detector and nearest neighbour search tracker. B: A scatter dot 
plot of mean±1SD of cell speed (three independent repeats, a minimum of 30 cells per mean) Kruskal-
Wallis (Dunn’s post hoc test), ****P < 0.0001. 
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Figure 3.18 Quantification of the effect of TXNDC13 knockdown upon single cell tracking 
in GFP-PC3 cells. 
Cells were transfected with 3 individual siRNAs targeting TXNDC13, or positive and negative control 
siRNA (Radx and NTC). Images were acquired every 15 minutes using a Nikon Eclipse Ti widefield 
microscope. A: a panel of representative images of cell tracks after knockdowns. Images were generated 
using Trackmate (ImageJ) using LoG detector and nearest neighbour search tracker. B: A scatter dot 
plot of mean±1SD of cell speed (three independent repeats, a minimum of 30 cells per mean) Kruskal-
Wallis (Dunn’s post hoc test), ****P < 0.0001. 
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Figure 3.19 Quantification of the effect of HMGCS2 knockdown upon single cell tracking 
in GFP-PC3 cells. 
Cells were transfected with 3 individual siRNAs targeting HMGCS2, or positive and negative control 
siRNA (Radx and NTC). Images were acquired every 15 minutes using a Nikon Eclipse Ti widefield 
microscope. A: a panel of representative images of cell tracks after knockdowns. Images were generated 
using Trackmate (ImageJ) using LoG detector and nearest neighbour search tracker. B: A scatter dot 
plot of mean±1SD of cell speed (three independent repeats, a minimum of 30 cells per mean) Kruskal-
Wallis (Dunn’s post hoc test), ****P < 0. 0001. 
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3.3! Bioinformatics analysis and lead targets  
3.3.1! Bioinformatics analysis of hit targets 
Of the 40 factors found to significantly affect PC3 growth (Figure 3.2), the 14 targets 
that inhibited proliferation were selected for bioinformatics analysis (Table 3.1). The Gene 
Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geoprofiles) was used to access the 
gene expression profiles of these 14 hits in order to investigate if expression correlates with 
disease progression. The analysis was also performed for hits that inhibited PC3 cell migration 
(Table 3.2). However, no data was available for some of the hits. Results of GEO analysis 
(Figure 3.20-3.21) showed that the transcript levels of some of these genes, including ALDOA, 
TYMS, NOS3, HAS3, GART, and STX1A, tended to be higher in samples from metastatic 
prostate cancer compared to primary and benign tumorous. The expression of the rest of the 
targets seemed not too significantly altered across prostatic cancer tissues. 
For further investigation, the Human Protein ATLAS (http://www.proteinatlas.org/) 
was employed to investigate changes in the protein levels in tissue samples of normal prostate 
and different grades of Prostate Cancer (Figure 3.22-3.23). The analysis was run for all 
proliferation and migration hits, however there was no data for some hits. Most hits were 
detected in normal and prostatic cancer tissues (Figure 3.22-3.23). Several targets including 
TYMS, FASN, and PAFAH2 showed some correlation with prostate cancer progression (P < 
0.05, Dunnett’s post hoc test). Although the number of samples in available the databases is 
small, the expression of these hits does appear to correlate with disease progression and this 
warrants future investigation. 
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Figure 3.20 Gene expression analysis of proliferation lead targets using Gene Expression 
Omnibus (GEO) database. 
The analysis included data on prostate cancer progression with respect to each individual target. The 
presented data represents mean±SD of 6-7 samples for each type and it was made relative to the Benign 
data average value of each target (re-scales to 1). ANOVA (Dunnett’s post hoc test), *P < 0.05, **P < 
0.01, ***P < 0.001. 
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Figure 3.21 Gene expression analysis of migration lead targets using Gene Expression 
Omnibus (GEO) database. 
The analysis included data on prostate cancer progression with respect to each individual target. The 
presented data is mean±SD of 6-7 samples for each type and it was made relative to the Benign average 
value of each target. ANOVA (Dunnett’s post hoc test), *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 3.22 Human Protein Atlas based analysis of protein expression levels of 
proliferation hits in normal prostate versus low- and high-grade prostatic cancer tissues. 
This dataset was made using the Human Protein Atlas database. The percentages of each staining 
category (negative, weak, moderate, and strong) were calculated in respect to the total number of 
samples in each tissue type (normal, low-grade, or high-grade). ANOVA (Dunnett’s post hoc test), 
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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Figure 3.23 Human Protein Atlas based analysis of protein expression levels of migration 
hits in normal prostate versus low- and high-grade prostatic cancer tissues. 
This dataset was made using the Human Protein Atlas database. The percentages of each staining 
category (negative, weak, moderate, and strong) were calculated in respect to the total number of 
samples in each tissue type (normal, low-grade, or high-grade). ANOVA (Dunnett’s post hoc test), 
*P < 0.05. 
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3.3.2! Lead targets 
For further work, the decisions on which targets to study was made according to several 
aspects but mainly dependent upon their effect on proliferation and/or motility of PC3 cells 
(Table 3.3). The first three hits that led to the highest anti-proliferative effect in PCa cell lines 
were selected. Those are UROS, GCAT, and ALDOA.  UROS and ALDOA also showed high 
anti-migratory profiles in PC3 cells. FDPS and ACSM1 showed interesting results on cell 
migration of PC3 (Figure 6.4). Finally, GCLC was chosen also for further study for its affect 
upon proliferation and according to supporting information from literature where other groups 
have shown that it can promote therapy resistance in tumour cells ( Mulcahy et al. 1994; Kuo 
et al. 1998; Oguri et al. 1998). 
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Table 3.3 Summary of the lead targets. 
Red means that there is an effect as opposed to white which means that there was no effect. NA = 
information is not available +++ means a strong effect, and + is a weak effect. RNA and protein data 
were obtained from GEO and the Human Protein ATLAS analysis tools respectively. 
 
Hit name 
Effect on 
Pc3 
growth 
Effect 
on PC3 
motility 
Transcript 
upregulation 
Protein 
staining 
UROS +++ +++  + 
GCAT +++ +   
ALDOA +++ +++ ++  
NOS3 +++ +++ ++  
TYMS +++  ++ ++ 
PAFAH2 +++ +++  + 
FDPS +++ +++   
ACSM1 +++ +  + 
MARS +++   + 
ACACA +++ +  + 
SLC27A1 +++   NA 
HAS3 +++ +++ +  
GART +++  ++  
GCLC +++    
FECH  +++   
FKBP11 + +++  + 
LLGL2 + +++ +  
HMGCS2  +++   
 
 
179 
STX1A + +++   
FKBP9L + +++  + 
LARS2  +++ +  
FASN + ++  ++ 
SLC27A5  ++ +  
OTOP3 + ++  NA 
TXNDC13  +++  NA 
MGC26963 + +++   
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3.4! The effect of siRNA depletion of the lead targets upon apoptosis and cell 
cycle 
To investigate if knockdown of the lead targets promotes apoptosis, PC3 cells 
transfected with the relevant pools of siRNAs were harvested and DNA hypodiploidy assays 
performed. Flow cytometry (Accuri C6) was used to measure the number of cells in the sub-
G1 phase. Silencing of all targets (except GCLIC) resulted in some elevation in apoptosis 
compared to NTC control or mock-transfected cells (Figure 3.24), although this was only 
significant for ACSM1, UROS and ALDOA (P < 0.05, Dunnett’s post hoc test). Noticeably, 
ACSM1 led to the highest rate of apoptosis in PC3, approximately 65%. Knockdown of UROS 
and ALDOA resulted in 30 % and 26 % apoptosis respectively.  
To further determine the mechanisms behind PC3 cell proliferation inhibition, the effect 
of gene knockdown upon cell cycle was determined using flow cytometry analysis of DNA 
content (Figure 3.25). Cells were harvested on day 6 after transfection, fixed, RNA digested 
with RNase, and DNA stained with PI. Knockdown of ACSM1, UROS and GCAT resulted in 
a significant decrease in the number of cells in G1 (Figure 3.25). This may be explained by the 
fact that the siRNA knockdown of these genes resulted in a significant increase in the total 
number of cells in S phase. Additionally, transfections against UROS and GCAT also increased 
the number of cells in G2/M phase. It, therefore, appears that, prior to apoptosis, knockdown of 
ACSM1 promotes growth arrest in S phase whereas UROS and GCAT depletion caused cells 
to arrest in S phase and G2/M. ALDOA knockdown induced cell death as detected by the 
apoptosis analysis above, although it showed no significant results in respect to cell cycle 
progression.  
 
 
 
181 
 
                    
Figure 3.24  Investigation of the effects of siRNA depletion of the lead targets upon cell 
death. 
Cells were transfected 24-hours after seeding and incubated for 7 days.  Cells were harvested and PI-
stained and immediately measured using FACS. (a) Shows representative images of sub-G1 profiles of 
controls and siRNA transfected PC3 cells; Y-axis represents the number of events or cells and the X-
axis is the PI signal. (b) Graphs indicate the effect of targets knockdowns on the number of cells in sub-
G1 phase. Data represent mean±1SD of 3 independent repeats. ANOVA (Dunnett’s post hoc test), 
*P < 0.05, **P < 0.01, ***P < 0.001.  
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Figure 3.25 Investigation of the effects of siRNA depletion of the lead targets upon cell 
cycle. 
Cells were transfected with a pool of 3 siRNAs against each target and incubated for 7 days.  Cells were 
harvested, fixed and RNase treated prior to staining with PI and analysis using flow cytometry. (a) 
Representative cell cycle profiles of controls and siRNA transfected PC3 cells. (b) Bar graphs represent 
the number of cells (%) in G1, S, and G2/M phases of the cell cycle. Data presented reflects the 
mean±1SD of at least three independent experiments. ANOVA (Dunnett’s post hoc test), *P < 0.05, 
**P < 0.01, ***P < 0.001. 
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3.5! Discussion 
In this study I applied a functional genetic approach to target metabolic signalling in 
CRPC using cell line models. The siRNA approach works on the basis of the association of the 
introduced siRNA with the protein components of the RNA-Induced Silencing Complex 
(RISC). The double stranded siRNA unwinds and its antisense strand binds to the 
complementary mRNA region, resulting in degradation of the bound mRNA and hence a 
subsequent decrease in the level of the corresponding protein (Zeng & Cullen 2002; Kroenke 
et al. 2004; Sledz & Williams 2005; Singh et al. 2016). Unlike in the case of overexpression 
studies, which might give more complex phenotypes, the siRNA-based knockdown of 
endogenous genes tends to give more precise phenotypes (Li et al. 2011).  
One limitation of RNAi approaches is that functional redundancy with other unknown 
genes may lead to a lack of a knockdown phenotype (Ros et al. 2012). Functional redundancy 
would suggest that a particular gene is less critical for a particular cellular function or signalling 
than others which should be prioritized. More importantly, another RNAi limitation is the 
possible off-target effects. siRNA may bind to non-target mRNA due to partial  
complementarity, and therefore downregulate other transcripts resulting in inaccuracy 
(Birmingham et al. 2009). However, this depends on factors such as the specificity of the 
algorithms used in designing siRNA and current algorithms ensure high specificity of siRNA 
sequences (Filhol et al. 2012). In addition, the use of several individual siRNAs for every target 
(the mean effect method) further dilutes the problem of the off-target effect and increases the 
certainty of knockdown specificity (Riba et al. 2017).   
The siRNA library utilized in this study was associated with three distinct siRNA 
sequences per gene and hits were prioritized according to their effect upon proliferation and 
motility, in comparison with non-targeting control siRNA. A gene was considered validated 
only when the average effect of the three siRNAs was statistically different (P < 0.05, LSD post 
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hoc test) from NTC control for the proliferation screen and only when the average effect of the 
three siRNAs was inside the used cut-off [1.25 < average speed (µm/min) > 0.65] for the 
migration screen (Figures 3.1-3.4). Therefore, false-positives should have been filtered out at 
this stage (Table 3.1,3-2) and in support of this, further validation studies confirmed the results 
of the screen.  
Following a stringent selection criteria 26 potential hits were identified; 14 genes down-
regulated proliferation, 18 genes significantly inhibited migration and 6 of which significantly 
affected both (Table 3.1,3-2). The validation experiments (Figure 3.3, Figures 3.10-3.19) led to 
conclude that the screening approach employed was reliable and efficient in identifying novel 
metabolic targets essential for prostate cancer. Importantly, several of the targets have already 
been identified as potential therapeutic targets for the treatment of cancer.  
3.5.1! Lipogenesis and prostate cancer progression  
Several of the identified targets are important factors for fatty acid and cholesterol 
biosynthesis. Some of those are well known enzymes such as FASN, ACACA, and FDPS 
(Chakravarty et al. 2004; Buhaescu & Izzedine 2007; Wang et al. 2009; Wang et al. 2010; 
Currie et al. 2013; Tsoumpra et al. 2015). In contrast, little is known about the role of ACSM1, 
SLC27A1, and SLC27A5 in metabolic signalling and cancer progression.  
3.5.1.1! Fatty acid synthase (FASN) 
Significant inhibition of PC3 cell migration was demonstrated by the siRNA 
knockdown of FASN (Figure 3.9, Table 3.2).  In addition, the Human Atlas analysis suggests 
that FASN expression correlates with disease progression, with some high-grade tumours 
showing higher staining for FASN compared to low-grade tumours and normal prostatic tissues 
(Figure 3.23).  
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FASN is a large homodimeric enzyme (552-kDa)  responsible for the de 
novo biosynthesis of long-chain fatty acids through the formation of palmitic acid from 
carbohydrates (Figure 3.26); palmitic acid is formed from acetyl-coenzyme A (acetyl-CoA) and 
malonyl-coenzyme A (malonyl-CoA) in the presence of NADPH (Chakravarty et al. 2004). 
FASN is a well-studied enzyme, and a significant volume of research has examined its 
biological function and validity as a potential cancer drug target. FASN was found to be over-
expressed in prostate carcinomas and many other cancers (Yoshii et al. 2013), and its inhibition 
resulted in apoptotic cell death and proliferation inhibition of PCa tumours in a dose-dependent 
manner (Pflug et al. 2003).  
In another study, high FASN expression was found to be significantly correlated with 
high Gleason scores and the development of CRPC and the expression of FASN was found 
to be down-regulated in response to ADT and chemotherapy (Huang et al. 2016). FASN 
activity suppression did not only affect cell proliferation but was also reported to halt 
pseudopodia formation and blocked cell adhesion, migration, and invasion (Yoshii et al. 2013). 
FASN inhibition also halted the expression of genes involved in the production of arachidonic 
acid and androgen, both of which stimulate tumour development (Yoshii et al. 2013). Because 
FASN upregulation positively correlated with poor prognosis and since it is expressed at low 
levels in normal tissues, it has been proposed as a therapeutic target (Madigan et al. 2014). 
Several chemical inhibitors of FASN have been developed and these have been shown to 
selectively kill cancer cells (Currie et al. 2013). However, severe side-effects were reported 
for FASN inhibitors in animal models, such as extreme weight loss (Loftus et al. 2000).   
The signalling pathways activated in response to FASN overexpression are not fully 
understood, however, it has been suggested that the upregulation of this gene is directly linked 
to the activation and nuclear accumulation of Akt (Van de Sande et al. 2005). Furthermore, a 
recent study by Huang et al. (2016) on high-fat diet (HFD) versus low-fat diet (LFD) mice with  
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Figure 3.26 Fatty acids de novo biosynthesis pathway. 
FASN, ACACA, and ACS (highlighted) play key roles in fatty acids biosynthesis. FASN is the key 
enzyme in converting citrate into active fatty acids, and ACACA is one of two enzymes of the ACAC 
family, which converts acetyl-CoA into malonyl-CoA. The illustration is adapted from (Currie et al. 
2016). 
ACAC
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LNCaP xenografts reported that the HFD correlated with prostate tumour progression and 
FASN was found to be up-regulated. The HFD resulted in Akt and extracellular signal-regulated 
kinase (ERK) activation and a simultaneous inactivation of 5' adenosine monophosphate-
activated protein kinase (AMPK). FASN inhibition led to a reduction in PCa proliferation via 
PI3K/mitogen-activated protein kinase (MAPK) downregulation and AMPK activation (Huang 
et al. 2016).  
3.5.1.2! Acetyl-CoA carboxylase alpha (ACACA) 
Another identified target that functions in fatty acid synthesis is Acetyl-CoA 
carboxylase alpha (ACACA). This protein is highly involved in lipogenic and oxidative tissues 
(Currie et al. 2013). ACACA enhances the production of malonyl -CoA from acetyl-CoA 
(Figure 3.26), which is suggested to act as a substrate for fatty acid synthesis as well ( Wang et 
al. 2009; Wang et al. 2010; Currie et al. 2013). ACACA has been found to be upregulated in 
several cancers, and it is believed to enhance lipogenesis and hence supports cancer cell growth 
and survival (Wang et al. 2015).  
siRNA knockdown of ACACA was demonstrated to inhibit cell proliferation and induce 
apoptotic cell death in prostate (Brusselmans et al. 2005) and breast cancers (Chajès et al. 2006) 
and did not affect control cells. These results agree with what has been found in this study where 
the knockdown of this target significantly inhibited prostate cancer cell proliferation (Figure 
3.3), and the analysis of tissue samples through the Human Atlas database demonstrated that 
this protein is upregulated in some high-grade PCa tissues (Figure 3.22). The exact molecular 
mechanisms of how ACACA is regulated remain unclear, however, the inactivation of these 
enzymes might occur downstream of kinases such as AMPK (Currie et al. 2013). Currie et al. 
(2013) also discussed that ACACA enzymes are positively and allosterically controlled by the 
availability of citrate and glutamate and negatively and allosterically by the presence of long 
and short-chain fatty acids.  
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3.5.1.3! Acyl-CoA synthetase medium chain family member 1 (ACSM1) 
The knockdown of (ACSM1), previously known as MACS1, resulted in a significant 
inhibition of PCa proliferation in all cell lines tested (Figure 3.3) and supressed PC3 cells’ 
migration (Figure 3.9). ACSM1 is an acyl-CoA synthetase and also known as fatty acid-CoA 
ligase (ACS, ACSL or FACL), which performs an essential step of fatty acid biosynthesis.  
Specifically, it leads to the bio-activation of fatty acids to form FA-CoA (Figure 3.26) (Mashek 
et al. 2007). ACSM1 is located in the mitochondrial matrix and it is believed to degrade 
medium-chain fatty acids to produce energy (Fujino et al. 2001). However, little is known about 
ACSM1 and no previous reports have linked this enzyme to cancer progression.  
3.5.1.4! Farnesyl-diphosphate synthase (FDPS) 
FDPS is another target that is involved in lipogenesis. FDPS is a key enzyme in the 
mevalonate metabolic pathway (Figure 3.27), which involves the synthesis of sterol and non-
sterol isoprenoids such as cholesterol, heme-A, dolichol, and other essential metabolites 
regulating signalling and growth (Buhaescu & Izzedine 2007; Tsoumpra et al. 2015). The 
knockdown of this gene inhibited PCa cell lines proliferation and migration (Figure 3.3, Figure 
3.9, and Figure 3.12). Interestingly, Ettinger et.al (2004) demonstrated the expression of FDPS, 
and FASN, increases during disease progression into CRPC and they added that FDPS and 
FASN are downstream of sterol response element-binding proteins (SREBPs). The latter are 
known to be androgen-regulated, linking AR signalling to cholesterol and fatty acid synthesis 
(Ettinger et al. 2004). In addition to prostate cancer, FDPS is involved in the progression of 
other cancers such as brain cancer (Abate et al. 2017) and colon cancer (Notarnicola et al. 2004), 
and in the therapy resistance in osteosarcoma (Ory et al. 2008).  
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Figure 3.27 Cholesterol biosynthesis through the mevalonate pathway. 
Farnesyl pyrophosphate synthase (FDPS) catalyses the conversion of isopentenyl-PP into farnesyl-PP 
and bisphosphonates are pyrophosphates analogues that can inhibit FDPS function. The illustration is 
adapted from (Griffin et al. 2017).  
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3.5.1.5! Fatty acids uptake and transport  
Solute carrier family 27 member 1 and member 5 (SLC27A1 and SLC27A 5) are other 
novel therapeutic targets identified by the screening. These transporters are relatively  
uncharacterized, however, SLC27A1 is known to be  involved in fatty acids uptake and 
transport (Sadowski et al. 2014). SLC27A5 may also play a role in transportation in lipogenic 
pathways. No work has linked those factors directly to prostate cancer development or 
progression. This study suggests that they might be important factors for PCa. SLC27A1 
knockdown caused significant inhibition of proliferation in androgen-dependent and 
independent cell lines but not in the benign prostatic cell line (BPH1) (Figure 3.3), and 
SLC27A5 inhibited PC3 cell migration (Table 3.2) and was found to be up-regulated at the 
RNA levels in metastatic prostate cancer samples (Figure 3.21). All these observations suggest 
that the metabolic signalling of lipid biosynthesis and uptake forms an important feature of PCa 
progression. 
3.5.2! Heme-biosynthesis and prostate cancer progression 
UROS (uroporphyrinogen III synthase), whose down regualtion showed interesting 
results in terms of cell proliferation (Figure 3.3), migration (Figure 3.11), cell death (Figure 
3.24) and cell cycle (Figure 3.25), and FECH (Ferrochelatase), that resulted in a reduction in 
PC3 cell migration upon its knockdown (Figure 3.13), are associated with heme-biosynthsis.  
Importantly, this pathway has been shown to be altered in cancer (Yang et al. 2015). Heme is 
utilized in the formation of hemoproteins such as cytochromes and hemoglobin that store and 
transport oxygen, and it is an important factor in the electron transport chain (Ajioka et al. 
2006). 
UROS catalyses the generation of the first cyclic tetrapyrrols intermediate, 
Uroporphyrinogen III (UROGEN) in the fourth step of the heme-biosynthesis pathway (Figure 
3.28). UROGEN is formed from a pre-uroporphyrinogen synthesized from 5-aminolevulinic  
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Figure 3.28 Heme-biosynthesis pathway in mammalian cells. 
Heme biosynthesis pathway is initiated in the mitochondria by the formation of 5-aminolevulinic acid 
by ALAS enzymes, that then travels to cytosol to form porphobilinogen by the action of ALAD. Several 
steps then take place in cytosol, by the action of many enzymes including UROS, to form 
coproporphobilinogen III that travels back to mitochondria for the final steps of the process by the action 
of several other enzymes including FECH which inserts ferrous heme into the protoporphyrin IX to 
finally form heme. Several of the heme-biosynthetic factors were detected as novel targets affecting 
prostate cancer cell progression including UROS, which catalyse the fourth step of heme synthesis, and 
FECH, which catalyses the final step. Other factors such as ALAS, ALAD, and UROD (Red circles) 
were just below the cut off criteria but still show some significance especially on prostate cell migration.  
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acid (ALA; which in mammals is formed by the condensation of glycine and succinyl-CoA by 
the enzyme 5-aminolevulinic acid synthase, ALAS) (Hunter & Ferreira 2009). Two molecules 
of ALA are used to generate monopyrrole porphobilinogen (PBG) by the action of the enzyme 
porphobilinogen synthase (PBGS, also known as ALA dehydratase; ALAD) (Layer et al. 2010). 
Four of the resulting PBG molecules are linked by another enzyme called porphobilinogen 
deaminase (PBGD, also called hydroxymethylbilane synthase) to form the linear tetrapyrrole 
pre-uroporphyrinogen (Ajioka et al. 2006). The latter is finally converted to UROGEN by the 
action of UROS and modifications of the side chains of the macrocycle by uroporphyrinogen 
decarboxylase (UROD) yield coproporphyrinogen III that then catalyzes the formation of 
protoporphyrinogen IX by the action of oxygen-dependent coproporphyrinogen III oxidase 
(CPO). Protoporphyrinogen IX is oxidised by oxygen-dependent protoporphyrinogen IX 
oxidase (PPO) prior to insertion of ferrous iron by FECH to complete the production of heme 
(Layer et al. 2010).  
UROS deficiency leads to a very rare autosomal recessive condition called Gunther's 
disease or congenital erythropoietic porphyria (CEP), which is associated with a metabolic error 
in heme production that leads to anemia and skin lesions due to the accumulation of porphyrins 
to toxic levels in the blood and skin (Shaik et al. 2012). No work has specifically investigated 
the role of UROS in cancer. However, this protein appears to be moderately over-expressed in 
high-grade prostatic tissues (Figure 3.22). Therefore, its upregulation might enhance the 
production of heme and hence increase oxygen consumption leading to increased cellular 
respiration and survival.  
The final step of heme-biosynthsis, as mentioned, is performed by FECH, a 
mitochonrial memebrane-bound enzyme, which inserts a ferrous heme into protoporphyrin (Wu 
et al. 2001). The inhibition of FECH has been shown to enhance ALA-photodynamic therapy 
(PDT)-induced cell death in PC3 cells through increasing the accummulation of protophorpyrin 
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IX (Fukuhara et al. 2013). ALA-PDT works on the basis of inducing the formation of the 
photosensitising protoporphyrin IX which accumulates in cancer tissues and absorbs a light of 
a particular wavelength leading to necrotic cell death of cancer cells (Zaak et al. 2004). Because 
protoporphyrin IX is formed in the heme synthesis cascade just before ferrous iron insertion by 
FECH to form heme, FECH depletion was suggested to enhance this accumulation and hence 
improve this therapy. The downregulation of FECH  also enhanced the potentency of 
photodynamic therapy (PDT) in glioma cells, promoting cell death and reducing proliferation 
(Teng et al. 2011).  
Regardless of these observations, there is no work directly linking either UROS or 
FECH to the progression of prostate cancer. Interestingly, other heme-biosynthsis related 
factors including ALAS2 and ALAD, and UROD also demonstrated some significant effects 
on PC3 cell prolferation and migration (Figure 3.29), but these targets fell below the cut off 
criteria used in this work. Therefore, this pathway seems to be important for PCa growth and 
progression and further investigations are required to investigate if this is a viable therapeutic 
target. Supporting this, other studies have shown that the inhibition of heme synthesis using the 
ALAD inhibitor succinylacetone (SA) successfully inhibited the proliferation of non-small cell 
lung cancer (NSCLC) and leaukemia models (Ebert et al. 1979; Weinbach & Ebert 1985; Hooda 
et al. 2013).       
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Figure 3.29 The effect of other heme-biosynthesis genes knockdowns on PC3 cell 
proliferation and migration. 
UROD, ALDA, and ALAS2 knockdowns significantly inhibited PC3 cell migration at least by two out 
of three siRNAs. The effect on proliferation was less significant except for ALAS2 which showed 
proliferation inhibition by two siRNAs transfections. ANOVA (Dunnett’s post hoc test), (ns= not 
significant *P < 0.05, **P < 0.01, ****P < 0.0001). 
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3.5.3! Glycolysis-related factors in prostate cancer  
Fructose bisphosphate aldolase (ALDOA) is the only glycolysis-associated target 
identified in this study. It is one of three isozymes (aldolase A, aldolase B, and aldolase C) that 
are encoded by three different genes (Zhang et al. 2017). ALDOA is the most commonly 
expressed of the aldolase isozymes (Mamczur et al. 2013). ALDOA catalyzes the reversible 
conversion of fructose-1,6-bisphosphate to glyceraldehydes-3-phosphate and 
dihydroxyacetone phosphate (Figure 3.30) (Kajita et al. 2001). This enzyme is found to be 
highly expressed in early embryos and adults muscles, and it functions in several cellular 
processes including muscle maintenance, regulation of cell shape, cell migration, striated 
muscle contraction, organization of actin filament, and ATP biosynthesis (Du et al. 2014). The 
deficiency of this enzyme also causes an autosomal recessive disease exhibiting a hereditary 
hemolytic anemia (Miwa et al. 1981; Kishi et al. 1987; Yao et al. 2004). The down-regulation 
of this enzyme, in this study, led to significant inhibition of PCa cell line proliferation (Figure 
3.3), induction of apoptosis (Figure 3.22) and impairment of PC3 cell migration (Figure 3.10).  
Analysis of the transcript levels of ALDOA (Gene Ontology database) demonstrated 
that the enzyme is upregulated in high-grade PCa (Figure 3.20). These results suggest that 
ALDOA is a critical factor for PCa progression and could be a potential therapeutic target for 
novel therapies. Chang et al. (2017) also identified ALDOA, through proteomic screening, as a 
potential biomarker of prostate cancer radioresistance. They reported that combining 
radiotherapy with ALDOA elimination supress survival, promote apoptosis and enhance 
radiosensitivity of radio-resistant PCa cells (Chang et al. 2017b). Additionally, ALDOA is also 
correlated with metastasis and poor prognosis in NSCLC (Chang et al. 2017a). Further, elevated 
expression of this enzyme was closely linked to the progression of several cancers including 
lung cancer (Du et al. 2014) and colon cancer (Ye et al. 2018). Furthermore, ALDOA 
expression was reported to correlate with the progression and treatment resistance in colorectal  
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Figure 3.30 The role of ALDOA in the glycolysis pathway. 
ALDOA (red box) catalyses the fourth step of glycolysis; reversibly converts fructose 1,6-phosphate to 
glyceraldehyde 3-phosphate and dihydroxyacetone phosphate.  
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cancer (CRC), and it is up-regulated in response to hypoxic conditions (Kawai et al. 2017). 
 These observations suggest that glucose metabolism is important in PCa progression. 
However, ALDOA has also been linked to pathways other than glycolysis. For example 
ALDOA has been linked to the HIF-1 (hypoxia-inducible factor-1) pathway and has been 
shown to play a role in and EMT (epithelial-mesenchymal transition) (Ye et al. 2018). In 
addition, a positive correlation of ALDOA with HIF-1, and downstream signalling, was 
reported in metastatic lung cancer. The upregulation of ALDOA expression enhanced the 
expression of matrix metalloproteinase-9 (MMP9) that functions downstream the HIF-1, and 
the inhibition of MMP9 suppressed lung cancer migration and invasion (Chang et al. 2017).  
Moreover, a recent microarray analysis study revealed that the transcriptional upregulation of 
ALDOA is co-expressed with several cell cycle-related genes in NSCLC and other solid 
tumours, suggesting that ALDOA might contribute to cancer progression through regulation of 
cell cycle factors (Zhang et al. 2017). These observations led to the hypothesis that ALDOA 
contributes to cancer progression by affecting several pathways, dependent upon the metabolic 
stress present in the tumour. 
3.5.4! Amino acids and protein biosynthesis  
The siRNA down regulation of several protein-synthesis related genes had a significant 
impact on PCa proliferation and migration; these included GCAT (glycine C acetyltransferase), 
Methionyl-tRNA synthetase (MARS), and Leucyl-tRNA synthetase 2 (LARS2). Little is 
known about the role of these factors in respect to cancer progression. The effect of these factors 
upon PCa suggests that the metabolic pathways related to amino acids and proteins biosynthesis 
are distorted perhaps to favour the rapid proliferation and survival of these cells.  
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3.5.4.1! GCAT (glycine C acetyltransferase)  
GCAT down-regulation by siRNAs significantly inhibited PCa cell proliferation (Figure 
3.3) and led to cell cycle arrest in S phase and G2/M (Figure 3.23). GCAT is involved in the 
mitochondrial synthesis of glycine, and the upregulation of glycine metabolism is associated 
with higher  proliferation rates and poor prognosis in several cancers (Amelio et al. 2014). In 
addition, Jain et al. (2012) demonstrated that the expression of glycine biosynthetic pathway 
and glycine intake rates correlate with proliferation potential of cancerous cells. Moreover, 
elevated expression of this pathway was reported to correlate with high mortality rates in breast 
cancer (Jain et al. 2012). Such observations support that GCAT could be an important factor in 
PCa progression and targeting this pathway might be a valid approach to tumour growth. 
3.5.4.2! Methionyl-tRNA synthetase (MARS)  
MARS plays a vital role in protein translation and is suggested to enhance this process 
by transferring methionine (Met) to initiator tRNA (Kwon et al. 2011). A recent work by Kim 
et al. (2017) suggested that this protein protects against oxidative stress and ROS-related 
damage, and hence its upregulation favours cancer cell growth and drug resistance. However, 
no work has linked MARS to the progression of PCa. This factor has been shown to be 
commonly over-expressed in NSCLC and its overexpression is correlated with poor clinical 
results (Kim et al. 2017). The knockdown of MARS significantly reduced PCa cell proliferation 
(Figure 3.3) and further experiments are required to elucidate and validate its potential role in 
PCa.   
3.5.4.3! Leucyl-tRNA synthetase 2 (LARS2)  
LARS2 is a mitochondrial aminoacyl tRNA synthase that carries out aminoacylation of 
specific tRNAs required for accurate protein synthesis. More specifically, LARS2 carries out 
the aminoacylation of the human mitochondrial tRNALeu(UUR) (Sohm et al. 2004). Little is 
known about this target, especially in terms of cancer, and no published data is available linking 
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LARS2 to prostate cancer. However, LARS2 was found to be genetically and epigenetically 
deregulated in nasopharyngeal carcinoma. Further, 3p21.3 (where the LARS2 gene is located) 
is frequently deleted in this disease (Samadder et al. 2016). siRNA-knockdown of LARS2 
inhibited PC3 single cell migration across three independent siRNAs (Figure 3.9) and impaired 
population cell motility across two siRNAs (Figure 6.4), however more validations and are 
needed.  
3.5.5! Nucleic acids biosynthesis  
3.5.5.1! Thymidylate Synthase (TYMS)  
TYMS plays a fundamental role in DNA synthesis, replication, and repair (Carreras & 
Santi 1995). TYMS is a target for 5-Fluorouracil (5-FU) which has been used as a palliative 
therapy for CRPC with or without other anti-cancer agents (Burdelski et al. 2015). The siRNA 
downregulation of TYMS resulted in significant inhibition of cell proliferation across three 
prostate cancer cell lines (Figure 3.3). Overexpression of TYMS has been shown to positively 
correlate with disease progression and PSA recurrence in PCa patients (Burdelski et al. 2015). 
This is consistent with the results of the mRNA and protein levels analyses performed here; 
TYMS was upregulated at the transcript and protein levels in metastatic PCa compared to 
primary disease and noncancerous tissues (Figure 3.20 and Figure 3.22). Moreover, TYMS 
knockdown significantly halted proliferation of the PCa cell lines tested (Figure 3.3). This 
factor has also been shown to play an essential role in chemo-resistance and  its overexpression 
correlated with the 5-FU efficacy in breast cancer patients (Yu et al. 2005), and therapy response 
of NSCLC patients to pemetrexed-containing therapy regimens (Chamizo et al. 2015). 
Therefore, TYMS has been suggested to be a predictive biomarker for cancer therapy efficacy 
(Shimizu et al. 2012; Chamizo et al. 2015; Yu et al. 2005).  
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3.5.5.2! Glycinamide ribonucleotide transformylase (GART) 
GART is an enzyme that functions in the third step of the purine biosynthesis pathway 
and it is s a validated target for cancer therapy (Manieri et al. 2007). This factor has been 
targeted using inhibitors such as 5,10-dideazatetrahydrofolate, which has been shown to have 
potent anti-tumour activity (Beardsley et al. 1989). GART has not previously been described 
as a target in PCa, although in this study it was demonstrated that its downregulation by siRNA 
halted proliferation of PCa cell lines (Figure 3.3). In addition, GART upregulation correlates 
with the progression of other cancers such as hepatocellular carcinoma (Cong et al. 2014).  
3.5.6! Free-radicals and redox status regulators 
3.5.6.1! Nitric oxide synthases3 (NOS3) 
The Nitric oxide synthase (NOS) family includes three enzymes NOS1, NOS2, and 
NOS3. These enzymes catalyse the synthesis of nitric oxide (NO) from L-arginine. NO is a 
reactive free-radical that plays an essential role in cell growth, apoptosis, neurotransmission, 
and immunological regulation (Y. Chen et al. 2014). NOS3 is predominantly expressed in 
endothelial cells regulating  blood pressure and blood vessels dilation, and has various other 
vasoprotective and anti-atherosclerotic effects (Förstermann & Sessa 2012). NOS 
polymorphisms have been shown to correlate with PCa risk, pathogenesis and disease 
aggressiveness (Lee et al. 2009; Nikolić et al. 2015; Branković et al. 2013). However, 
contradictory findings are associated with this gene, as some studies found that it is anti-
tumorigenic and others have described its pro-tumorigenic activity (Burke et al. 2013; Vahora 
et al. 2016). Therefore, the mechanism of action of this gene in cancer progression is unclear 
and might depend on the conditions within the tumour. The inactivation of NO occurs through 
its reaction with a superoxide anion (O2−•) to form the oxidant peroxynitrite (ONOO−), the latter 
could lead to oxidative stress, nitration, and S-nitrosylation of biomolecules including proteins, 
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lipids, and DNA (Förstermann & Sessa 2012). Nitrosative stress by ONOO− has been linked to 
DNA single-strand breaks, followed by the activation of poly-ADP-ribose polymerase (PARP) 
(Ridnour et al. 2004). 
NO enzymes have been implicated in cancer progression e.g. tumour growth, migration 
and invasion, survival, angiogenesis, and metastatic behaviour (Baritaki et al. 2010; Burke et 
al. 2013). In PCa, high expression of endothelial NOS (encoded by NOS3) is associated with 
anti-apoptotic characteristics; specifically NOS overexpression in PCa cell lines inhibited 
TRAIL (Tumour necrosis factor-related apoptosis-inducing ligand)-induced apoptosis (Tong 
& Li 2004).  In a different study, that analysed patient tissues, NOS3 was found to be over-
expressed in 68 % of patients and this was associated with high PSA levels (Aaltomaa et al. 
2000). These observations correlate with the findings in this work regarding NOS3; the 
bioinformatics analysis showed that NOS3 is upregulated at the RNA level in metastatic PCa 
compared to primary PCa and benign prostatic tissues (Figure 3.20). Moreover, NOS3 
knockdown significantly halted proliferation across three prostate cancer cell lines (Figure 3.3) 
and inhibited PC3 cell migration (Figure 3.14). Therefore, NOS3 might act as oncogene rather 
than a tumour repressor in PCa. 
3.5.6.2! Glutamate-cysteine ligase catalytic subunit (GCLC) 
GCLC or gamma-glutamylcysteine synthetase (!-GCS) functions in glutathione 
biosynthesis (Lushchak 2012). The latter is a natural tripeptide found within almost all cells 
which is usually bound to other molecules (Balendiran et al. 2004). Glutathione forms an 
important mean of protection against oxidative stress (Lushchak 2012), and it is involved in 
other homeostatic roles such as maintenance modulation of the immune response and 
detoxification of xenobiotics (Balendiran et al. 2004; Lushchak 2012). Glutathione levels have 
been found to be raised in drug-resistant cells in cancer, including PCa (Bailey et al. 1992). 
This increase in glutathione was associated with elevation in the activity and the mRNA levels 
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of GCLC  (Bailey et al. 1992; Mulcahy et al. 1994a; Mulcahy et al. 1994b; Cai et al. 1997; 
Kigawa et al. 1998; Tatebe et al. 2002; Li et al. 2014).  
GCLC downregulation by siRNA abrogated the proliferation of PC3 and LNCaP cells 
but not DU145 cells (Figure 3.3). Although GCLC showed no upregulation at the RNA or 
protein level in this work, GCLC has been shown to be up-regulated by oxidative stress (Cai et 
al. 1997). Supporting this, the promoter of GCLC was found to have transcription factors sites, 
such as nuclear factor erythroid 2-related factor 2 (NRF2), nuclear factor (NF)-κB and activator 
protein-1 (AP-1), that regulate oxidative stress mechanisms (Dequanter et al. 2016).  
3.5.7! Other identified metabolic factors/pathways  
3.5.7.1! Platelet activating factor acetylhydrolase 2 (PAFAH2)  
PAFAH2 was identified by Marques et al. (2002) as a phospholipase enzyme that plays 
an important anti-inflammatory role through the conversion of pro-inflammatory autocoid 
(PAF) into inactivate lyso-PAF by the removal of the SN-2 group of this platelet-activating 
factor. PAFAH enzymes also degrade the toxic poly-unsaturated-fatty-acid-containing 
phospholipids (Marques et al. 2002). The role of this enzyme in tumorigenesis is unknown and 
has not been investigated. However, it might be involved in PCa progression as its 
downregulation inhibited proliferation and migration (Table 3.2 and Figure 3.3).  
Overexpression of PAFAH2 inhibits oxidative stress-induced cell death (Adibekian et 
al. 2010). These observations suggest that PCa cells might utilise this factor to supress cell death 
induced by oxidative stress. In addition, the inhibition of other platelet activating factor 
acetylhydrolases (PAFAH1a/b) has also been shown to impair tumour cell survival (Chang et 
al. 2015).  
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3.5.7.2! Hyaluronan Synthase 3 (HAS3) 
HAS3 is one of three enzymes that synthesise hyaluronan (HA), a polysaccharide 
consisting of several units of D-glucuronic acid and N-acetyl-glucosamine.  HA plays a role in 
several cellular functions including proliferation, migration, cell adhesion, and homeostasis (Kuo et al. 
2017). siRNA depletion of HAS3 significantly reduced cell proliferation and migration of PCa cells 
(Figure 3.3 and Table 3.2), which is consistent with previous data showing that HAS3 overexpression 
induced the growth of PCa cells (Liu et al. 2001). HAS3-induced overexpression of hyaluronan 
was demonstrated to enhance growth, extracellular matrix accumulation of HA and 
angiogenesis in TSU cell line (a cell line established from prostatic adenocarcinoma that has 
metastasised to the lymph nodes) (Itano et al. 1999). It is also postulated that the overexpression 
of HAS3 and other hyaluronan synthases leads to the accumulation of hyaluronan on the cell surface 
which is believed to enhance adhesion to bone marrow.  This has been suggested as a reason as to why 
PCa predominantly metastasis to the bones (Simpson et al. 2001).  This factor was also found to 
promote colon cancer progression and metastasis (Bullard et al. 2003; Teng et al. 2011; Lai et al. 2010).  
3.5.7.3! Scribble cell polarity complex component (LLGL2) 
LLGL2 protein is one of three related proteins that interact to form the Scribble 
complex; a highly conserved complex that is implicated in cell polarity and other cellular 
functions such as proliferation, cell migration and invasion, cell survival, assembly of 
components of adherens junctions and tight junctions that appear to act as tumour suppressors 
(Humbert et al. 2008; Su et al. 2012).  The deregulation of the Scribble complex has been linked 
to the progression of several cancers (Pearson et al. 2011), although the mechanistic processes 
behind this complex and its components, including LLGL2 remain unclear (Humbert et al. 
2008). The loss or knockdown of LLGL2 was shown to inhibit PC3 cell migration in this work 
(Figure 3.17), although this contradicts previous findings where loss of  Scribble resulted in 
PCa progression, but this was in addition to an oncogenic mutation in Kras (Pearson et al. 
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2011). The results of this study and the mentioned role of this complex in cell polarity, cell 
migration and invasion suggest that LLGL2 may play an oncogenic role in PCa. 
3.5.7.4! FK506 binding protein member 11 (FKBP11) and member 9 (FKBP9) 
FK506 binding protein 11 (FKBP11, and named FKBP19 as well) and FK506 binding 
protein 9 (FKBP9) have peptidyl-prolyl cis/trans activity and assist in folding of proline-
containing polypeptides (Rulten et al. 2006). The roles of those two factors in prostate and other 
cancers have not been elucidated, although their ligands have been suggested to be effective 
anticancer agents (Romano et al. 2011). FKBP9 and FKBP11 downregulation by siRNA 
inhibited PCa proliferation and migration, respectively (Figures 3.3 and 3.15). FKBP9 and 
FKBP11 have been found to be highly up-regulated in osteosarcoma tissues and hepatocellular 
carcinoma, respectively, compared to non-tumour tissues (Endo-Munoz et al. 2010; Lin et al. 
2013).  In addition, similar factors from the same family, such as FKBP51 have been found to 
have oncogenic activity in melanoma cells and its expression correlates with melanoma 
progression and aggressiveness (Romano et al. 2013). FKBP51 expression was also higher in 
prostatic cancer tissues compared to normal tissues, and its expression in LNCaP is elevated in 
response to androgen (Velasco et al. 2004).  
3.5.7.5! Syntaxin 1A (STX1A) 
STX1A belongs to a group of proteins that are involved in vesicle transport (Zhang et 
al. 2009), cell trafficking, cell proliferation, and exocytosis and neurotransmission (Ulloa et al. 
2015). Syntaxin 1 was shown to be correlated with the progression of several cancers such as 
breast carcinoma (Fernández-Nogueira et al. 2015) and glioblastoma (Ulloa et al. 2015). In this 
study, siRNA knockdown of this gene led to a significant reduction of PC3 cell migration which 
agrees with previous data that has shown that it is involved in neuron migration (Cotrufo et al. 
2012). These observations suggest that STX1A is a novel target that could be exploited to 
modulate the migratory nature PCa. 
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3.5.7.6! Otopetrin3 (OTOP3) 
Otop3 belongs to a gene family called Otopetrin, which encodes multi-transmembrane 
domain proteins that have no homology to known transporters, channels, exchangers, or 
receptors (Hughes et al. 2008). The Otopetrin family includes three genes OTOP1 and two 
homologues (OTOP2 and OTOP3) (Hughes et al. 2008), which have unknown functions. The 
down-regulation of OTOP3 led to significant reduction of PC3 cell migration (Figure 3.9), 
however further investigations are required to identify the functional roles of this factor in 
normal and cancer cells. 
3.5.8! Summary  
The screen identified several targets, such as FASN, FDPS, ACACA, and ALDOA 
which are already well validated as therapeutic targets and potential biomarkers for PCa and 
other cancers. This validates the findings of this screen. Other targets like GCLC, LLGL2, 
HAS3, and NOS3 have been shown to be important in PCa and other cancers. However, several 
targets including STXA1, FKBP11, FKBP9, LLGL2, GCLC, GART, LARS2, MARS, GCAT, 
UROS, and FECH have not been linked to the progression of PCa before, although they have 
been found to be associated directly, or at least indirectly, with other tumour types. Some of the 
identified targets, such as OTOP3, ACSM1, PAFAH2, LARS2, SLC27A1 and SLC27A5 are 
novel and no work has previously linked them to cancer development/progression which 
highlights the need for further experimentation to characterise their roles in PCa.  
The data demonstrates that a number of the targets identified are indispensable for PCa 
proliferation and motility. More interestingly, the benign cell line (BPH1), utilized as a 
noncancerous cell line control, exhibited no significant inhibition of proliferation when most of 
these factors were knocked down (Figure 3.3). This suggests that the signalling activity of these 
metabolic factors is specifically altered in PCa cells to suit metabolic demands.  
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Several pathways were found to be important for PCa proliferation and motility (Figure 
3.31), including fatty acid/ lipid biosynthesis, heme biosynthesis, and glycolysis.  It should be 
noted that glucose metabolism is linked to fatty acids metabolism at the point of citrate, an 
intermediate in the Krebs cycle (Currie et al. 2013). In addition, heme present in oxygen 
transporters will also provide the Krebs cycle with the required oxygen enhancing oxidative 
respiration and energy production.  
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Figure 3.31 Overall key metabolic alterations and their participation in prostate cancer 
metabolism. 
Deregulated factors (Red) and pathways identified by the siRNA screening of 217 metabolic and cell 
traffic factors in PCa cells. PCa cells halt the accumulation of citrate and Zn and resume the citrate 
oxidation through the TCA cycle. This might be accompanied by the elevation of ALDOA glycolytic 
activity to produce more citrate and other essential intermediates such as acetyl-CoA that is converted 
into lipids/fatty acids by the action of factors such as FASN and ACACA. Fatty acid uptake might be 
further enhanced by the upregulation of transporter proteins like SLC27A1. Heme biosynthesis enzymes 
(UROS and FECH) enhance the production of hemoproteins that feed the Krebs cycle with the required 
oxygen, enhancing the oxidative respiration and energy production. The activity of these signalling 
pathways and the production of energy and building macromolecules support the proliferation and 
survival of PCa cells. 
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4 Chapter 4 Results II 
4! Further validations and investigation into UROS and ALDOA 
The development of techniques to manipulate gene expression have greatly assisted in 
the identification of novel targets for the treatment of cancer (Perwitasari et al. 2013).  One of 
these approaches is small interfering RNAs (siRNAs) (Carthew & Sontheimer 2009; Wilson & 
Doudna 2013; Wittrup & Lieberman 2015).  I have used an siRNA screen to identify novel 
targets for the treatment of prostate cancer.  Uroporphyrinogen III synthase (UROS) was chosen 
for further investigation as its knockdown showed the strongest effects on proliferation and 
migration in prostate cancer cells. UROS depletion also significantly inhibited cell cycle 
progression and induced apoptosis in PC3 cells. UROS catalyses the fourth step in heme-
biosynthesis  (Figure 3.28) (Aizencang et al. 2000) and deficiency in this enzyme leads to the 
rare autosomal recessive condition called Gunther's disease or congenital erythropoietic 
porphyria (CEP).  This disease is associated with a metabolic error in heme synthesis that leads 
to anemia and skin lesions due to the accumulation of porphyrins at toxic levels in the blood 
and skin (Shaik et al. 2012). UROS and other heme-synthetic enzymes exist in the cytoplasm 
(Ajioka et al. 2006), however UROS and UROD are believed to occur in a supramolecular 
complex close to the mitochondrial compartment (Hamza & Dailey 2012).  
UROS catalyses the generation of the first cyclic tetrapyrrols intermediate, 
Uroporphyrinogen III (UROGEN) (Figure 3.28). UROGEN is formed from pre-
uroporphyrinogen that has been synthesized from 5-aminolevulinic acid, ALA, which in 
mammals is formed by the condensation of glycine and succinyl-CoA by the enzyme 5-
aminolevulinic acid synthase, ALAS (Hunter & Ferreira 2009). Tow molecules of ALA 
generate a pyrrole derivative porphobilinogen (PBG) by the action of an enzyme called 
porphobilinogen synthase (PBGS, also known as ALAD) (Layer et al. 2010). Then four of the 
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resulted PBG molecules are linked by another enzyme called porphobilinogen deaminase 
(PBGD, also called hydroxymethylbilane synthase) to form the linear tetrapyrrole pre-
uroporphyrinogen which is finally converted to UROGEN by the action of UROS, and changes 
in side chains of the macrocycle occurs prior to inserting iron to complete the production of 
heme (Layer et al. 2010).  
The second target nominated for further characterization, because of its significant 
effects upon PC3 proliferation is fructose-bisphosphate-aldolase A (ALDOA). ALDOA is one 
of three isozymes (aldolase A, aldolase B, and aldolase C) encoded by three different genes 
(Cibelli et al. 1996). These enzymes are involved in glycolysis, catalyzing the reversible 
conversion of fructose-1,6-bisphosphate to glyceraldehydes-3-phosphate and 
dihydroxyacetone phosphate (Figure 3.30) (Kajita et al. 2001). ALDOA is found highly 
expressed in early embryos and adults muscles, and it functions in several cellular processes 
including muscle maintenance, regulation of cell shape, cell migration, striated muscle 
contraction, organization of actin filament and ATP biosynthesis (Du et al. 2014). The 
deficiency of this enzyme also causes an autosomal recessive disease exhibiting a hereditary 
hemolytic anemia (Miwa et al. 1981; Kishi et al. 1987; Yao et al. 2004). Previous investigations 
of ALDOA demonstrated that it is involved in the progression and metastasis of lung and 
pancreatic cancer and is associated with poor prognosis (Ji et al. 2016; Du et al. 2014).  
To date, little is known about the role of UROS or ALDOA in the progression of prostate 
cancer. The aim of this chapter was therefore to validate successful knockdown of UROS and 
ALDOA, investigate the expression of these enzymes in tumorigenic and nontumorigenic 
controls, determine cellular localization and confirm the effect upon cell motility using wound 
healing assays.  
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4.1! Validation of UROS and ALDOA knockdowns  
 
To confirm successful knockdown of UROS and ALDOA, PC3 were transfected with 
the individual siRNAs and qPCR and western blotting conducted. UROS and ALDOA were 
successfully depleted by the three siRNAs with an average knockdown at the RNA level of 
85% and 95 % respectively (Figure 4.1a and b). To confirm knockdown at the protein level, 
western blotting was also performed (Figure 4.1 c). Mock and NTC transfections were used as 
controls. UROS protein levels were reduced by more than 65 % while ALDOA was reduced by 
approximately 35% (calculated by densitometry analysis; ImageJ). 
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Figure 4.1 QPCR and western blotting to confirm UROS and ALDOA knockdowns. 
PC3 were transfected with siRNAs and incubated for 72 hours. (a) and (b): Cells were harvested, RNA 
extracted and cDNA synthesised.  UROS or ALDOA expression was subsequently quantified using 
qPCR. Data represent mean±1SD of three independent repeats. ANOVA (Dunnett’s post hoc test), 
****P < 0.0001. (c): Cells were harvested, and proteins separated using SDS-PAGE.  Immunoblotting 
was subsequently performed using antibodies specific for UROS, ALDOA, or %-tubulin (loading 
control). 
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4.2! Investigation of UROS and ALDOA basal levels in cancerous and 
noncancerous cells 
To see if the expression of UROS and ALDOA is altered in prostate cancer, the 
transcript levels of UROS and ALDOA were measured in PC3, DU145, LNCAP, and BPH1 
(Figure 4.2). UROS expression is significantly higher in the PCa cell lines compared to the non-
tumorigenic BPH1(P < 0.05, Dunnett’s test) (Figure 4.2 a). Similar results were also evident 
for ALDOA (Figure 4.2. b). To investigate if these differences were also evident at the protein 
level, immunoblotting was performed on a range of prostate cancer and noncancerous cell lines 
(PC3, LNCaP, DU145, 22RV1, C42, C42B, BPH1, and PNTA1). Similar to the changes seen 
at the RNA level, UROS protein levels were found to be higher in the cancer cell lines compared 
to BPH1 and PNT1A (Figure 4.3). In contrast, the levels of ALDOA were relatively consistent 
in all cell lines (Figure 4.4).  
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Figure 4.2 Transcript levels of UROS and ALDOA in PCa cell lines (PC3, LNCaP and 
DU145) and a non-cancerous cell line BPH1. 
Cells were pelleted, RNA extracted, cDNA synthesised, and qPCR performed to quantify (a) UROS or 
(b) ALDOA expression. Data presented is the mean±1SD of three repeats prepared separately with 
identical conditions. ANOVA (Dunnett’s post hoc test), *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 4.3 UROS protein levels in PCa cell lines and non-tumorigenic controls. 
Cell pellets were lysed in RIPA buffer and protein levels quantified.  Immunoblotting was subsequently 
performed using antibodies specific for UROS or %-tubulin (loading control). Densitometry analysis 
was performed using ImageJ. Data is mean±1SD of three repeats. ANOVA (Dunnett’s post hoc test), 
*P < 0.05, **P < 0.01. 
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Figure 4.4 ALDOA protein levels in PCa cell lines and non-tumorigenic controls. 
Cell pellets were lysed in RIPA buffer and protein levels quantified.  Immunoblotting was subsequently 
performed using antibodies specific for ALDOA or %-tubulin (loading control). Densitometry analysis 
was performed using ImageJ. Data is mean±1SD of three repeats. ANOVA (Dunnett’s post hoc test), 
P* < 0.05. 
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4.3! UROS and ALDOA localisation in PC3 cells 
The localisation of UROS and ALDOA has been investigated in prostate cancer cells 
(PC3 cells) in order to gain insights into their cellular functions and if their localisation assists 
drugs’ molecules accessibility. The 2 genes were PCR-cloned into pEGFP-C1. PC3 cells were 
transiently transfected with pEGFP-C1 Empty/UROS/ALDOA. After 24 hours, PC3 cells were 
fixed, stained with DAPI and visualised using laser scanning confocal microscope (Nikon Ti). 
In addition, immunostaining was performed using antibodies specific for UROS and ALDOA, 
and fluorophore conjugated secondary antibodies.  Negative controls (no primary antibody) 
were included and cells imaged using confocal microscopy using the same parameters. 
Immunostaining demonstrated that ALDOA is predominantly localised in the cytosol, 
however some nuclear staining is evident (Figure 4.5 a). This was further validated through 
imaging of GFP-ALDOA, which was also found to be predominantly localised in the cytoplasm 
of PC3 cells (Figure 4.5 b). UROS was localised in the nucleus and cytosol (Figure 4.6 a-b). 
GFP-tagged UROS showed a similar localisation to the immunostained samples, with staining 
being more punctate in the latter (Figure 4.6 b).  
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Figure 4.5 Confocal microscope images to show ALDOA localization in PC3. 
(a): PC3 immuno-stained using anti-ALDOA antibody or no antibody control. (b): PC3 cells were 
transfected with either pEGFP C1-emptry or pEGFP C1-ALDOA.  Cells were fixed, stained with DAPI 
and imaged. All imaging was performed using 60X objective on Nikon Ti laser scanning confocal 
microscope. Scale bar is 5 µm. 
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Figure 4.6 Confocal microscope images to show UROS localization in PC3. 
(a): PC3 immuno-stained using anti-UROS antibody or no antibody control. (b): PC3 cells were 
transfected with either pEGFP C1-emptry or pEGFP C1-UROS.  Cells were fixed, stained with DAPI 
and imaged. All imaging was performed using 60X objective on Nikon Ti laser scanning confocal 
microscope. Scale bar is 5 µm. 
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4.4! Validation of UROS and ALDOA implication in PC3 migration by wound 
healing assays 
4.4.1! Knockdown of Radixin reduces PC3 population cell motility 
Cell migration is the movement of cells that occur to favour several physiological and 
pathological processes. Cancer cells metastases could occur by the dissemination of individual 
cells through blood or lymph nodes and/or by the movement of sheets or clusters of cells from 
the tumour origin into other secondary sites (Xu & Deng 2006). Therefore, wound healing 
assays have been performed to investigate into the relationship between lead targets and the 
invasive and metastatic properties of PCa cells collectively as populations. As has been stated 
before, radixin depletion has been shown to decrease the speed or motility of PC3 cells 
(Valderrama et al. 2012), and hence knockdown of this protein was used to optimise wound 
healing assays. PC3 were seeded in 6-well plates, transfected with siRNA (Radixin-siRNA, 
NTC-siRNA or mock transfected) and left 72 hours in reduced serum medium. Cell monolayers 
were “wounded” using a 200 µl pipette tips, and images acquired using brightfield microscopy 
(NikonTi widefield microscope, objective 2X). The cells were re-imaged hours after 
introduction of the scratches.  
In order to segment scratches from the background of images, an edge detection 
technique was used. This technique of object segmentation is based on intensity discontinuity 
detection in digital images (Muthukrishnan & Radha 2011). Several edge detection algorithms 
are available including Sobel filter which simply detects horizontal and vertical edges; it detects 
significant changes in pixel values in the two directions and highlights them (Uchida 2013). 
This simple method was adequate to segment wounds from the background and precisely 
calculate the area. The scratch closure rate over time was then evaluated. Radixin depletion 
significantly decreased PC3 migratory potential (with 24 % scratch closure at 20 hours),  
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Figure 4.7 Inhibition of PC3 cell migration in response to Radixin knockdown. 
Cells were seeded in 12 well plates and transfected by radixin (Radx) or non-targeting (NTC)-siRNAs, 
or mock transfected control. 24 hours post-transfection, media was changed to fresh RPMI and left for 
72 hours. 24 hours before introducing wounds media was changed to phenol red-free RPMI containing 
5% charcoal stripped FCS. Wounds were then made, cells washed with PBS and fresh RPMI added. (a) 
Images were acquired using brightfield microscopy (Nikon Widefield Microscope, 2x objective) and 
representative images given.  (b) Wounds were segmented and analysed by edge detection and 
automated area detection. Mean±1SD of three independent repeats with at least 3 scratches quantified 
per experiment. ANOVA (Dunnett’s post hoc test), ns= not significant, ***P < 0.001, ****P < 0.0001. 
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compared with mock and NTC transfections which had closure rates of 57% and 46% 
respectively (Figure 4.7). 
4.4.2! Investigation of the effect of UROS and ALDOA knockdown upon PC3 
migration 
To further investigate the role of UROS and ALDOA in PC3 cell migration, wound 
healing assays were performed as previously described in Section (2.3.4). The results 
demonstrated that the scratch closure, in response to knockdown of UROS and ALDOA 
(average of three individual duplexes per target), was significantly decreased in comparison 
with NTC transfected cells. UROS knockdown reduced wound closure from 78% and 67% for 
the mock and NTC respectively, to < 29% for the different siRNAs used (P < 0.05, Dunnett’s 
post hoc test) (Figure 4.8). For ALDOA, 2 of the siRNAs significantly reduced wound closure 
to 33% and 26 %, while the third siRNA showed no significant effect on the population motility 
of PC3 cells (Figure 4.8).  
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Figure 4.8 Inhibition of PC3 cell migration in response to ALDOA and UROS knockdown. 
Cells were seeded in 12 well plates and transfected with siRNA (3 individual duplexes per target). 
siRNA Radixin (Radx) was used as a positive control and non-targeting (NTC)-siRNA and mock 
transfection were used as negative controls. 24 hours after transfection media was changed to fresh 
RPMI and cells left for 72 hours. 24 hours before introducing wounds, media was changed to phenol 
red- free RPMI containing 5% charcoal stripped FCS. Wounds were then made, cells washed with PBS 
and fresh media added. Images were captured using brightfield microscopy (Nikon Widefield 
microscope, 2x objective). (a) Representative images and (b) and wounds were segmented and analysed 
by edge detection and automated area detection. Data is mean±1SD of three independent repeats (at 
least 3 scratches per experiment were quantified). ANOVA (Dunnett’s post hoc test), ns= not significant, 
****P < 0.0001. 
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4.5! Discussion 
 
4.5.1! The effect of UROS depletion upon prostate cancer  
UROS converts the linear tetrapyrrole pre-uroporphyrinogen to a cyclic tetrapyrrole 
uroporphyrinogen III (UROGEN) in the heme-biosynthesis pathway (Figure 3.28) (Layer et al. 
2010). UROS and other heme-synthetic enzymes exist in the cytoplasm (Ajioka et al. 2006), 
however UROS and UROD are believed to exist in the mitochondrial compartment as well 
(Hamza & Dailey 2012). This, therefore, might explain the cytoplasmic localisation of UROS 
obtained by immunofluorescence and transient transfections of the pEGFP C1-UROS vector.  
However, UROS was also found to be partially nuclear and this has not been previously 
described (Figure 4.6). 
To date, no previous studies have linked UROS expression/activity to PCa. However, 
the porphyrins and heme-biosynthetic pathway intermediates have been found to be upregulated 
in cancers such as leukaemia and breast cancer (Navone et al. 1990; Fukuda et al. 2017). 
However, the mechanisms underlying heme-biosynthesis deregulation are still unknown. In this 
study, UROS transcript levels were shown to be significantly higher in PC3, LNCaP, and 
DU145 cells in comparison with BPH1 cells (Figure 4.2). In addition, the protein levels were 
found to be higher in several PCa cell lines compared to the noncancerous cell lines BPH1 and 
PNT1A (Figure 4.3). These findings suggest that UROS is over-expressed in prostate cancer 
cells which support the hypothesis that heme-biosynthesis is upregulated in prostate cancer. 
The expression of UROS mRNA was found, in a previous study, to be reduced under hypoxic 
conditions and this correlated with increased levels of hypoxia inducible factor 1 alpha (HIF1%) 
(Vargas et al. 2008). This therefore suggests that UROS expression is regulated in response to 
oxidative stress.  
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In addition to the inhibition of proliferation, single cell migration and induction of 
apoptosis as demonstrated in Chapter 3, UROS downregulation resulted in reduced migration 
in wound healing assays (Figure 4.8). This demonstrates the role of heme biosynthesis and its 
key enzymes in PCa progression and suggests that the upregulation of UROS in PCa cells 
enhances cell survival and metastatic potential. Other heme metabolism key factors such as 
ALAS1 and heme uptake proteins (HCP1 and hrg-1) were also reported recently by Hooda et 
al. (2015) to be upregulated in NSCLC. They also found that the levels of oxygen-utilizing 
haemoproteins such as cytochromes and cytoglobins are elevated in NSCLC cells compared to 
normal cells (Hooda et al. 2015a).  
Blocking heme-biosynthesis has also been reported to inhibit mitochondrial oxygen 
consumption and supress proliferation, colony formation and migration in NSCLC (Hooda et 
al. 2013), and a similar effect was also previously demonstrated in leukaemia cells (Weinbach 
& Ebert 1985). These observations suggest that the upregulated factors and the increased 
activity of this pathways could be targeted as a novel therapeutic approach against PCa and 
other cancers. Inhibitors of heme-biosynthesis do exist, such as succinylacetone (SA, 4,6-
dioxoheptanoic acid), which (as indicated in the last chapter) targets the activity of ALAD, the 
enzyme responsible for the second step of heme production (Figure 3.28). SA is a potent 
competitive inhibitor of ALAD that has been shown to successfully inhibit heme-biosynthesis 
(Sassa & Kappas 1983; Tschudy et al. 1983).  
4.5.2! Investigations of ALDOA in prostate cancer  
ALDOA is a key enzyme in glycolysis, catalysing the reversible conversion of fructose-
1,6-bisphosphate to glyceraldehydes-3-phosphate and dihydroxyacetone phosphate (Figure 
3.30) (Du et al. 2014). ALDOA was demonstrated to localize in both the cytoplasm and nucleus, 
however, the enzyme was found to be more abundant in the cytosol (Figure 4.5). Mamczur et 
al. (2103) also found ALDOA to be present in the cytosol and nucleus, and it was demonstrated 
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to localize preferentially into the nucleus upon stimulation of proliferation in lung cancer cells. 
Further, the group showed that ALDOA’s nuclear localization correlated with the expression 
of the proliferation marker Ki-67 and that chemical inhibition of cell cycle progression resulted 
in the translocation of ALDOA from the nucleus to the cytosol (Mamczur et al. 2013).  
As discussed in the last chapter, the upregulation of ALDOA was correlated with the 
progression of several cancers, however no previous studies have investigated its expression 
profile in relation to PCa. ALDOA was reported to be highly expressed in other cancers such 
as colorectal cancer, lung cancer, osteosarcoma, oral squamous cell carcinomas, and 
hepatocellular carcinomas (Zhang et al. 2017). Contradictory to this, the protein levels of 
ALDOA in prostate cancer cells was found to be similar to the levels in the noncancerous cells 
(Figure 4.4). However, qPCR analysis demonstrated that ALDOA mRNA levels are 
considerably higher in PCa cell compared to BPH1 cells (Figure 4.2). This discrepancy might 
be explained by differences in the stability or half-life of ALDOA between the cells. This 
hypothesis might be the case because when ALDOA was depleted in PC3 cells (Figure 4.1), 
transcript levels were efficiently down-regulated in response to the siRNA while the protein 
level was only reduced by approximately 35 % (Figure 4.1).   
ALDOA downregulation, as shown in the Chapter 3, inhibited proliferation and single 
cell migration and induced apoptosis. In addition to that, wound healing assay analysis of PC3 
cells transfected with siRNA targeting ALDOA showed that two siRNAs significantly inhibited 
cell migration (Figure 4.8). These results suggest that ALDOA is an important regulator of 
prostate cancer progression and motility. However, I demonstrated in the last chapter that BPH1 
cells were also sensitive to ALDOA knockdown (Figure 3.3). This indicates that targeting this 
axis may result in toxicity in noncancerous cells and this requires further investigation.  
Further investigations are also required to investigate the exact role of ALDOA in PCa 
as it has been demonstrated to also be involved in non-glycolytic pathways. For instance, 
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previous work by Lew and Tolan (2012) demonstrated that knockdown of ALDOA inhibited 
the proliferation of NIH-3T3 and Ras-3T3 transformed cells. Measurement of glycolytic flux 
(lactate levels), rate of glucose consumption and intracellular ATP levels demonstrated that 
ALDOA knockdown did not affect glycolysis. Further, they found that ALDOA-depleted cells 
had a three-fold higher number of binucleated cells compared to mock control.  For this reason, 
the authors suggested that ALDOA knockdown impairs cancer cell proliferation via a non-
glycolytic mechanisms probably as a result of disruption to the cell cycle at the cytokinesis step 
(Lew & Tolan 2012). Such observations highlight the need for further investigations of the role 
of ALDOA in PCa.  
4.5.3! Summary 
Depletion of UROS and ALDOA resulted in strong anti-proliferative and anti-migratory 
effects on PCa cells. The results of this chapter validated the previous knockdown data and the 
involvement of ALDOA and UROS in prostate cancer progression. However, further 
investigations are required to elucidate their mechanisms of action in altering the metabolic 
signalling of PCa. The aim of this work was to develop novel therapeutic approaches against 
CRPC by targeting metabolic signalling, therefore the inhibition of heme biosynthesis pathway, 
where UROS functions, was of interest and further work regarding this is provided in Chapter 5. 
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5 Chapter 5 Results III 
5! Heme-biosynthesis inhibition: a therapeutic approach to inhibit 
prostate cancer progression 
As indicated before, one of the roles that UROS plays is its function as the fourth step 
in heme-biosynthesis. Heme is found in all tissue types but at different levels and an alteration 
in heme biosynthesis is associated with several disease conditions such as anaemia, neuropathy 
and cancer (Hooda et al. 2015b). Further, heme forms an important factor in mitochondrial 
respiration and there is evidence that heme levels are elevated in cancer tissues (Alam et al. 
2016). Heme forms a prosthetic group for several hemoproteins such as hemoglobin, myoglobin 
and cytochromes and hence it is crucial for transporting, storing, and utilizing oxygen. The 
increased levels of heme biosynthesis in cancer cells results in high levels of hemoproteins and 
therefore increased oxygen consumption (Hooda et al. 2013; Hooda et al. 2014; Hooda et al. 
2015a). The latter will result in higher levels of energy generated to meet the cellular demands 
enabling unlimited growth and progression.  
To explore if heme biosynthesis could be a valid therapeutic axis to suppress PCa 
proliferation, the heme synthesis inhibitor succinylacetone (SA) was used. This inhibitor works 
by blocking the second enzyme in the heme synthesis pathway, ALAD (δ- aminolevulinic acid 
dehydratase), that functions upstream of UROS (Hooda et al. 2015a). This inhibitor prevents 
the step when two ALA molecules are fused to form porphobilinogen (Zhang & Gerhard 2009). 
This chapter investigated the impact of heme synthesis inhibition on prostate cancer cell 
proliferation and migration. Evaluation of cell death and cell cycle analysis of heme depleted 
cells were followed to examine the pathways triggered upon the inhibitory effect of SA. Further, 
we hypothesized that combining heme synthesis inhibition with ROS will further increase PCa 
cell death after the prior action of SA upon cells as a result of inhibition of heme synthesis and 
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subsequent loss of downstream hemoproteins, which are known to protect against ROS damage. 
This hypothesis is based on the fact that solid tumours are usually hypoxic and maintain high 
levels of ROS. In addition, the presence of necrotic cells in the microenvironment of the tumour 
in vivo will facilitate damage signals (cytokines) that induce T-cells receptor (TCR) signaling, 
and the latter will be associated with the infiltration of immune/inflammatory cells to the tumour 
microenvironment (Chen et al. 2016). Immune cells, such as macrophages and neutrophils, 
produce high levels of ROS and hence accumulation of ROS in the tumour microenvironment 
will follow which leads to further cellular stress upon cancer cells (Liou & Storz 2010). 
Therefore, in this part different ROS sources (e.g. H2O2) were combined with SA treatment to 
explore the validity of this approach as a therapeutic strategy against prostate cancer 
progression. 
5.1! Reduction of cellular heme content inhibits proliferation of PCa cells 
 
Firstly, a time-course treatment with SA was performed to find the time required for the 
inhibitor to show its effect. Three PCa cell lines (PC3, DU145, and LNCaP) were treated with 
a dose range (1-1000 µM) of SA and cells left to grow for 2, 4, and 6 days. Crystal violet assays 
were performed to quantify proliferation and data made relative to the untreated control. Figure 
5.1 shows a dose-dependent decrease in the proliferation of all cell lines starting at 4 days. The 
6 days incubation demonstrated a more significant growth inhibition at the higher 
concentrations of SA. There was no significant effect on the growth at the 2 days treatment. 
Therefore 6 days treatment was selected for further experiments. 
 To investigate if this anti-proliferative effect of SA on PCa cell lines was specifically 
due to heme-synthesis reduction, PC3 cells were seeded and treated in the same manner with 
SA doses for 6 days. Cells were harvested, counted, and pelleted in equal numbers prior to 
quantification of heme content. As expected, SA significantly decreased heme levels in a dose-  
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Figure 5.1 Time-course treatment of prostate cancer cell lines with succinylacetone (SA). 
Cells were plated and left for 24 hours prior to treatment with SA. Cells were incubated for 2, 4, or 6 
days and proliferation assessed using crystal violet (CV) assays. Data represent mean±1SD of three 
independent repeats. ANOVA (Dunnett’s post hoc test), *P < 0.05, **P < 0.01, ****P < 0.0001. 
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dependent manner (Figure 5.2). This decrease started at 10 µM of SA but was more 
considerable at 100 µM and 1000 µM. 
To examine if reducing exogenous heme levels in the growth medium enhanced any the 
inhibitory activity of cell proliferation, cells (PC3, DU145, LNCaP and BPH1) were grown in 
either 5% FBS medium or 5% heme-depleted FBS medium and treated with SA doses (1-
1000 µM) for 6 days. Heme-depleted medium was prepared by following a previously 
published protocol (Zhu et al. 2002). As before, SA was found to inhibit the proliferation of all 
cell lines, but heme-depleted medium did not enhance this effect (Figure 5.3). This may be 
because the exogenous heme level is not as critical as the endogenous heme for PCa cells’ 
survival or that the heme depletion was sufficient to show any impact on these cells.  
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Figure 5.2 Heme content of PC3 cells treated with succinylacetone (SA). 
PC3 cells were treated with SA 24 hours after seeding. Cells were left for a further 6 days, harvested, 
counted and pelleted. Heme was extracted by heating cells to 100 °C in a concentrated oxalic acid 
solution for 30 mins. Heme content was determined by measuring fluorescence of porphyrin at 400 
nm excitation and 662 nm emission. Data represents mean±1SD of three independent repeats. 
ANOVA (Dunnett’s post hoc test), *P < 0.05, **P < 0.01. 
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Figure 5.3 Heme-depletion and succinylacetone (SA) treatments upon the proliferation of 
prostate cancer cell lines and BPH1 cells. 
Cells were seeded in either media containing standard FBS or in heme-depleted FBS for 24 hours prior 
to treatment with SA doses. Cells were left to grow for 6 days proliferation assessed using crystal violet 
(CV) assays. Data represent mean±1SD of three independent repeats. ANOVA (Dunnett’s post hoc test), 
*P < 0.05, **P < 0.01, ****P < 0.0001. 
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5.2! Inhibition of heme synthesis reduces the metastatic potential of PCa cells 
To further evaluate the effect of heme synthesis upon prostate cancer cells, the migratory 
potential of PC3 cells with and without SA was examined. Wound healing assays and single 
cell tracking experiments were performed on day 4 post SA treatment. Figure 5.4 shows that 
inhibition of heme synthesis significantly reduced the population motility of PC3 cells in a dose 
dependant manner. SA led to a more than 30 % decrease in scratch closure at 10 µM and more 
than 50 % when higher concentrations were applied. These results matched the single cell 
tracking data where PC3 cells showed a significant decline in single cell speed in comparison 
with untreated controls (Figure 5.5). These findings suggest that heme biosynthesis in PCa is 
crucial for proliferation and the migratory potential of PCa cells. 
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Figure 5.4 Succinylacetone (SA) inhibition of the population motility of PC3 cells. 
Cells were seeded in 12 well plates and treated after 24 hours. 3 days later the media was changed to 
5% hormone-depleted RPMI, retreated, and left for 6 hours. Wounds were then made, cells washed with 
PBS once and fresh hormone-depleted RPMI added (retreatment with SA was included). A large-scale 
brightfield image was captured using a Nikon widefield microscope (2x objective), and 24 hours later 
another image was captured. (a) Representative images were generated using Nikon NIS-elements 
software and wounds were segmented and analysed by edge detection and automated area detection. (b) 
the mean wound closure was calculated for at least 9 scratches. Data is mean±1SD of three independent 
repeats. ANOVA (Dunnett’s post hoc test), *P < 0.05, **P < 0.01, ****P < 0.0001. 
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Figure 5.5 Evaluation of the effect of succinylacetone (SA) on single cell migration of PC3 
cells. 
PC3 were seeded sparsely, treated with SA doses 24 hours later, and left for 3 days. On day 4, images 
were acquired by Nikon Ti widefield microscope every 20 minutes using 10X 0.3 N.A objective lens, 
20-30 % illumination, and 3-5 seconds exposure. GFP was excited using blue light 470 nm via a 
CoolLED pE excitation system. The time-lapse image sequences were analysed using ADAPT plugin 
(ImageJ).  (a) Images showing tracks of untreated (no SA) versus treated (100 µM and 1000 µM SA) 
cells. Images were made using Trackmate plugin (ImageJ). The scatter dot plot (b) represents mean±1SD 
of more than 50 trajectories of three independent repeats. Kruskal-Wallis (Dunn’s test) P**<0.01, 
P**** < 0.0001. 
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5.3! Inhibition of heme synthesis blocks cell cycle progression and enhances 
necrotic and apoptotic cell death in PCa cells 
To investigate the mechanisms behind the reduced PCa cells’ proliferation and 
migration induced by heme biosynthesis inhibition, cell death and cell cycle analyses using 
flow cytometry were performed. Briefly, PC3 cells were treated with SA as previously 
indicated. Cells then were pelleted and stained with propidium iodide (PI) for either cell cycle, 
apoptosis, or necrosis analysis (Figure 5.5a).  PI staining is absorbed by cells at different extents 
according to cells properties, and because cells at different phases of cell cycle or when they 
pass through different cell death modalities exhibit different physical properties and DNA 
contents such type of staining is beneficial when analysed by flow cytometry. The latter is 
utilized to gate each population according to cells’ physical characteristics and DNA content.  
PC3 cells appear to be arrested in G2-phase following treatment with SA at the highest 
dose (Figure 5.6a and b). The number of cells in G2-phase was 50 % higher in SA-treated cells 
(1000 µM) compared to the untreated control. In addition, the highest dose of SA led to a 
significant increase in the number of apoptotic cells compared to the control; 15 % and 5 % 
respectively. More interestingly, accessing the necrotic profile of the cells revealed that the SA-
treatment enhanced the number of cells dying as a result of necrosis by 20 % and 15 % at the 
100 µM and 1000 µM SA-doses respectively (Figure 5.6 c). These results suggest that heme is 
important for cell cycle progression in PCa cells, and that metabolic stress enhanced by heme 
deficiency leads to cellular arrest at G2-phase, apoptotic and necrotic cell death.  
The evaluations of apoptosis and necrosis were expanded further to other prostate cancer 
cell lines, LNCaP and DU145 (Figure 5.7). An increase in necrosis was seen in DU145 at 
100 µM, however no elevation at the higher concentration of SA. Further, LNCaP cells 
demonstrated only a slight increase in necrosis upon all SA doses, however this increase was 
not significant. 
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Figure 5.6 Flow cytometry analysis of PC3 cells treated with succinylacetone (SA). 
Cells were treated with SA and incubated for 6 days prior to being harvested and PI stained. An Accuri 
C6 was used to read and analyse the samples and cells were gated to include only cells whilst debris was 
excluded. (a) a panel of representative of cell cycle, apoptosis, and necrosis profiles where the y axis 
represents the number of cells and x axis is the PI signal. (b) Cell cycle analysis exhibits the mean of 
three independent repeats. (c) Quantification of the number of cells undergoing apoptosis and necrosis. 
Data represents mean±1SD of three repeats. ANOVA (Dunnett’s comparison test), ***P < 0.001. 
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Figure 5.7 Cell death analysis by flow cytometry of succinylacetone (SA) treated DU145 
and LNCaP cells. 
Cells were treated with SA and incubated for 6 days prior to being harvested and PI stained. An Accuri 
C6 was used to read and analyse the samples and cells were gated to include only cells whilst debris was 
excluded. Box plots represent mean±1SD of number of cells undergoing apoptosis and necrosis (%) of 
at least three independent repeats. ANOVA (Dunnett’s comparison test), *P< 0.05, ***P < 0.001. 
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5.4! Inhibition of heme synthesis sensitizes prostate cancer cells to ROS damage 
and enhances necrotic cell death 
5.4.1! ROS potently inhibits prostate cancer proliferation following heme synthesis 
inhibition 
To further test my hypothesis that SA inhibition of heme synthesis will make cells 
sensitive to ROS, H2O2 was applied (100-500 µM) to cells that had been treated with/without a 
sub-lethal dose of SA (50 µM). H2O2 was found to have a synergistic effect with SA in a dose-
dependent manner (Figure 5.8). 50 µM of SA reduced cell viability to 28 %, 13 %, 60 %, and 
28 % for PC3, LNCaP, DU145, and BPH1 respectively. H2O2, in contrast, exhibited no 
significant effect when added to the cell lines except for LNCaP. The latter showed a 44 % 
decrease in proliferation at 500 µM of H2O2, however, there was little effect on LNCaP growth 
for the other H2O2 concentrations tested. The combined treatment of, SA and H2O2, exhibited 
a significantly higher effect on PCa cells’ proliferation than that of each treatment alone. A 
synergistic effect on PC3, LNCaP, and DU145 cells was obtained starting at 300 µM, 200 µM, 
and100 µM of H2O2, respectively. DU145 seemed to be the most sensitive cell line to both SA 
alone and SA combined with H2O2. Interestingly, H2O2 doses showed no effect at all on BPH1 
proliferation, alone or combined with SA.  
This experiment was also repeated with a higher more toxic dose of SA, 500 µM. 
Similarly, combining SA with H2O2 led to an additive inhibition of PCa cell proliferation 
(Figure 5.9). The growth inhibition rate was again greater than each treatment alone, and the 
effect was more significant at the lower concentration of H2O2 than that when a sub-lethal SA 
dose was used (Figure 5.8). This inhibition was specific for cells treated with SA except LNCaP 
cells, which again showed some sensitivity to H2O2 dose-treatment, however, the combination 
was more efficacious. Additionally, as we observed in Figure 5.8, BPH1 cells were unaffected  
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Figure 5.8 Inhibition of prostate cancer cell proliferation by succinylacetone (SA) in 
combination with dose-treatment of hydrogen peroxide (H2O2). 
Prostate cancer cell lines and BPH1 cells were seeded 24 hours prior to treatment with 50 µM SA. Cells 
were left to grow for 5 days and then treated with H2O2 (0-500 µM) and left for a further 24 hours before 
CV staining. (a) Representative images of CV stained cells, and (b) dose-response curves of PC3, 
LNCaP, DU145, and BPH1 +/- SA and +/-H2O2. Data were normalized to untreated cells and represents 
mean±1SD of three independent repeats. Two-way ANOVA (Sidak’s comparison test), **P < 0.01, 
****P < 0.0001.  
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Figure 5.9  Inhibition of prostate cancer cell proliferation with a high dose of 
succinylacetone (SA) in combination with hydrogen peroxide (H2O2). 
Prostate cancer cell lines and BPH1 cells were seeded 24 hours prior to treatment with 500 µM SA. 
Cells were left to grow for 5 days and then treated with H2O2 (0-500 µM) and left for a further 24 hours 
before CV staining. The data presented is dose-response curves of PC3, LNCaP, DU145, and BPH1 +/- 
SA and +/-H2O2. Data were normalized to untreated cells and represents mean±1SD of three independent 
repeats. Two-way ANOVA (Sidak’s comparison test), *P < 0.05, **P < 0.01, ***P< 0.001 ****P < 
0.0001. 
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by H2O2 treatment in the presence and absence of the high concentration of SA. These results 
suggest that exposing heme-deficient cells to ROS further initiates anti-proliferative pathways 
in prostatic cancer cells but not in noncancerous cells. In addition, the level of sensitivity of 
PCa cells to H2O2 is associated with the SA dose. These findings suggest that this approach 
represents a targeted therapeutic strategy that will have minimal cytotoxic effects upon normal 
cells. 
5.4.2! Necrotic-like cell death of PCa cells following heme synthesis inhibition in 
combination with ROS 
To investigate the effect of SA plus H2O2 upon cell death, cells were treated as for the 
proliferation assays (Section 2.6). DNA content was analysed using flow cytometry to access 
the effect upon apoptosis and necrosis when cells were treated with a low (50 µM, Figure 5.10) 
and a high (500 µM, Figure 5.10) dose of SA. Both concentrations of SA ± H2O2 had no effect 
upon apoptosis for all of the cell lines tested (Figure 5.10 and 5.11). In contrast, necrosis was 
significantly increased in all cell lines when SA and H2O2 were combined (P < 0.05, Sidak’s 
test). LNCaP exhibited increased levels of necrotic cell death at the higher concentrations of 
H2O2 (400 µM and 500 µM). This is consistent with the inhibition of proliferation for LNCaP 
which was also significant at the higher concentrations of H2O2. Interestingly, BPH1 cells 
showed no significant increase in apoptosis or necrosis in response to all treatments (P > 0.05, 
Sidak’s test), which again supports the hypothesis that targeting heme synthesis, in combination 
with ROS damage, is more specific for PCa cells compared to non-tumorigenic controls (Figure 
5.11). Figure 5.12 demonstrates the cell cycle profiles of PC3 cells upon the combination 
treatments of SA and H2O2. Cells accumulated in G2-phase in response to heme synthesis 
inhibition as shown before. However, this accumulation steadily declined upon the addition of 
H2O2 with no sign of cell accumulation in either S-or G2-phase (P > 0.05, Sidak’s test). 
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Figure 5.10 Induction of necrotic-like cell death of prostate cancer cell lines by a sub-lethal 
dose of succinylacetone (SA) in combination with hydrogen peroxide (H2O2). 
Prostate cancer cell lines were seeded 24 hours prior to treatment with 50 µM SA. Cells left to grow for 
5 days, treated with H2O2 (0-500 µM) and incubated for 24 hours before PI staining and flow cytometry 
analysis. Mean±1SD of at least three independent repeats. Two-way ANOVA (Sidak’s comparison test), 
ns= not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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Figure 5.11 Induction of necrotic-like cell death of prostate cancer cell lines with a high 
dose of succinylacetone (SA) in combination with hydrogen peroxide (H2O2). 
Prostate cancer cell lines and BPH1 cells were seeded 24 hours prior to treatment with 500 µM SA. 
Cells left to grow for 5 days, treated with H2O2 (0-500 µM) and incubated for 24 hours before PI staining 
and flow cytometry analysis. Mean±1SD of at least three independent repeats. Two-way ANOVA 
(Sidak’s comparison test), ns= not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
 
0
10
0
20
0
30
0
40
0
50
0
0
20
40
60
80
100
N
um
be
r 
of
 n
ec
ro
tic
 c
el
ls
 (%
)
Without SA
With SA
0
10
0
20
0
30
0
40
0
50
0
0
20
40
60
80
100
N
um
be
r 
of
 n
ec
ro
tic
 c
el
ls
 (%
)
Without SA
With SA
0
10
0
20
0
30
0
40
0
50
0
0
20
40
60
80
100
N
um
be
r 
of
 n
ec
ro
tic
 c
el
ls
 (%
)
Without SA
With SA
PC3
LNCaP
DU145
BPH1
Apoptosis Necrosis/Necroptosis
0
10
0
20
0
30
0
40
0
50
0
0
20
40
60
80
100
N
um
be
r 
of
 n
ec
ro
tic
 c
el
ls
 (%
)
without SA
with SA****
**** **** *
ns
nsnsnsnsnsns
ns
****
**** ****
***
**** **** **** ****
ns
ns ns
ns
H2O2: (µM)
H2O2: (µM)
H2O2: (µM)
H2O2: (µM)
0
10
0
20
0
30
0
40
0
50
0
0
5
10
15
N
um
be
r 
of
 a
po
pt
ot
ic
 c
el
ls
 (%
)
Without SA
With SA
**
0
10
0
20
0
30
0
40
0
50
0
0
10
20
30
N
um
be
r 
of
 a
po
pt
ot
ic
 c
el
ls
 (%
)
Without SA
With SA
H2O2: (µM)
ns ns ns nsns
nsns
ns
ns
ns
ns
0
10
0
20
0
30
0
40
0
50
0
0
5
10
15
20
25
N
um
be
r 
of
 a
po
pt
ot
ic
 c
el
ls
 (%
)
Without SA
With SA
H2O2: (µM)
ns
***
ns
*
ns ns
0
10
0
20
0
30
0
40
0
50
0
0
5
10
15
N
um
be
r 
of
 a
po
pt
ot
ic
 c
el
ls
 (%
)
Without SA
With SA
H2O2: (µM)
H2O2: (µM)
ns
ns
ns
ns
ns
ns
 
 
245 
                      
Figure 5.12 Cell cycle analysis of PC3 cells treated with succinylacetone (SA) and 
hydrogen peroxide (H2O2). 
PC3 cells were treated with 50 µM SA and incubated for 5 days. H2O2 (0-500 µM) were added and the 
cells left for an additional 24 hours before they were harvested, fixed with 70% Ethanol, and PI stained. 
An Accuri C6 flow cytometer was used to read and analyse the samples and cells were gated to include 
only cells whilst debris was excluded. Cell cycle analysis included three independent repeats and data 
represents mean±1SD. Two-way ANOVA (Sidak’s comparison test), ns= not significant, *P < 0.05, 
**P < 0.01, ***P < 0.001. 
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5.4.3! Succinylacetone induces caspase-independent cell death 
The mechanism of cell death, activated in response to SA treatment, was further 
examined to test whether it is initiated through a caspase-independent process. ZVAD-FMK, a 
pan caspase inhibitor, was employed to investigate if cell death induced by SA was caspase 
dependent. Figure 5.13 demonstrated that ZVAD-FMK was unable to reverse the % of cells 
undergoing necrotic cell death following treatment with SA alone and SA+H2O2. This supports 
the hypothesis that cell death is via necrosis, which is known to be a caspase-independent 
mechanism of cell death (Golstein & Kroemer 2007; Ouyang et al. 2012).  
Mitochondrial membrane potential (MMP) was also measured for SA alone and 
SA+H2O2 treated cells to determine if MMP is disrupted. In response to apoptotic signals, 
mitochondria lose membrane which coincides with release of cytochrome C, SMAC/Diablo 
and AIF into the cytosol apoptotic cascade (Ly et al. 2003). Therefore, loss of MMP is a 
hallmark of apoptotic cell death and applied as evidence for its occurrence. Cells were treated 
with SA, and on day 3 H2O2 was added and cells incubated for a further 24 hours. Cells were 
stained with 3,3′dihexyloxacarbocyanine, DIOC(6)3, fluorescent dye which emits a green 
fluorescent signal when the molecule accumulates in the mitochondria. Disruption of MMP 
results in a drop in signal intensity (Mohr et al. 2008). Since loss of MMP is an early step in 
apoptosis, for this experiment, cells were harvested at an earlier timepoint to avoid complete 
cellular destruction. Figure 5.14 shows no decrease in the DIOC(6)3 signal upon the treatment 
with either only SA or SA+H2O2 in comparison with untreated control in all cell lines. This 
indicates that loss of MMP is not involved in SA± H2O2-induced death, and this supports my 
previous results demonstrating that cell death is via necrosis. 
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Figure 5.13 Succinylacetone (SA) and hydrogen peroxide (H2O2) promote caspase-
independent cell death. 
PC3 cells were treated with SA ± H2O2 (500 µM SA, 300 µM H2O2) ± 10 µM the caspase inhibitor 
ZVAD and left 6 days prior to flow cytometric analysis. Flow cytometry analysis was performed using 
an Accuri C6 to evaluate the percentage of apoptotic and necrotic cells. Data presented are mean±1SD 
of three independent repeats. Two-way ANOVA (Sidak’s comparison test), ns= not significant; 
P-values > 0.05. 
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Figure 5.14 Analysis of mitochondrial membrane depolarization (MMD) of cells treated 
with succinylacetone (SA) and hydrogen peroxide (H2O2). 
PC3, LNCaP, DU145, and BPH1 cells were treated with either 50 µM or 100 µM of SA and left 72 
hours. On day 3, 300 µM H2O2 was applied to cells that has been treated with/without 50 µM SA and 
cells incubated for a further 24 hours. Cells were harvested, washed with PBS and resuspended in 1 ml 
of PBS containing the fluorescent dye DIOC(6)3. Cells were gated to exclude debris and for cells with 
a positive signal (green fluorescence). (a) Flow cytometric profiles show the detected DIOC(6)3 signal 
and the associated number of cells for control (blue) and SA+H2O2 treated cells (red). (b) Data is 
mean±1SD of three independent repeats. ANOVA (Dunnett’s comparison test), ns= not significant. 
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5.4.4! Bleomycin shows no additive effect in combination with heme synthesis 
inhibition 
 As my results indicated that heme synthesis inhibition sensitizes PCa cells to ROS, I 
hypothesised that combining SA with drugs reported to induce ROS will further inhibit 
proliferation. Bleomycin sulfate (BLM) is a glycopeptide antibiotic produced by the fungus 
Streptomyces Verticillus, and has been clinically used as an anti-tumour drug against several 
cancers including head and neck cancer, Hodgkin lymphomas, and testicular cancer (Williams 
et al. 1987; Tobias et al. 2010; Meyer et al. 2012). This chemotherapeutic has been shown to 
induce apoptosis of other cancers’ cells and supress their growth, migration, and invasion partly 
as a result of ROS production. An example is the work of Liu and co-workers where they 
demonstrated that BLM promoted cell cycle arrest, induced cell death and inhibited the 
proliferation, migration and invasion capability of cell line models of gastric cancer (Liu et al. 
2016). 
 BLM is activated through chelation with iron (FeII) and the following reaction with 
oxygen and free electrons to form activated bleomycin (ABLM), ferric hydroperoxide complex 
(BLM–FeIII–OOH) which is the last detected complex before DNA cleavage onset (Burger et 
al. 1981; Hecht 1986; Chow et al. 2008). ABLM produces free radicals (ROS) which in turn 
breaks down the existing DNA and induces apoptosis (Wallach-Dayan et al. 2006). The 
mechanism of action of DNA scission by BLM action has been established in vitro by multiple 
groups (Suzuki et al. 1969; Müller et al. 1972; Caputo 1976; Hecht 1986; Stubbe & Kozarich 
1987; Burger 1998) . The fact that BLM utilises iron and oxygen species as well as its associated 
ROS release led me to propose that a joint action of this drug with heme biosynthesis inhibition 
might lead to enhanced anti-proliferative effects on PCa cells. Therefore, a dose treatment of 
BLM was applied to PC3 and BPH1 cells that were pre-treated with or without a low dose of 
SA (50 µM). The results showed that there is no additive effect induced by using BLM in 
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combination with SA, however, both reagents had an impact on proliferation separately (Figure 
5.15). BLM showed a high cytotoxicity levels on both PC3 and BPH1 at concentrations as low 
as 0.5 nM and this was not altered by the presence and absence of SA.   
5.4.5! Docetaxel shows no additive effect in combination with heme synthesis 
inhibition 
Docetaxel forms the first-line treatment option for CRPC since it was approved by the 
FDA in 2004. This chemotherapy is associated with improved overall survival despite its 
cytotoxicity, limitations, and side effects (Hwang 2012). Docetaxel was also reported to induce 
ROS production through increasing phosphorylation of protein kinase C beta C (PKC") and 
NADPH oxidase activity in human umbilical vein endothelial cells (HUVECs); which 
ultimately led to their dysfunction (Hung et al. 2015). Therefore, I examined whether combining 
a low dose of this agent with heme inhibition improves SA efficacy. PCa cell lines (PC3, 
LNCaP, and DU145) and BPH1 were treated with SA (0-1000 µM) ± 1 nM docetaxel. Cells 
were incubated for 6 days and proliferation assessed using crystal violet assays. Figure 5.16 
demonstrates that docetaxel enhanced the cell death of all PCa cell lines, especially LNCaP, 
however an equal effect was seen in cells with or without heme synthesis inhibition. This means 
that no additive effect obtained of combining docetaxel to SA doses which might suggest that 
each of them inhibits PCa cell growth via unrelated mechanisms. 
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Figure 5.15 Induction of PC3 and BPH1 cell death by succinylacetone (SA) and bleomycin 
sulfate (BLM) combination. 
Cells were treated with 50 µM SA and BLM 24 hours post seeding. Cells were left to grow for 6 days 
before fixation and proliferation assessed using CV assays. Data plotted is mean±1SD of three 
independent repeats. Two-way ANOVA (Sidak’s comparison test), *P < 0.05, ns = not significant.  
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Figure 5.16 Docetaxel does not enhance the inhibitory action of Succinylacetone (SA). 
Prostate cancer cell lines and BPH1 cells were seeded 24 hours prior to treatment with SA ± 1 nM 
docetaxel. Cells were incubated for 6 days before proliferation was assessed using CV assays. (a) 
Representative images of CV stained cells, and (b) dose-response curves of PC3, LNCaP, DU145, and 
BPH1 ± docetaxel. Data was normalized to untreated cells and is mean±1SD of at least 3 independent 
repeats (each performed at least in triplicates). Two-way ANOVA (Sidak’s comparison test), *P < 0.05, 
***P < 0.001, ****P < 0.0001. 
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5.5! Discussion 
5.5.1! Heme biosynthesis inhibition impairs prostate cancer progression  
As mentioned previously, de novo heme biosynthesis is intensified in cancer cells and 
is believed to be implicated in the progression of cancers such as breast and lung (Navone et al. 
1990; Hooda et al. 2013; Hooda et al. 2014; Hooda et al. 2015a). Therefore, I explored whether 
the inhibition of this pathway by SA would abrogate PCa progression. The results demonstrated 
that heme depletion by SA significantly reduced proliferation of PCa cells including PC3, 
DU145, and LNCaP (Figure 5.1) as well as halted PC3 cell migration (Figure 5.4 and Figure 
5.5). However, heme-depletion from medium showed no enhancement of SA effect (Figure 
5.3). This may suggest that de novo heme synthesis operates at intensified levels sufficient for 
PCa growth and survival regardless of the levels of extracellular heme.  
The effect of SA was more significant in incubations longer than 72 hours. The latter 
could be explained by the postulation that the toxic effect of the inhibition of heme synthesis 
would eventually occur in cells as heme levels decline upon each cell division, hence the effects 
of heme deficiency, upon the administration of SA, occur according to the cell division speed 
so rapidly dividing cells or those with high intracellular heme turnover will show the effect 
earlier (Tschudy et al. 1983). Other studies on erythroleukemia observed similar results and the 
authors demonstrated that these effects could be reversed upon the addition of hematin 
(Tschudy et al. 1980). It has also been demonstrated that SA can be safely administered in vivo 
with minimum side-effects. For instance, a study on animal models bearing W256 tumours or 
Novikoff hepatoma demonstrated growth inhibition upon heme biosynthesis inhibition with no 
evident toxicity; the animals stayed healthy and active for 30-60 days regardless of the 
administration of SA (Tschudy et al. 1983).   
The benign prostatic cell line BPH1 also exhibited a significant decrease in growth upon 
SA treatment (Figure 5.3).  However, SA had a weaker effect on the proliferation of this line in 
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comparison to the cancer cell lines. SA led to a maximum 50 % inhibition of BPH1 proliferation 
at the highest concentration of SA compared to more than 70 % reduction in the PCa cell lines, 
PC3, DU145, and LNCaP. This suggests that PCa cells might possess more sensitivity to heme 
biosynthesis inhibition than noncancerous cells. This suggestion is consistent with previous 
data on non-small cell lung cancer (NSCLC), as demonstrated by Hooda et al. (2015), where 
heme synthesis inhibition by SA had more significant effects on the proliferation of HCC4017 
cells (cancer cells) than HBEC30KT (normal cells). In addition, they found that oxygen-
utilizing proteins such as cytoglobin and other hemoproteins levels are intensified in cancer 
cells compared to normal cells, and their levels declined significantly upon SA administration. 
Moreover, the rate of oxygen consumption was significantly higher in NSCLC cells than normal 
cells, and upon SA treatment oxygen consumption rates were considerably reduced and this 
effect was more severe in cancer cells compared to normal cells (Hooda et al. 2015a). These 
observations suggest that heme biosynthesis pathway is an essential metabolic pathway for 
cancer cells and could be a valid axis to develop novel drugs and approaches to inhibit PCa 
progression. 
5.5.2! Intracellular heme depletion induces necrotic-like cell death  
Cell death is an important mechanism for different biological events like 
morphogenesis, maintenance of homeostasis, and removal of harmful cells in normal tissues 
(Arakawa et al. 2015). This process could be induced by several regulated cell death (RCD) 
pathways such as apoptosis, autophagy, and regulated necrosis or recently as 
‘necroptosis’(Ashkenazi & Salvesen 2014; Ouyang et al. 2012; Tait et al. 2014). Recent 
accumulating evidence suggests that programmed cell death is largely associated with anti-
cancer therapies and closely related to drug resistance (Sun & Peng 2009). In cancer tissues, 
cell death pathways, especially apoptosis, are largely distorted to facilitate uncontrolled growth 
and survival of cancer cells (Gerl & Vaux 2004; Su et al. 2015; Labi & Erlacher 2015). To 
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further assess the mechanism of cell death initiated in response to heme biosynthesis inhibition, 
the levels of apoptosis and necrosis were accessed. Results indicated that SA induced a G2/M 
arrest and resulted in apoptotic (at high concentration of SA) and necrotic-like cell death (Figure 
5.6).  
The occurrence of both necrosis-like cell death and apoptosis in prostate cancer cells 
upon SA administration may suggest that these pathways are interconnected. The 
interconnection between cell death pathways has been previously suggested (Conrad et al. 
2016), and may be explained by TNF-induced cell death. TNF-induced cell death can induce 
apoptosis, through the activation of caspase-8 and other downstream proteases, or promote non-
apoptotic cell death (necroptosis) upon caspase-8 failure or inhibition (Laster et al. 1988). The 
presence of necrotic-like cell death in response to heme biosynthesis inhibition further suggest 
that the cells are more sensitive to ROS damage because ROS is believed to be closely related 
to the initiation of necrosis (Morgan et al. 2008). Further, due to the attenuation of heme 
biosynthesis, intracellular iron (Fe+2) may accumulate to a lethal level leading to iron-dependent 
ROS formation (Cao & Dixon 2016; Yang & Stockwell 2016; Altman et al. 2016). This 
accumulation was not reported before in cancer cells upon SA addition, however, it was 
demonstrated that heme biosynthesis-related alterations in autosomal anaemic conditions is 
associated with intracellular iron overload. For example, the sideroblastic anaemias are 
characterized by reduced heme biosynthesis and increased mitochondrial and cytoplasmic iron 
levels that leads to arrested differentiation in erythroid cells (Nakajima et al. 1999; Chiabrando 
et al. 2014). In addition, SA was utilized to artificially boost the cytosolic iron levels in 
erythroblasts differentiation studies (Schranzhofer et al. 2006). Iron is able to induce signalling 
pathways associated with cell death and survival as it is redox-active and hence it can form 
reactive oxygen species (ROS) (Figure 5.17), resulting in oxidative stress and cell death 
initiation (Bogdan et al. 2016).  
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Figure 5.17 The formation of ROS species upon Fe+2 and hydrogen peroxide (H2O2) 
reaction (Fenton reaction). 
Iron is a redox-active and hence it can form hydroxyl radicals (OH.) and hydroxyl anion (OH-) when it 
reacts with H2O2, resulting in oxidative stress and cell death initiation. Adapted from: (Kalinowski & 
Richardson 2005) 
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The accumulation of cellular iron is suggested to induce a form of cell death that is 
distinct from apoptosis and necroptosis and is called ferroptosis (Morgan et al. 2008; Dixon et 
al. 2012; Bogdan et al. 2016). Ferroptosis [ferro, ‘ferrous ion’ (Fe2+); ptosis, ‘fall’] means the 
damage caused by iron overload, with cellular iron essential to this regulated form of oxidative 
cell death (Yang & Stockwell 2016). This form of cell death might had occurred in PCa cell 
lines upon SA administration, because SA would prevent the use of ferrous iron to synthesise 
heme, so intracellular iron accumulation is proposed (Figure 5.18). Ferroptosis occurs as 
explained by recent studies on the basis of the accumulation of iron-dependent lipid-ROS (or 
lipid peroxidation) which can be normally alleviated by antioxidants such as iron chelators 
and/or glutathione peroxidase (GPX4) (Figure 5.18) (Cao & Dixon 2016). The latter have been 
directly linked to the process of ferroptosis, as the inhibition of GPX4 by system-Xc- (glutamate-
cystine antiporter) manipulations through cysteine depletion through the use of erastin or other 
glutathione synthesis inhibitors (e.g. RSL3) also induce this form of cell death (Bogdan et al. 
2016; Cao & Dixon 2016; Yang & Stockwell 2016; Dixon et al. 2012). Further, cancers with 
distorted system-Xc- have been reported to be more susceptible to ferroptosis. For instance, the 
growth of B cell lymphoma with reduced expression of SLC7A11(a subunit in system-Xc-) was 
abrogated by sulfasalazine (a system Xc- inhibitor) (Yang & Stockwell 2016). Furthermore, 
SLC7A11 expression was demonstrated to be repressed by TP53 resulting in ferroptosis 
induction (Jiang et al. 2015). These insights suggest that ferroptosis is highly implicated in cell 
death and survival signalling pathways. However, it remains not evident whether ferroptosis 
is induced in response to heme synthesis inhibition.  Experiments utilising the ferroptosis 
inhibitor ferrostatin-1 would clarify this (Dixon et al. 2012).  
As mentioned, ROS is believed to induce necrotic cell death. For instance, accumulated 
ROS can induce necrosis in response to metabolic stress and antioxidants can shift the 
mechanism of cell death from necrosis to apoptosis (Lim et al. 2009). The latter might explain  
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Figure 5.18 The proposed accumulation of iron due to SA inhibition of heme biosynthesis 
leads to accumulation of lipid-ROS and cell death by ferroptosis. 
SA inhibits heme biosynthesis, which leads to the accumulation of ferrous iron (Fe+2). The excess Fe+2 
generates ROS (Fe OH) resulting in lipid peroxidation, and DNA and protein damage leading to cell 
death. Iron chelators and glutathione peroxidase (GPX4) reduce this effect in unstressed cells by 
detoxification. The process is suggested to occur due to the imbalance between iron-dependent lipid-
ROS accumulation and antioxidant enzymes in prostate cancer cells. 
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why SA treatment induced a mixture of apoptosis and necrosis; heme biosynthesis impairment 
would gradually reduce heme and then steadily increase the intracellular iron amounts. 
Therefore, apoptosis might switch into necroptosis or ferroptosis as ROS increases. In addition 
to the lipid peroxidation, iron-dependant ROS might also cause DNA and protein damage 
leading to genome instability and cell death (Jiang et al. 2015). 
5.5.3! H2O2 treatment of heme biosynthesis-inhibited prostate cancer cells further 
halted proliferation 
Caspase-independent cell death has been proposed as a mechanisms to eradicate tumour 
cells that have established strategies to escape apoptosis (Festjens et al. 2006). Cell death by 
necrotic-like or other non-apoptotic pathways may form a valid strategy to overcome therapy 
resistance; which occur mainly through apoptotic escape and evading the immune system in 
malignant cells (Vinay et al. 2015). However, it is argued that necrotic cell death enhances 
tumour progression by inflammation and angiogenesis and correlates with poor prognosis 
(Vakkila & Lotze 2004; Demirag et al. 2005; Minardi et al. 2008). On the other hand, the 
inflammatory nature of such pathways, upon the direct release of the cellular content into the 
extracellular matrix, could induce the immune system to react against cancer cells and kill them 
(Bullough 2010).  
H2O2 was used in this work as a method to enhance oxidative damage. H2O2 was applied 
to heme biosynthesis inhibited PCa cells, and as expected, this strategy significantly enhanced 
the inhibition of proliferation compared to that induced by SA only. This effect was significant 
using both low (50 µM) and high (500 µM) concentrations of SA (Figure 5.8 and Figure 5.9). 
Interestingly, the impairment of the heme metabolic cascade did not sensitize the noncancerous 
cells (BPH1) to H2O2. This might suggest that heme biosynthesis is specifically critical for 
prostate cancer cell survival and protection against ROS.  
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Some detoxification and redox status-implicated factors such as NOS3 (produces the 
free radical NO; that might have a dual function in inducing growth and cell death) and GCLIC 
(that is implicated in glutathione synthesis, an antioxidant) were found to be critical for PCa 
cells as siRNA knockdown of these factors halted tumour progression. In addition, normal or 
noncancerous cells (BPH1) might still have their ROS-regulatory signaling pathways and 
antioxidants defense system unmodified and functioning normally to remove any excess iron-
ROS induced by SA treatment. Therefore, non-cancerous cells like BPH1 might still be able to 
maintain a balanced redox-status even in the presence of elevated ROS.  
The specificity of SA+H2O2 in PCa cells highlights a potential therapeutic window. PCa 
cells appear to be more prone to SA-induced ROS damage because levels of ROS are known to 
be elevated in PCa and is known to promote an aggressiveness phenotype (Wang et al. 2018). 
This was supported by previous work by Kumar et al. (2008) where ROS levels were found to 
be specifically elevated in PC3, DU145, and LNCaP cells compared to normal prostate cell 
lines. They also found that the inhibition of the Nox system or extra-mitochondrial ROS 
production halted the aggressiveness of these cells (Kumar et al. 2008). ROS elevation in 
tumour cells is oncogenic and generally linked to the apoptotic signalling impairment, induction 
of cell cycle progression and proliferation, cell to cell adhesion, angiogenesis, migration, 
morphological features of cells, and metabolic alterations (Liou & Storz 2010). However, ROS 
levels need to remain within certain limits, since further elevation of ROS will result in 
oxidative stress and cell death. The latter approach has been translated into radiation therapy 
for the treatment of metastatic PCa (Haimovitz-Friedman 1998; Freitas et al. 2012). This was 
also supported by our findings that the down-regulation of a glutathione synthesis implicated 
factor (GCLC) inhibited prostate cancer progression (Chapter 3). In addition, to glutathione, 
other antioxidants like metallothionein, a cysteine-rich and heavy metal-binding protein that 
plays an essential role in maintaining metals homeostasis and toxic metals detoxification 
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(Ruttkay-Nedecky et al. 2013), were found to be upregulated in metastatic prostate cancer cells 
(Suzuki et al. 2000). This might further suggest that targeting glutathione and other 
detoxification factors might overcome resistance to such therapies.  
5.5.4! H2O2 enhances SA-induced caspase-independent cell death 
Succinylacetone exerted a dose-dependent cytotoxic effect across all PCa cell lines. 
Importantly, SA sensitized PCa cells, but not noncancerous control cells, to H2O2. Therefore, 
further investigations were undertaken to analyse the cell death mechanism induced following 
these treatments. The administration of H2O2 doses in addition to low or high doses of SA 
demonstrated a dose-dependent increase in the necrotic-like cell population, while H2O2 alone 
demonstrated no significant increase in the number of necrotic cells in almost all cells (Figure 
5.10 and Figure 5.11). No evidence of apoptosis was found in response to these treatments. 
Interestingly, BPH1 cells were resistant to the combined treatment and no increase in apoptosis 
or necrosis was evident.  
Low or sub-lethal levels of ROS have been reported to induce cellular senescence rather 
than apoptosis in normal fibroblast and lung cancer cells (Chen & Ames 1994; Yoshizaki et al. 
2009). Therefore, it is suggested that the level of oxidative stress determines the cell fate to 
induce apoptosis, necrosis or growth arrest (Baigi et al. 2008). This was demonstrated by a 
previous work by Gradner et al. (1997) using the murine L929 fibroblast cell line. The group 
demonstrated that H2O2 concentrations of more than 10 mM induced necrotic cell death, while 
exposing cells to concentrations of less than 10 mM stimulated apoptotic cell death. They also 
showed that the apoptosis stimulated by 0.1-0.5 mM of H2O2 could be halted by BCL-2 
overexpression but the latter had no effect when higher concentrations of H2O2 were applied 
(Gardner et al. 1997). It should be noted that these concentrations are significantly higher than 
the concentrations used in this study.  
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Cell death upon treatment of SA with or without H2O2 did not involve a loss of 
mitochondrial potential. This was evidenced by the unchanged mitochondrial membrane 
potential upon heme biosynthesis inhibition and H2O2 administration (Figure 5.14). Further, 
cell death was also suggested to be caspase-independent since the pan-caspase inhibitor FMK-
ZVAD did not block cell death induced by these treatments (Figure 5.13). This further supports 
the hypothesis that inhibition of heme biosynthesis ± H2O2 promotes cell death via a necrotic-
like mechanism. 
5.5.5! Chemotherapeutic treatments did not enhance the efficacy of heme 
biosynthesis inhibition in prostate cancer cells 
As chemotherapeutic often promote cell death in part via ROS production, I investigated 
if combining heme depletion with chemotherapeutics, specifically docetaxel and the DNA-
damaging agent bleomycin (BLM), will enhance efficacy. Results demonstrated that no 
additive effect was obtained by these compounds. This might be explained by the fact that these 
drugs do not function primarily as inducers of ROS and instead promote cell death by 
alternative mechanisms.  The mode of action of docetaxel depends on two major mechanisms; 
the first is the attenuation of microtubule depolarisation leading to G2/M cell arrest, and the 
second effect is its inhibition of bcl-2 and bcl-xL gene expression which results in the induction 
of apoptosis (Pienta 2001).  
The addition of BLM to SA treated cells also failed to enhance toxicity (Figure 5.15). 
The action of this agent is argued to be ROS-dependant DNA damage-related. This drug is 
activated upon the presence of DNA, its chelating iron forms an oxygenated-iron complex 
(BLM–FeIII–OOH) which interacts with DNA, promoting degradation (Burger et al. 1981; 
Hecht 1986; Chow et al. 2008).  BLM-promoted DNA damage is likely to induce TP53 activity 
and subsequent release of mitochondrial cell death factors. This mechanism of cell death 
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therefore differs to that induced by SA and may explain why these therapeutics do not have an 
additive effect. 
As mentioned previously, cell death induced by SA and H2O2 may be as a result of lipid 
peroxidation. Peroxidation of lipids including unsaturated phospholipids, glycolipids, and 
cholesterol can be stimulated by free radical species (oxyl radicals, peroxyl radicals, and 
hydroxyl radicals) as a result of iron-associated reduction of H2O2 or the non-radical species 
such as singlet oxygen, ozone, and peroxynitrite that are usually formed by superoxide and the 
nitric oxide reaction (Girotti 1998). It is explained by Trachootham et al. (2008) that lipid 
radicals, produced as a result of lipid peroxidation, could consequently damage additional lipid 
molecules, therefore inducing a chain reaction. This chain-reaction includes three stages: 
initiation, propagation, and termination (Trachootham et al. 2008). Trachootham et al. (2008) 
added that radicals react on different positions present on the unsaturated fatty acid residues of 
the phospholipid. The action can occur at one end of the fatty acid residue or at an internal 
position, leading to the generation of a peroxyl radicals. The damage at internal positions can 
further facilitate the cyclisation of peroxyl radicals resulting in the formation of reactive alkoxyl 
radicals. The  fatty acid can subsequently generate a hydroperoxide or experience further 
cyclisation resulting in the formation of aldehydes, including malondialdehyde (MDA) and 4-
hydroxy-2-nonenal (HNE) (Trachootham et al. 2008). MDA and HNE can then promote DNA 
damage and HNE has also been shown to lead to protein damage, leading to the impairment of 
various signalling pathways (Vasilaki & McMillan 2011).  
5.5.6! Summary 
In this chapter it was shown that heme biosynthesis inhibition abrogated PCa cells 
progression and demonstrated less toxic effect on noncancerous cells. The cell death induced, 
following heme synthesis inhibition, is mitochondrial- and caspase-independent and proposed 
to be ferroptosis (Yang & Stockwell 2016). Ferroptosis is suggested to occur upon the 
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accumulation of high levels of intracellular iron ( Dixon et al. 2012; Cao & Dixon 2016; Bogdan 
et al. 2016; Altman et al. 2016), that I suggested to occur upon heme synthesis inhibition. Iron 
radicals are largely associated with lipid peroxidation and membrane damage, but DNA and 
proteins damage has also been described. The additive toxicity of H2O2 to heme biosynthesis 
inhibition was only evident in the cancerous cell lines. This specificity demonstrates that 
targeting heme synthesis could be a novel targeted approach for CRPC. 
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6! Chapter 6 Final Discussion  
6.1! Metabolic features of prostate cancer in relation to screening outcomes 
Most solid tumours lack sufficient oxygen and nutrients leading them to generate in a 
hypoxic, nutrient-poor microenvironment (Saggar et al. 2013). These conditions cause cancer 
cells to adapt leading to metabolic reprogramming. This reprogramming results in alterations 
in pathways associated with key metabolic factors and redox homeostasis related factors 
(Cutruzzolà et al. 2017). The normal prostate gland exhibits specific metabolic features that 
cannot be found in other types of cells; prostate epithelial cells accumulate and produce citrate 
upon the accumulation of zinc and exhibit lower rates of oxidative phosphorylation for energy 
production (Zadra et al. 2013). Further, prostate epithelial cells rely on aerobic glycolysis, rather 
than aerobic oxidation, as a main resource of the ATP production (Wu et al. 2014). 
Interestingly, these secretory cells are found in the peripheral zone where prostate cancer mostly 
occurs (Costello et al. 2005).  
Changes accompanied with the transformation of prostatic epithelial cells include a shift 
to citrate-oxidising cells associated with halted Zn accumulation and elevated oxygen 
consumption (Figure 6.1). Further, citrate re-enters the TCA cycle to produce ATP and is 
utilized in lipid synthesis instead of being secreted (Costello et al. 2004; Franklin et al. 2005; 
Franklin et al. 2005; Costello & Franklin 2006; Dakubo et al. 2006; Eidelman et al. 2017). 
Citrate formation through the glycolytic pathway probably remains constitutively active in 
cancer cells facilitating uncontrolled proliferation (Cutruzzolà et al. 2017).  
In addition to the alterations in citrate-zinc metabolism, other metabolic differences 
have been described in PCa. For example, PCa appears to rely on citrate oxidation for ATP and 
macromolecule production rather than Warburg effect or increased glycolysis rates through the 
lactic acid pathway; however, elevated glycolysis might appear in late stages of PCa  
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Figure 6.1 The alterations of citrate metabolism in prostate cancer cells. 
Cells switch from zinc-accumulating, citrate-producing to citrate-oxidising that reactivates the Krebs 
cycle production of ATP. The lack of Zn accumulation leads to the reactivation of Acotinase which 
converts citrate to isocitrate, facilitating the completion of the TCA cycle and ATP generation. 
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(Eidelman et al. 2017). The general specificity of cancer cell metabolism and the unique 
metabolic features present in prostate cells makes targeting of metabolism a potential 
therapeutic option for the disease.  
In this study, a screen targeting 217 metabolic and cell traffic factors was performed. 
The screen results depended on the phenotypic changes (proliferation and migration) upon the 
knockdown of different metabolic factors using siRNA. Three siRNAs were used individually 
against each target to reduce the risks of off-target effects/ineffective siRNA. The screen 
identified several factors that have already been proposed as drug targets and biomarkers for 
prostatic and other cancer progression (Baron et al. 2004; Ettinger et al. 2004; Notarnicola et 
al. 2004; Brusselmans et al. 2005; Chajès et al. 2006; Ory et al. 2008; Yoshii et al. 2013; 
Burdelski et al. 2015; Wang et al. 2015; Abate et al. 2017). Those included FASN, FDPS, 
ACACA, and TYMS. The identification of such factors is validation of the screening approach 
applied. Other identified factors including STXA1, FKBP11, FKBP9, GCLC, GART, MARS, 
GCAT, UROS, FECH, LLGL2, HAS3, and NOS3 have also been demonstrated to be important 
for the progression of PCa and/or other types of cancer (Beardsley et al. 1989; Bailey et al. 
1992; Liu et al. 2001; Endo-Munoz et al. 2010; Pearson et al. 2011; Romano et al. 2011; Jain 
et al. 2012; Burke et al. 2013; Hooda et al. 2015; Hooda et al. 2013; Lin et al. 2013; Amelio et 
al. 2014; Cong et al. 2014; Fernández-Nogueira et al. 2015; Ulloa et al. 2015; Yang et al. 2015; 
Vahora et al. 2016; Kim et al. 2017). In addition, the screen identified new targets that have not 
previously been linked to cancer progression, including OTOP3, ACSM1, PAFAH2, LARS2, 
SLC27A1 and SLC27A5.  
Several factors including FASN, FDPS, ACSM1, and ACACA function in lipogenesis 
signalling (Chakravarty et al. 2004; Buhaescu & Izzedine 2007; Mashek et al. 2007; Wang et 
al. 2009; Wang et al. 2010; Currie et al. 2013; Tsoumpra et al. 2015). Normal cells rely on the 
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uptake of exogenous fatty acids coming from diet as opposed to malignant cells that utilise 
endogenous biosynthesis of lipids (Wang et al. 2015). Lipogenesis is known to be deregulated 
in PCa and has hence been proposed as a novel therapeutic approach to selectively target cancer 
cells (Liang & Mulholland 2014). It is likely that lipogenesis enzymes are up-regulated in PCa 
to facilitate the shift from citrate-accumulation to citrate-utilisation, promoting acetyl-CoA 
production and the subsequent fatty acid and cholesterol biosynthesis. This hypothesis that 
lipogenesis is important for PCa proliferation is supported by the findings in this study that 
demonstrated that siRNA depletion of lipogenic factors (FASN, FDPS, ACSM1, and ACACA) 
halted proliferation (Chapter 3). These observation are consistent with previous studies which 
showed that the in vitro and in vivo down-regulation of lipogenic factors abrogates the 
progression of PCa (as reviewed in (Swinnen et al. 2004)).  
It is indicated that factors like FDPS and FASN, and probably other lipogenesis factors, 
are downstream of sterol response element-binding proteins (SREBPs), which are controlled 
by androgen signalling.  Androgen signalling therefore at least in part, regulates cholesterol and 
fatty acid synthesis in PCa (Ettinger et al. 2004). Lipogenesis is predominantly controlled via a 
feedback regulatory system mediated by SREBP transcription factors. These factors are found 
bound to the membranes of the endoplasmic reticulum in their inactive state and when 
cholesterol and fatty acids levels decrease SREBPs become active upon androgen signalling, 
are released from membranes and travel to the nucleus to stimulate transcription of target genes 
necessary for lipid synthesis and uptake (Ye & DeBose-Boyd 2011). Interestingly, SREBP 
transcription factors have been demonstrated to be constitutively activate in CRPC and lose 
their androgen dependency (Ettinger et al. 2004), and hence continued lipogenesis and the 
accumulation fatty acids have been reported and regarded as hallmarks of prostatic malignancy 
(Ettinger et al. 2004; Swinnen, Esquenet, et al. 1997; Swinnen, Ulrix, et al. 1997).  
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Other factors, identified in the screen to regulate PCa proliferation, are also known to 
be important in fatty acid synthesis and signalling. These included ACACA, which is a 
lipogenesis factor that converts acetyl-CoA to the fatty acid substrate malonyl-CoA (Currie et 
al. 2013; Wang et al. 2010; Wang et al. 2009), and ACSM1 that is believed to be implicated in 
the bio-activation of fatty acids as an essential step in lipid metabolism (Mashek et al. 2007). 
In addition, the screening picked transporter proteins such as SLC27A1/5 that have been 
implicated in fatty acid uptake and transport. These findings, taken together with previous 
studies linking lipogenesis with androgen signalling and CRPC (Eidelman et al. 2017) suggest 
that targeting lipogenesis and fatty acid synthesis might be a valid axis for the development of  
novel therapeutic approaches to control CRPC. 
In this study, few metabolic targets involved in glycolysis were found to affect 
proliferation or motility. The exception was Aldolase A (ALDOA), with depletion of this 
enzyme found to decrease proliferation and motility. The function of ALDOA is well 
established; it catalyses the conversion of fructose 1,6-bisphosphate into glyceraldehyde 3-
phosphate and dihydroxyacetone phosphate (Kajita et al. 2001; Du et al. 2014). However, to 
date, no work has linked ALDOA to PCa. ALDOA might be elevated in cancer tissues to favour 
the upregulation of the glycolytic pathway and this warrants further investigation. In support of 
this, ALDOA has been identified as a novel biomarker for colorectal cancer because it was 
found to be highly expressed in cancer tissue samples (Yamamoto et al. 2016). Further, serum 
levels of ALDOA were also found to be increased in patients with lung and renal cancers (Asaka 
et al. 1994; Takashi et al. 1992).  
Some studies have suggested that ALDOA can enhance cancer progression through 
non-glycolytic pathways in addition to its role in glyceraldehyde 3-phosphate production. 
ALDOA was reported to interact with factors that are not related to glycolysis such as the 
cytoskeletal proteins F-actin and tubulin (Arnold & Pette 1970; Volker & Knull 1997). In 
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addition, recent work demonstrated that ALDOA expression is positively correlated with 
increased canonical Wnt signalling (Caspi et al. 2014). Therefore, the molecular regulation of 
ALDOA signalling and its exact roles in cancer are still unclear and needs to be further 
elucidated.  
In addition to lipogenesis and glycolysis, the screening identified several other pathways 
essential for cell proliferation/motility. These included the heme-biosynthesis pathway (UROS 
and FECH), amino acids and protein biosynthesis (GCAT, MARS, and LASR2), nucleic acids 
biosynthesis, (TYMS and GART) and factors important in the regulation of free radicals and 
redox status (NOS3 and GCLC). Additional experiments to validate and characterise these 
targets are needed. Further, elucidating the signalling functions of the identified targets might 
help further our understanding of the complex signalling pathways associated with metabolic 
alterations in PCa.  
6.2! Inhibition of heme biosynthesis in combination with elevated oxidative stress 
as a novel approach to treat prostate cancer 
The highly significant effect of UROS depletion upon cells, and the lack of knowledge 
of heme-biosynthesis in PCa, were the reasons that this pathway was investigated further. Heme 
biosynthesis inhibition has been investigated in other tumour types, including lung cancer. For 
example, the reduction of heme levels in response to SA resulted in significant inhibition of 
lung cancer progression and was associated with a reduction in oxygen consumption and in the 
levels of hemoproteins (Hooda et al. 2013; Hooda et al. 2015a).  
Heme biosynthesis inhibition was therefore further investigated in PCa cell lines and 
BPH1, a noncancerous cell line. Inhibition of heme synthesis using SA led to a dose-dependent 
inhibition of prostate cancer cell proliferation (Figure 5.1 and 5.3) and also considerably 
inhibited migration of PC3 cells (Figure 5.4 and 5.5). The relation of heme-biosynthesis 
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inhibition to iron-overload and the subsequent iron-ROS production (Schranzhofer et al. 2006; 
Altman et al. 2016; Bogdan et al. 2016; Cao & Dixon 2016; Yang & Stockwell 2016)  led to 
the hypothesis that increasing H2O2 levels would further enhance the oxidative stress upon 
cancer cells and subsequently cell death will be further promoted through ROS accumulation. 
This approach selectively promoted cell death in the PCa cells, but not the noncancerous cells 
(Figure 5.6 and 5.7).  
Inhibition of heme synthesis was found to promote caspase-independent cell death. This 
is of particular importance, because recent work has demonstrated that cell death induced via 
this mechanism can enhance tumour clearance due to engagement of the hosts immune system 
(Giampazolias et al. 2017). It could be proposed that necrotic-like cell death of some cells upon 
SA administration will lead to loss of membrane integrity and release of cytosolic content with 
inflammatory molecules such as high mobility group box 1 (HMGB1). This will promote 
inflammation and result in the upregulation of NF-κB, p38 mitogen activated protein kinase 
(MAPK) pathways and the elevated secretion of pro-inflammatory cytokines (Lim et al. 2009). 
The damage signals (cytokines) will induce T-Cell Receptor (TCR) signalling, promoting the 
infiltration of all types of immune/inflammatory cells to the tumour microenvironment (Chen 
et al. 2016).  
Activated immune cells such as macrophages and neutrophils will produce high levels 
of ROS as a defense mechanism to kill cancer cells (Liou & Storz 2010). This ROS is mainly 
made through the phagocytic form of NADPH oxidase (Nox2) (Morgan et al., 2008). This 
burst of superoxide formation by immune cells will result in ROS formation involving hydroxyl 
radicals and peroxynitrite radicals (ONOO-) (Liou & Storz 2010; Segal & Shatwell 1997). 
Therefore, accumulation of ROS in tumour microenvironment will follow which will lead to 
further cellular stress and a second wave of cell death after SA administration (Figure 6.2).  
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Figure 6.2 Schematic representation of the necrosis/necroptosis feed-forward mechanism. 
Treatment of tumours with the heme synthesis inhibitor succinylacetone (SA) will promote 
necrosis/necroptosis in some cells. These cells will release damage signals (cytokines), which will 
promote immune cell infiltration.  The infiltrating immune cells, such as neutrophils, will produce ROS 
leading to ROS accumulation in the microenvironment. The remaining tumour cells are sensitive to ROS 
damage as a result of the SA treatment and therefore a second wave of cell death is initiated, enhancing 
tumour death. 
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It is possible that immune check-point regulators could be stimulated shortly after T-
cell activation through the interaction of receptors expressed on the surface of T-cells with 
inhibitory ligands found on malignant cells, leading to a negative regulation of their anti-tumour 
effect (Figure 6.3) (Śledzińska et al. 2015). For example, this could occur through the activation 
of T-lymphocyte antigen 4 (CTLA-4) and the programmed death 1 receptor (PD-1) and its 
receptor PD-L1 (Freeman et al. 2000; Walunas et al. 1994; Black et al. 2016; Buchbinder & 
Desai 2016). Such effect may be inhibited by combining inhibition of heme synthesis inhibition 
with immune check-point inhibitors. A similar strategy has been shown to be enhance the 
efficacy of conventional PCa treatments, such as chemotherapy and radiotherapy (Finkelstein 
et al. 2015; Modena et al. 2016; Sharabi et al. 2015; Dewan et al. 2009; Demaria et al. 2005; 
Kareva 2017; Ramsay 2013). 
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Figure 6.3 Rationale for the combination of heme synthesis inhibition with immune 
checkpoint inhibition. 
Treatment of tumours with the heme synthesis inhibitor succinylacetone (SA) will promote cell death 
and tumour antigen presentation. This will activate T-cells, however, up-regulation of e.g. PD-L1, on 
tumour cells could block T-cell activity. The addition of immune check-point inhibitors (antibodies 
against PD-L1/PD-1 or CTLA4) could therefore facilitate T-cell activation ensuring that the immune 
response is fully utilised to promote tumour death. 
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6.3! Final conclusion 
Non-organ confined PCa is predominantly treated with hormone therapy and such 
therapies are successful initially. However, remission is temporary as the disease eventually 
recurs into the more aggressive CRPC. The complexity of this stage of the disease limits the 
therapeutic options available. This thesis illustrates the power of biological techniques such as 
siRNA screens in the identification of novel targets for the management of prostate cancer. 
Metabolic specificity of cancers, especially PCa, provides potential therapeutic targets that 
should be specific for the disease, reducing off-target effects.  
Various metabolic factors were identified in this study to be important in PCa and these 
were involved in pathways such as lipogenesis, glycolysis, amino acids and protein 
biosynthesis, heme biosynthesis, redox homeostasis, and nucleic acids synthesis. The down-
regulation of these factors altered PCa proliferation and migration and hence they are suggested 
to be involved in the oncogenesis and progression of PCa. However, further investigations and 
validations are required for some of these targets. This work illustrated that potential targets 
belonged to several interconnected metabolic pathways, so combinational studies of inhibiting 
such pathways could result in more efficacious outcomes.  
Depletion of UROS, the fourth step of heme biosynthesis, significantly repressed 
prostate cancer proliferation and migration, promoted cell cycle arrest and induced cell death. 
Further, inhibition of heme biosynthesis pathway where this UROS functions was found to 
significantly induce caspase-independent cell death and to sensitise cells to ROS. The results 
of heme biosynthesis inhibition and H2O2 administration suggest that this therapeutic approach 
could be of clinical significance. The apparent ROS sensitivity of PCa cells upon heme 
biosynthesis inhibition suggests that the redox homeostasis is not efficiently maintained in these 
cells as in noncancerous cells which provides a therapeutic window to target the disease. The 
combination of heme biosynthesis inhibition with ROS-inducing therapeutics e.g. radiotherapy 
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should be investigated to translate this hypothesis into a therapeutic strategy that can be used in 
PCa patients.   
6.4! Future work 
Targeting PCa metabolic signalling for novel therapeutics has been an attractive 
approach due to the metabolic specificity of PCa cells. However, the excessive interconnection 
between various metabolic signalling pathways and the commonality of metabolic pathways 
found in cancerous and non-cancerous cells have been problematic for researchers. Therefore, 
further understanding of prostate cancer metabolism will assist in finding therapeutic windows 
to design new agents that are highly efficacious but exert minimum side-effects upon non-
cancerous tissues. 
Multiple factors were found to significantly affect prostate cancer cell proliferation and 
migration and many of these have not been previously described to play a role in PCa.  The role 
of these factors in PCa progression therefore requires additional studies. Preliminary assays 
were performed on some these targets e.g. LARS2, FDPS, and ACSM1. In agreement with the 
results of the screen, siRNA depletion of these factors was found to reduce PC3 cell migration 
in wound healing assays (Figure 6.4). Figure 6.5 is a preliminary data on siRNA knockdown 
validation of LARS2 and FDPS. Further, testing the effects of inhibitors of such targets upon 
aspects such as cell cycle, cell death, migration, invasion could follow. 
The novel approach of targeting heme-biosynthesis in PCa is a promising approach, 
especially as it showed specificity for cancer cells when combined with elevated oxidative 
stress. I propose that work should continue to validate this target and a drug development project 
be undertaken to improve target inhibition and drug specificity. The work should also be 
progressed to more physiologically relevant pre-clinical models, including patient derived 
organoids and transgenic mouse models of PCa. This data would provide the necessary 
evidence to support clinical trials of this therapeutic strategy in men with PCa. 
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Figure 6.4 Inhibition of PC3 cell migration in response to LARS2, FDPS, and ACSM1 
knockdown. 
PC3 cells were seeded in 12 well plates and transfected with siRNA (3 individual duplexes per target). 
siRNA-Radixin (Radx) was used as a positive control and non-targeting (NTC)-siRNA and mock 
transfection were used as negative controls. 24 hours after transfection media was changed to fresh 
RPMI and cells left for 72 hours. 24 hours before introducing wounds, media was changed to phenol 
red-free RPMI containing 5% charcoal stripped FCS. Wounds were then made, cells washed with PBS 
and fresh media added. Images were captured using brightfield microscopy (Nikon Widefield 
microscope, 2x objective). Data is mean±1SD of three independent repeats (at least 3 scratches per 
experiment were quantified). ANOVA (Dunnett’s post hoc test), ns= not significant, *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001. 
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Figure 6.5 QPCR to confirm LARS2 and FDPS knockdowns. 
PC3 were transfected with siRNAs and incubated for 72 hours. Cells were harvested, RNA extracted 
and cDNA synthesised. LARS2 or FDPS expression was subsequently quantified using qPCR. Data 
represent mean of one repeat. 
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8! Appendix 
Table 8.1 Summary of the targets identified in the siRNA screen to elevate PC3 
proliferation. 
Symbol 
(symbol 
in screen) 
Gene Description    Pathways Elevation of Relative 
Proliferation 
P-value 
CA12 Carbonic anhydrase 
12 
A member of zinc 
metalloenzymes that catalyse 
the reversible hydration of 
carbon dioxide. 
 
88% 0.0112 
ADCY1 Adenylate cyclase 1 Encodes a member of the of 
adenylate cyclase gene family 
that is primarily expressed in 
the brain. 
 
88% 0.0338 
CA3 Carbonic anhydrase 
3 
A member of a multigene 
family that encodes carbonic 
anhydrase isozymes. 
 
89% 
 
0.0335 
STX16 Syntaxin 16 This gene encodes a member 
of the syntaxin or t-SNARE 
(target-SNAP receptor) 
protein family which present 
on cell membranes and serve 
as the targets for V-SNARES. 
 
95% 0.0191 
SYP Synaptophysin This gene encodes an integral 
membrane protein of small 
synaptic vesicles in brain and 
endocrine cells.  
 
97% 0.0114 
MOCS2 Molybdenum 
cofactor synthesis 2 
A unique molybdenum 
cofactor (MoCo) consisting 
of a pterin, termed 
molybdopterin, and the 
catalytically active metal 
molybdenum. 
 
 
100% 0.0116 
HAS1 Hyaluronan synthase 
1 
Hyaluronan or hyaluronic 
acid (HA) is a high molecular 
weight unbranched 
polysaccharide and is a 
constituent of the 
extracellular matrix. 
 
100% 0.0094 
GALE UDP-galactose-4-
epimerase 
Encodes UDP-galactose-4-
epimerase which catalyses 
the epimerization of UDP-
103% 0.0289 
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glucose to UDP-galactose, 
and the epimerization of 
UDP-N-acetylglucosamine to 
UDP-N-acetylgalactosamine. 
 
SYT7 Synaptotagmin 7 Encodes a protein similar to 
other family members that 
mediate calcium-dependent 
regulation of membrane 
trafficking in synaptic 
transmission.  
 
103% 0.0188 
HDC Histidine 
decarboxylase 
 
Encodes a member of the 
group II decarboxylase 
family and forms a 
homodimer that converts L-
histidine to histamine. 
 
105% 0.0104 
SYNPR Synaptoporin Unknown.  
 
105% 
 
0.0070 
CA5A Carbonic anhydrase 
5A 
Encodes a member of zinc 
metalloenzymes that catalyse 
the reversible hydration of 
carbon dioxide.  
 
108% 0.0112 
BIN3 Bridging integrator 3 
 
This gene encodes a member 
of the BAR domain protein 
family. 
 
110% 0.0075 
ACACB Acetyl-CoA 
carboxylase beta 
 
A member of ACC family 
which catalyse the 
carboxylation of acetyl-CoA 
to malonyl-CoA, the rate-
limiting step in fatty acid 
synthesis.  
 
112% 0.0253 
ADCY6 Adenylate cyclase 6 
 
This gene encodes a member 
of the adenylyl cyclase family 
of proteins, which catalyse 
the synthesis of cyclic AMP.  
 
 
120% 0.0241 
PROM1 Prominin 1 
 
This gene encodes a protein 
which localises to membrane 
protrusions and is often 
expressed on adult stem cells 
to halt their differentiation.  
 
123% 0.0228 
CA2 Carbonic  
anhydrase 2 
 
The encoded protein 
catalyses reversible hydration 
of carbon dioxide. 
 
125% 0.0038 
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FKBP8 FK506 binding 
protein 8 
 
The encoded protein is a 
member of the immunophilin 
protein family, which play a 
role in immunoregulation, 
protein folding, and 
trafficking. 
 
129% 0.0009 
SYT2 Synaptotagmin 2 
 
The encoded protein is 
thought to function as a 
calcium sensor in vesicular 
trafficking and exocytosis. 
 
134% 0.0030 
ADCY3 Adenylate cyclase 3 
 
The encoded protein 
catalyses the formation of the 
secondary messenger cyclic 
adenosine monophosphate 
(cAMP). 
 
137% 0.0105 
TXNDC5 Thioredoxin domain 
containing 5 
 
This gene encodes one of the 
endoplasmic reticulum (ER) 
proteins that catalyse protein 
folding and thiol-disulfide 
interchange reactions.  
 
138% 0.0067 
SYT12 Synaptotagmin 12 
 
This gene encodes a protein 
similar to other family 
members that mediate 
calcium-dependent regulation 
of membrane trafficking in 
synaptic transmission.  
 
140% 0.0004 
SYT10 Synaptotagmin 10 
 
This gene encodes a protein 
similar to other family 
members that mediate 
calcium-dependent regulation 
of membrane trafficking in 
synaptic transmission.  
 
143% 0.0004 
PDXDC2 Pyridoxal dependent 
decarboxylase 
domain containing 2 
 
 
Unknown. 148% 0.0017 
SGPL1 
 
Sphingosine-1-
phosphate lyase 1 
 
Unknown. 163% 0.0007 
SYPL1 Synaptophysin like 1 
 
Unknown. 217% < 0.0001 
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Table 8.2 Summary of extra 37 targets identified in the siRNA screen to significantly 
reduce cell motility. 
Symbol 
(symbol in 
screen) 
Gene Description    Pathways Inhibition/Elevation 
of Motility (%) 
GUCY1B2 Guanylate cyclase 1 
soluble subunit beta 2 
Unknown. 49% 
SRM Spermidine synthase 
 
Carries out the final step of 
spermidine biosynthesis. 
48% 
DYSF Dysferlin 
 
Implicated in muscle 
contraction and contains 
C2 domains that play a role 
in calcium-mediated 
membrane fusion events. 
 
47% 
FSD1L Fibronectin type III 
and SPRY domain 
containing 1 like 
 
Unknown. 46% 
TXNDC11 Thioredoxin domain 
containing 11 
 
Unknown. 46% 
AMD1 Adenosylmethionine 
decarboxylase 1 
Polyamine biosynthesis. 
 
46% 
TYMS Thymidylate 
synthetase 
Catalyzes methylation of     
deoxyuridylate to 
deoxythymidylate. 
46% 
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SYT1 Synaptotagmin 1 
 
A membrane protein of 
synaptic vesicles thought to 
act as Ca2+ sensors in the 
process of vesicular 
trafficking and exocytosis. 
 
45% 
SDCBP Syndecan binding 
protein 
 
Linking syndecan-
mediated signalling to the 
cytoskeleton. 
 
44% 
SYT4 Synaptotagmin 4 
 
Unknown. 43% 
CLN3 CLN3, battenin 
 
 Lysosomal function. 
 
42% 
HDC histidine 
decarboxylase 
 
Conversion of L-histidine 
to histamine in a pyridoxal 
phosphate dependent 
manner. 
 
42% 
FKBP6 FK506 binding protein 
6 
 
May be involved in 
immunoregulation and 
basic cellular processes 
involving protein folding 
and trafficking. 
 
41% 
GSS Glutathione synthetase 
 
Protection of cells from 
oxidative damage by free 
radicals, detoxification of 
xenobiotics, and membrane 
transport.  
 
41% 
TXNDC5 Thioredoxin domain 
containing 5 
 
Protein folding and thiol-
disulfide interchange 
reactions. 
 
40% 
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ALDOB Aldolase, fructose-
bisphosphate B 
 
Conversion of fructose-1,6-
bisphosphate to 
glyceraldehyde 3-
phosphate and 
dihydroxyacetone 
phosphate. 
 
40% 
HAS2 Hyaluronan synthase 2 
 
Constitutes the 
extracellular matrix. 
 
40% 
FKBP1A FK506 binding protein 
1A 
 
A member of the 
immunophilin protein 
family, which play a role in 
immunoregulation and 
basic cellular processes 
involving protein folding 
and trafficking.  
 
40% 
CA7 carbonic anhydrase 7 
 
Reversible hydration of 
carbon dioxide. 
 
40% 
ECH1 enoyl-CoA hydratase 1 
 
Functions in the auxiliary 
step of the fatty acid beta-
oxidation pathway. 
 
40% 
SYT16 Synaptotagmin 16 
 
Unknown. 38% 
TMEM23 Sphingomyelin 
synthase 1 (SGMS1) 
 
 
Predicted to be a five-pass 
transmembrane protein. 
 
38% 
SEC22B SEC22 homolog B, 
vesicle trafficking 
protein 
(gene/pseudogene). 
 
A vesicle trafficking 
protein. 
 
37% 
 
 
335 
CA1 Carbonic anhydrase 1 
 
Catalysation of the 
reversible hydration of 
carbon dioxide. 
 
37% 
STX5 Syntaxin 5 
 
A member of membrane 
proteins that serve as the 
targets for v-SNAREs 
(vesicle-SNAP receptors), 
permitting specific synaptic 
vesicle docking and 
fusion.  
 
37% 
DDC Dopa decarboxylase 
 
Decarboxylation of L-3,4-
dihydroxyphenylalanine 
(DOPA) to dopamine. 
 
37% 
SLC27A4 Solute carrier family 
27 member 4 
 
Fatty acid transport. 
 
36% 
STX12 Syntaxin 12 
 
Unknown. 35% 
MVD Mevalonate 
diphosphate 
decarboxylase 
 
Conversion of mevalonate 
pyrophosphate into 
isopentenyl pyrophosphate 
in cholesterol biosynthesis. 
 
34% 
STX6 Syntaxin 6 
 
Unknown 33% 
UROD Uroporphyrinogen 
decarboxylase 
 
Heme biosynthetic 
pathway. 
 
32% 
 
 
336 
ACSM1 Acyl-CoA synthetase 
medium chain family 
member 
 
Fatty acid biosynthesis. 32% 
IDI1 Isopentenyl-
diphosphate delta 
isomerase 1 
 
Interconversion of 
isopentenyl diphosphate 
(IPP) to its highly 
electrophilic isomer, 
dimethylallyl diphosphate 
(DMAPP). 
 
28% 
ADCY9 Adenylate cyclase 9 
 
Formation of cyclic AMP 
from ATP. 
27% 
SYT2 Synaptotagmin 2 
 
A vesicle membrane and 
cell trafficking protein. 
 
29% 
SYT9 Synaptotagmin 9 
 
A vesicle membrane and 
cell trafficking protein. 
 
34% 
SYPL1 Synaptophysin like 1 
 
Unknown. 38% 
  
